










The handle http://hdl.handle.net/1887/48025 holds various files of this Leiden University 
dissertation. 
 
Author: Nuijten, M.A.A. 
Title: CATCH: New pharmacological treatment options for crack-cocaine dependence. 
Results from three randomised controlled trials 





New pharmacological treatment options 
for crack-cocaine dependence  











































©2017 M. Nuijten 
ISBN: 978-94-6332-142-6 
 
Cover photo: Vincent Hendriks 
Cover design: Onno ten Broek 
 
The research described in this thesis was a cooperation between the Parnassia 
Addiction Research Centre of Brijder Addiction Care in The Hague and the 
Department of Psychiatry of the Academic Medical Centre of the University of 
Amsterdam in Amsterdam, the Netherlands. 
 
Financial support for this thesis was provided by ZonMw (project number 
31160012) and the Parnassia Academy. 
 
CATCH 
New pharmacological treatment options  
for crack-cocaine dependence  






ter verkrijging van  
de graad van Doctor aan de Universiteit Leiden, 
op gezag van Rector Magnificus prof.mr. C.J.J.M. Stolker, 
volgens besluit van het College voor Promoties 
te verdedigen op woensdag 19 april 2017 







Mascha Anna Adriana Nuijten 
geboren te Bergen op Zoom  
in 1975  
 
Promotores:  Prof. dr. V.M. Hendriks 
   Prof. dr. W. van den Brink 
Copromotor:  Dr. P. Blanken 
Promotiecommissie: Prof. dr. A.M. van Hemert  
Prof. dr. A.J.W. van der Does 
   Prof. dr. A.E. Goudriaan, Universiteit van Amsterdam 
   Prof. dr. D.J. Korf, Universiteit van Amsterdam 





Chapter 1 General introduction 
 
7 
Chapter 2 Treatment of crack-cocaine dependence with topiramate: 




Chapter 3 Modafinil in the treatment of crack-cocaine dependence 
in the Netherlands: Results of an open-label randomised 
controlled feasibility trial 
 
47 
Chapter 4 Impulsivity and attentional bias as predictors of modafinil 
treatment outcome for retention and drug use in crack-




Chapter 5 Sustained-release dexamfetamine in the treatment of 
chronic cocaine-dependent patients on heroin-assisted 




Chapter 6 Summary and general discussion 113 
   
 Nederlandse samenvatting 135 
 References 143 
 Curriculum Vitae 169 
 List of Publications 171 
































* This general introduction is an updated and extended version of the study 
protocol published as: Mascha Nuijten, Peter Blanken, Wim van den Brink, & 
Vincent Hendriks (2011). Cocaine Addiction Treatments to improve Control and 
reduce Harm (CATCH): New Pharmacological Treatment Options for Crack-Cocaine 
Dependence in the Netherlands. BMC Psychiatry, 11: 135. 
 




Chapter 1: General introduction 9 
Introduction 
Compulsive cocaine use, particularly crack-cocaine (i.e. smoking or ‘basing’ 
cocaine), is associated with serious negative consequences, including physical, 
mental and social problems, and is a great burden for both the user and society 
(Degenhardt et al., 2014; Degenhardt and Hall, 2012; European Monitoring Centre 
for Drugs and Drug Addiction, 2014; Karila et al., 2012; Oteo Perez et al., 2015; 
Pomara et al., 2012). 
The number of estimated cocaine users worldwide in 2013 was 16 million, 
corresponding to 0.4% of the global adult population (United Nations Office on 
Drugs and Crime, 2015). Overall in Europe, cocaine is the most commonly used 
illicit stimulant drug and approximately 3.4 million Europeans aged 15-64 years 
(1.0% on average) are estimated to have used cocaine in the last year (European 
Monitoring Centre for Drugs and Drug Addiction, 2015). Compared with this 
European average, in the Netherlands, this percentage was slightly higher with 
1.6%, corresponding to an estimated 170,000 cocaine users in 2014 (Trimbos-
instituut, 2015).  
Cocaine users can be roughly divided into recreational, integrated users, who 
generally snort their cocaine and often use other (semi)legal substances (e.g. 
alcohol, cannabis), and socially marginalised compulsive users, who mostly inject 
cocaine or smoke crack-cocaine and often use other illegal drugs (e.g. opioids) 
(European Monitoring Centre for Drugs and Drug Addiction, 2012). Nearly 6% of 
first users are estimated to become cocaine dependent within the first two years 
(O'Brien and Anthony, 2005; Wagner and Anthony, 2002) and about 20% of first 
time users are estimated to ultimately become cocaine dependent (Lopez-
Quintero et al., 2011), with a higher risk to become cocaine dependent when 
cocaine is smoked (crack) or injected than when it is snorted (Chen and Anthony, 
2004; O'Brien and Anthony, 2005; Reboussin and Anthony, 2006). In the 
Netherlands, the prevalence of crack-cocaine dependence between 2009 and 
2011 in the three largest cities (i.e. Amsterdam, The Hague and Rotterdam) was 
estimated to be 0.51%, corresponding with 6,660 persons in the age of 15-64 
years (Oteo Perez et al., 2013).  
With respect to annual cocaine-related treatment demand in Dutch addiction 
care, the number of patients increased from approximately 9,300 in 1995 to 
nearly 17,000 in 2008, subsequently declined to 14,500 in 2012, and stabilised 
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around 14,000 between 2012 and 2014 (Trimbos-instituut, 2015). Most of these 
cocaine dependent patients have a history of multiple and extensive treatment 
episodes (Wisselink et al., 2015), and for 45% of these cocaine-related treatment-
seekers smoking or basing cocaine was the predominant route of administration, 




Almost all treatment-seeking cocaine dependent patients receive psychosocial 
treatment (Lingford-Hughes et al., 2012), including cognitive behavioural therapy 
(CBT) and relapse prevention. However, psychosocial treatments for cocaine 
dependence have generally produced modest results (Dutra et al., 2008; Shearer, 
2007), and both study data and practice-based experiences indicate that poor 
compliance is a major complicating factor in these treatments, with dropout rates 
up to 42% in cocaine dependent patients in trials (Dutra et al., 2008). Patients 
with dual cocaine and heroin dependence often participate in methadone 
maintenance treatment, but in a systematic review and meta-analysis, including 
3,029 patients from 37 studies, it was concluded that opiate maintenance therapy 
alone is not effective in achieving cocaine abstinence and that additional 
interventions, such as co-prescribed pharmacotherapy or contingency 
management, are essential (Castells et al., 2009). In addition, case management is 
offered to this  often chronic  patient population, but there is no convincing 
evidence that case management reduces drug use (Hesse et al., 2007).  
One of the more effective psychosocial treatments for cocaine dependence to 
date is contingency management (CM), an intervention in which positive 
reinforcement is used to improve medication adherence and/or clinical outcomes 
(Stitzer and Vandrey, 2008). CM has shown positive results in terms of improved 
treatment retention (Schierenberg et al., 2012; Van Horn et al., 2011), medication 
adherence (Lussier et al., 2006; Petry et al., 2012; Schierenberg et al., 2012), and 
reductions in cocaine use (Blanken et al., 2016; Dutra et al., 2008; Farronato et al., 
2013; Lussier et al., 2006; Petitjean et al., 2014; Prendergast et al., 2006; 
Schierenberg et al., 2012), although evidence supporting the persistence of the 
effect of CM after treatment termination is equivocal (DeFulio and Silverman, 
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2012; Farronato et al., 2013). Furthermore, application of CM in clinical practice 
has been problematic: reasons are both practical obstacles, including cost and 
time restraints to administer CM, and ideological criticisms on bribery and paying 
for behaviour that should be exhibited anyway, as well as concerns about 
negative consequences of external reinforcement, such as replacing internal by 
external motivation to change and increased risk of relapse when reinforcement 
stops (Carroll, 2014; Marteau et al., 2009; Petry, 2010). It should be noted, 
however, that research has demonstrated that CM does not negatively affect 
motivation to change substance use (Ledgerwood and Petry, 2006; Walter and 
Petry, 2015) and that it also does not contribute to the use of other substances 
(Kadden et al., 2009). 
 
Pharmacological treatment 
The modest results of psychosocial treatments and the growing knowledge about 
the neurobiology of cocaine dependence have led to an increasing number of 
studies searching for effective pharmacological agents to reduce (chronic) cocaine 
use, including antipsychotics (Alvarez et al., 2013; Amato et al., 2007; Kishi et al., 
2013), anticonvulsants (Alvarez et al., 2010; Minozzi et al., 2015b), 
antidepressants (Pani et al., 2011), indirect dopamine agonists or 
psychostimulants (Mariani and Levin, 2012; Perez-Mana et al., 2011; Shearer, 
2008), direct dopamine agonists (Amato et al., 2011; Minozzi et al., 2015a), 
cocaine vaccines (Kosten et al., 2013), and cocaine catalysts (Shram et al., 2015). 
The largest series of studies of pharmacological treatment options for cocaine 
dependence conducted were the Cocaine Rapid Efficacy Screening Trials (CREST), 
in which a paradigm was developed to systematically screen a range of drug 
classes and medications for potential utility in the treatment of cocaine 
dependence (Leiderman et al., 2005). Within five years, 18 medications were 
screened of which only four appeared to be worthy of further investigation: 
tiagabine, reserpine, cabergoline and sertraline (Kampman et al., 2005). However, 
none of them showed convincing efficacy in subsequent studies (Gonzalez et al., 
2007; Winhusen et al., 2007a; Winhusen et al., 2007b), although sertraline 
showed significant results in terms of delayed relapse in depressed, abstinent 
cocaine dependent patients, but not on the primary outcome measure, i.e. 
cocaine use (Mancino et al., 2014; Oliveto et al., 2012). Despite considerable 
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efforts in the research field, there are still no proven effective medications for 
cocaine dependence to date. 
Basically, pharmacological research has focused on two different strategies 
(American Psychiatric Association Practice Guidelines, 2007): one directed at 
cocaine abstinence or substantial reduction, and the other directed at minimising 
cocaine-related harm by replacing uncontrolled and harmful cocaine use with 
regulated and safer stimulant use, in terms of dose, route of administration and 
adverse effects (Grabowski et al., 2004b; Herin et al., 2010; Mariani and Levin, 
2012; Shearer, 2008). Concerning the first strategy, from the wide range of 
medications tested so far, topiramate and modafinil constitute abstinence or 
stimulant use reduction oriented medications, which are registered for indications 
other than cocaine dependence and have shown promise in several studies in 
cocaine dependent populations in terms of cocaine abstinence or cocaine use 
reduction (Ballon and Feifel, 2006; Kim and Lawrence, 2014; Martinez-Raga et al., 
2008; Shinn and Greenfield, 2010). With respect to the second strategy, harm 
reduction treatment with an agonist medication, a growing number of pre-clinical 
and human studies have suggested that the indirect dopamine agonist 
dexamfetamine, more specifically sustained-release (SR) dexamfetamine with a 
slower onset and limited peak effect, is an important candidate for replacement 
therapy in cocaine dependence (Castells et al., 2010; Castells et al., 2007; Kim and 
Lawrence, 2014; Rush and Stoops, 2012; Stoops and Rush, 2013). The basic 
rationale for this substitution treatment for cocaine dependence is similar to that 
for other addictions, such as nicotine replacement therapy in tobacco smokers 
and methadone or buprenorphine in opioid dependent patients. In addition to 
harm reduction, replacement therapy also facilitates engagement with health care 
services by attracting and retaining addicted individuals in treatment (Shearer, 
2008; Shearer and Gowing, 2004), and the regular supervised prescription 
regimen may by itself help patients structure their daily life.  
Hence, numerous pharmacological agents have been tested for their efficacy in 
cocaine dependence, but generally with disappointing or, at best, equivocal 
results. Topiramate, modafinil and SR dexamfetamine still constitute promising 
medications, covering both abstinence-oriented and harm reduction treatment 
strategies. Investigating these agents as potentially new treatment options will 
contribute to opening up new lines of research and – dependent upon the results 
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– new lines of treatment for the most problematic group of cocaine users, i.e. 
crack-cocaine dependent patients.  
 
Topiramate 
Topiramate was originally registered as an anticonvulsant and is also approved in 
Europe for the treatment of migraine, but through its different mechanisms of 
action, topiramate was also investigated for its efficacy in the treatment of 
substance use disorders (Shinn and Greenfield, 2010). Topiramate indirectly 
suppresses dopamine release in the corticomesolimbic system, a brain region 
involved in reward and reinforcement, by enhancing the gamma-aminobutyric 
acid (GABA) system and antagonising the glutamatergic system, and, therefore, 
topiramate is likely to attenuate the reinforcing and rewarding properties of 
addictive substances and to alleviate withdrawal symptoms (Johnson, 2005; Shinn 
and Greenfield, 2010).  
Topiramate has shown efficacy in the treatment of alcohol dependence by 
promoting abstinence, reduced alcohol intake, and reduced craving (Arbaizar et 
al., 2010; Blodgett et al., 2014; De Sousa, 2010; Guglielmo et al., 2015; Hammond 
et al., 2015; Kenna et al., 2009). In methamphetamine dependent patients, 
topiramate did not promote abstinence, but it did contribute to reductions in 
methamphetamine use and relapse rates (Elkashef et al., 2012; Rezaei et al., 
2016). In cocaine dependence, prior to the start of our study, two trials with 
topiramate showed positive effects on cocaine abstinence (Kampman et al., 2004) 
and cocaine craving (Reis et al., 2008). 
 
Modafinil 
Modafinil is currently registered to promote wakefulness in adult patients with 
excessive sleepiness associated with narcolepsy with or without cataplexy. 
Modafinil has a diverse mechanism of action, but is primarily a selective dopamine 
reuptake inhibitor that increases extracellular levels of dopamine (Federici et al., 
2013; Wisor, 2013; Zolkowska et al., 2009). Modafinil interacts differently with the 
dopamine transporter compared with other conventional stimulants, which is 
suggested to underlie the low abuse potential (Minzenberg and Carter, 2008; 
Wisor, 2013). As with all dopamine enhancing medications, however, there is a 
risk for addiction and this should not be disregarded (Volkow et al., 2009). 
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The various neurobiological actions make modafinil an interesting agent for 
several clinical conditions that are characterised by reduced wakefulness, energy, 
cognition or attention, such as in chronic fatigue syndrome, attention-
deficit/hyperactivity disorder (ADHD), depression, Parkinson’s disease and 
schizophrenia (Ballon and Feifel, 2006; Kumar, 2008; Minzenberg and Carter, 
2008; Wisor, 2013). Moreover, modafinil has shown promise in the treatment of 
stimulant dependence. For example, in methamphetamine dependent patients, 
modafinil showed improved treatment retention and reduced methamphetamine 
use (De La Garza et al., 2010; Heinzerling et al., 2010; McElhiney et al., 2009; 
Shearer et al., 2009), but modafinil had no effect on abstinence (Anderson et al., 
2012) or withdrawal (Lee et al., 2013). Prior to the start of our study, the efficacy 
of modafinil in the treatment of cocaine dependence was suggested in two 
studies: modafinil contributed to cocaine abstinence and protracted abstinence 
(Dackis et al., 2005), particularly in cocaine dependent patients without a 
comorbid alcohol use disorder (Anderson et al., 2009).  
In addition to the positive clinical outcomes of modafinil in patients with a 
stimulant use disorder, there is evidence suggesting that modafinil also improves 
cognitive functioning in patients with substance use disorders (Mereu et al., 
2013). For instance, in alcohol dependent patients, modafinil improved cognitive 
control (Schmaal et al., 2013a) and impulsive decision making (Schmaal et al., 
2014), whereas in patients with methamphetamine dependence verbal memory 
recall (Hester et al., 2010) and learning performance (Ghahremani et al., 2011) 
improved. Furthermore, in patients with cocaine dependence, modafinil reduced 
risk-taking (Canavan et al., 2014), improved working memory and attention 
(Kalechstein et al., 2013), and attenuated neural reactivity to cocaine-related cues 
and self-reported craving (Goudriaan et al., 2013). Finally, modafinil-related 
improvements were found in subgroups with poor baseline cognitive 
performance, including response inhibition (Schmaal et al., 2013b) and memory 
(Joos et al., 2013b) in alcohol dependent patients and working memory in 
methamphetamine dependent volunteers (Kalechstein et al., 2010), or in 
inhibitory control and processing speed in methamphetamine dependent patients 
with low baseline methamphetamine use (Dean et al., 2011). 
Hence, modafinil is a promising agent for the improvement of both clinical 
outcomes and cognitive performance in substance use disorders. Still, to date, 
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there has only been one study relating modafinil administration to both cognitive 
performance and clinical outcomes: in a randomised, placebo-controlled trial in 
alcohol dependent patients, 300 mg/day modafinil was investigated for its effects 
in reducing alcohol use and impulsivity (Joos et al., 2013a). Although modafinil did 
not increase abstinence or reduce heavy drinking in the total sample, modafinil 
prolonged the time to alcohol relapse in patients with poor baseline response 
inhibition, whereas it increased heavy drinking and reduced abstinence in those 
patients with good baseline response inhibition (Joos et al., 2013a). These findings 
suggest that the effect of modafinil on reduced substance use and abstinence may 
be mediated by improvements in cognitive functions of patients with impaired 
baseline cognitive control. 
 
Dexamfetamine  
Dexamfetamine is an indirect dopamine agonist or psychostimulant that is 
registered and prescribed for the treatment of patients with attention deficit 
hyperactivity disorder (ADHD) or adult patients with excessive sleepiness in the 
context of narcolepsy. Through increases in extracellular concentrations of 
dopamine, norepinephrine and serotonine, dexamfetamine shares 
pharmacological mechanisms with cocaine and is therefore considered a potential 
replacement therapy for stimulant dependence (Grabowski et al., 2004b; Herin et 
al., 2010), particularly in sustained-release (SR) preparations, which are used to 
maintain steady blood levels and have lower abuse potential compared with 
immediate-release preparations (Mariani and Levin, 2012). 
Agonist replacement therapy with SR dexamfetamine has been investigated 
among stimulant dependent patients in several studies. Results are equivocal for 
problematic (meth)amphetamine use (Perez-Mana et al., 2013) with one study 
showing dexamfetamine to be associated with amphetamine use reduction and 
higher treatment adherence (Longo et al., 2010) and other studies failing to show 
superiority of dexamfetamine (Galloway et al., 2011; Shearer et al., 2001). In 
studies among cocaine dependent patients that were conducted prior to our 
study, dexamfetamine prescription was generally associated with reduced cocaine 
use (Grabowski et al., 2001; Grabowski et al., 2004a; Shearer et al., 2003), but 
small sample sizes in all trials, as well as administration of the immediate-release 
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preparation in the study of Shearer and colleagues (2003) are likely to be 
responsible for the lack of a robust effect of dexamfetamine so far.  
 
The CATCH project 
Given the burden that is associated with compulsive crack-cocaine use, the high 
prevalence of cocaine dependence and cocaine-related treatment demand, as 
well as the limited treatment options to date, the search for new pharmacological 
treatment options should be high on the research agenda. Against this 
background, in January 2007 we submitted a study proposal on “Prevalence, 
treatment needs and new pharmacotherapeutic treatment options for crack-
cocaine dependent people in the Netherlands” to The Netherlands Organisation 
for Health Research and Development (ZonMw), which consisted of two sub-
studies: (1) an epidemiological sub-study to determine the prevalence of crack-
cocaine use in the three largest cities in the Netherlands, and (2) a 
pharmacotherapeutic sub-study. The results of the first sub-study have been 
described elsewhere (Oteo Perez et al., 2015; Oteo Perez et al., 2012; Oteo Perez 
et al., 2013) and the results of the second sub-study are the subject of the present 
thesis.  
It is noteworthy that the study protocol concerning the pharmacotherapeutic 
sub-study originally consisted of four separate feasibility trials, with modafinil and 
rimonabant directed at abstinence or drug use reduction as the treatment goal, 
and SR dexamfetamine and – if acceptable in medical-ethical and legal terms – 
medically prescribed inhalable cocaine directed at harm reduction or drug use 
reduction as the treatment goal. At that time, pre-clinical studies on the 
cannabinoid CB1 receptor antagonist rimonabant had shown potential efficacy in 
attenuating reinforcement and relapse across different classes of drugs, including 
cocaine (Carai et al., 2005; Le Foll and Goldberg, 2005). In humans, rimonabant 
was found to be effective in reducing food intake (Black, 2004; Boyd and 
Fremming, 2005) and was approved as an anorectic anti-obesity drug in Europe in 
2006. Moreover, rimonabant had shown promise in treating nicotine dependence 
(Cohen et al., 2005; Steinberg and Foulds, 2007). However, in 2008 rimonabant 
was withdrawn from the market due to potentially serious side effects, including 
depression and suicide (Christensen et al., 2007; Topol et al., 2010). Therefore, 
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the proposed trial with rimonabant was cancelled and replaced by a trial with 
topiramate. 
The feasibility trial with inhalable cocaine had to be cancelled as well. Although 
administering medically prescribed inhalable cocaine under strict medical 
conditions as agonist replacement therapy for chronic, treatment-refractory 
cocaine dependent patients (Grabowski et al., 2004b) would be an analogue to 
medically prescribed heroin to opiate dependent patients (Blanken et al., 2010b), 
the proposed feasibility trial with inhalable cocaine was rejected for ethical and 
safety reasons. Thus, an adapted study proposal on new pharmacotherapeutic 
treatments for crack-cocaine dependence was proposed, incorporating three 
medications: topiramate, modafinil and SR dexamfetamine. In November 2007, 
this proposal was approved and funded by The Netherlands Organisation for 
Health Research and Development (ZonMw).  
The overall objective of the pharmacotherapeutic sub-study was to evaluate 
the acceptability, efficacy and safety of 200 mg/day topiramate, 400 mg/day 
modafinil, and 60 mg/day SR dexamfetamine in the treatment of crack-cocaine 
dependent patients in the Netherlands, in three separate randomised controlled 
feasibility trials, and – dependent on the results – to yield one or more candidate 
medications for future investigation in a large-scale confirmatory trial. As in any 
medication study, our primary focus was on the balance between (potential) 
benefit and harm associated with the medications, taking into consideration the 
personal and societal damage linked to continued illicit use of cocaine, in a 
situation without effective pharmacological treatment options. 
Given the aim of the study  investigating treatment effectiveness with both 
abstinence and harm reduction as treatment strategies for cocaine dependent 
patients  the study’s acronym is CATCH: Cocaine Addiction Treatments to 
improve Control and reduce Harm. 
 
Methods  
Design & setting 
All three pharmacological trials of the CATCH project were parallel-group, 
randomised controlled, feasibility studies of 12 weeks duration, conducted at 
different addiction treatment centres.  
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Topiramate and modafinil trials 
In the topiramate and the modafinil trials, the originally proposed pre-
randomisation, double-consent (‘Zelen’-) design (Zelen, 1979) was used to assign 
patients to the experimental group (12 weeks cognitive behavioural therapy (CBT) 
plus study medication: 200 mg/day topiramate [trial 1] or 400 mg/day modafinil 
[trial 2]) or the control group (12 weeks CBT only; no placebo). According to the 
Zelen-design, randomisation takes place prior to seeking (final) informed consent: 
in our study, a first informed consent (to participate in a study evaluating CBT) 
was obtained from all patients before randomisation, and a second informed 
consent (to participate in add-on pharmacotherapy) was obtained after 
randomisation, but only in patients allocated to the experimental group (Figure 1).  
In this pre-randomisation, double-consent design, patients in the control 
condition receive standard care and are unaware of the experimental condition 
that they are compared with. This design is considered to be particularly useful 
when the experimental intervention is expected to be highly attractive to the 
participants, which is likely to result in recruitment difficulties, non-compliance 
and selective dropout among control subjects in a traditional randomised design 
when expectations, raised by the possible prescription of the active medication, 
are not met (Schellings et al., 1999; Torgerson and Roland, 1998). 
Alternatively, a series of small-scale placebo-controlled randomised trials could 
have been conducted, corresponding with the previously mentioned Cocaine 
Rapid Efficacy Screening Trials (Leiderman et al., 2005). However, the occurrence 
of substantial dropout (i.e. about 30% overall) in the  already small  control 
groups in these trials limited conclusions with regard to the medication effect 
(Elkashef et al., 2005; Kampman et al., 2005). This led us to conclude that, given 
the proposed small sample sizes of the CATCH feasibility trials, and the potentially 
high risk of premature dropout and biased results, a placebo-controlled 
randomisation design would not be desirable at this stage. 
Instead, the pre-randomisation, double-consent design has the advantage of 
providing a more naturalistic control condition than a traditional randomised 
design (e.g. no placebo, less data collection), but without information or selection 
bias due to patients being aware that they are control subjects, as in a fully 
naturalistic study in which patients know that they either receive active 
medication or not. Still, the pre-randomisation, double-consent design maintains 
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the strength of a randomised design by providing treatment allocation of patients 
to one of the conditions based on chance (Zelen, 1979). In addition, since 
acceptance of pharmacotherapy by the target population (i.e. crack-cocaine 
dependent patients) would be an important aspect of feasibility, the pre-
randomisation, double-consent design in which only patients in the experimental 
condition would be exposed to medication intake, seemed to be the best option.  
 
Figure 1. Overview pre-randomisation, double-consent design. 
 
    
 
Nevertheless, the pre-randomisation, double-consent design has some 
disadvantages as well. Selective dropout can occur when second informed 
consent has to be provided, which may also result in an extended patient 
enrolment to achieve the required sample size (Torgerson and Roland, 1998). 
Moreover, blinding of participants who receive the experimental treatment is not 
Assessment for eligibility 
Randomisation 
Allocation to experimental group  
(CBT plus study medication) 
 
Informed consent II 
Start study treatment 
Informed consent I 
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possible, which may cause an expectation bias in patients, as well as in treatment 
staff and investigators. This may influence post-randomisation treatment 
decisions and reported outcomes, and might partly limit the evidence of clinical 
benefit of the study medication. Comparable problems can also occur when 
patients in the control condition become aware of the experimental condition, for 
instance when patients share the same drug scene and talk about study 
participation. Despite these disadvantages, we believed that this choice was 
defendable given the feasibility character of the trials, in which  for the first time 
in the Netherlands  acceptance, safety and efficacy of pharmacotherapy would 
be explored in crack-cocaine dependent patients, before executing one or more 
full-scale randomised controlled trials. 
 
The topiramate and modafinil trials were conducted in outpatients of the 
addiction treatment services in The Hague (Brijder Addiction Care; both trials) and 
Amsterdam (Jellinek, Mentrum; modafinil trial) among patients who were either 
new referrals or already received treatment for concurrent substance 
dependence, including case management or methadone maintenance treatment, 
but with insufficient results regarding their crack-cocaine use. 
 
SR dexamfetamine trial 
In the SR dexamfetamine trial, a standard randomised, placebo-controlled design 
was used, which was different from the original study protocol and this choice 
was based on two major arguments. First, the acceptance of pharmacotherapy in 
terms of providing second informed consent, which was an important outcome 
variable in all three feasibility trials and was also reason to use the pre-
randomisation, double-consent design, had meanwhile been demonstrated in the 
topiramate and modafinil trials; the vast majority agreed to sign the second 
informed consent. Thus, a design in which both treatment groups would receive 
medication was plausible. Second, from correspondence with professor 
Grabowski, who conducted several trials with 60 mg/day SR dexamfetamine 
among cocaine dependent patients (Grabowski et al., 2001; Grabowski et al., 
2004a), we learned that patients were generally unable to distinguish active 
medication from placebo. This suggested that dropout would not be different 
between the patients from the active and inactive medication group, since their 
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expectations of the study medication were likely to be comparable in terms of 
both effects and side-effects. Given that the randomised double-blind, placebo-
controlled design is the most powerful research design, as well as the fact that the 
SR dexamfetamine for the current trial was manufactured in the Netherlands and 
that manufacturing of identical placebo tablets could also be accomplished, it was 
decided to change the original pre-randomisation, double-consent design to a 
standard randomised, double-blind, placebo-controlled design.  
Also different from the original study protocol, the SR dexamfetamine trial was 
conducted in crack-cocaine dependent patients with comorbid heroin 
dependence, participating in heroin-assisted treatment (HAT), based on the 
following line of reasoning: 
1. The vast majority of chronic, crack-cocaine dependent patients in the 
Netherlands – both inside and outside the addiction treatment system – have a 
concurrent chronic heroin dependency (Oteo Perez et al., 2012). 
2. From those in treatment for combined crack-cocaine and heroin dependence, 
the vast majority of patients participate in an opioid substitution program, 
predominantly methadone maintenance treatment. Studies have consistently 
shown that the effect of methadone maintenance on cocaine use in heroin 
dependent patients is limited at best (Castells et al., 2009; Van den Brink, 2012). 
3. Approximately 500-600 patients in the Netherlands with combined crack-
cocaine and heroin dependence currently participate in an opioid substitution 
program with medically prescribed heroin: heroin-assisted treatment (HAT). 
Studies have indicated that HAT results in substantial reductions in illegal heroin 
use, and large improvements in physical and mental health and social functioning 
in chronic, treatment-resistant heroin dependent patients (Blanken et al., 2010b; 
Van den Brink et al., 2003). However, among patients who concurrently used 
crack-cocaine – 84-90% of the patients in HAT – only modest reductions in crack-
cocaine use were observed (Blanken et al., 2010b). 
4. For reasons of both medical and public order safety, and given that SR 
dexamfetamine is not (yet) a registered medication in the Netherlands and is 
subject to the Dutch Opium Act, it was important that the present study would be 
conducted in a treatment setting with sufficient – treatment and research – 
experience in using strict safety procedures with respect to the storage, staff-
supervised prescription, and prevention of diversion of controlled study 
 
22  CATCH 
medication, monitoring of (serious) adverse events, and drug accountability. 
Given their extensive experience with prescribing diacetylmorphine to heroin 
dependent patients, heroin-assisted treatment programs were fully equipped to 
meet these requirements. Two HAT-settings in Amsterdam (Public Health Care 
[GGD]), one in Rotterdam (Bouman) and one in The Hague (Brijder Addiction 
Treatment) were involved. Patients who participated in the SR dexamfetamine 
study received either 12 weeks 60 mg/day SR dexamfetamine or placebo parallel 
to their medically prescribed heroin and methadone. 
 
Participants 
Participants in the three trials were adult outpatients who were cocaine 
dependent (American Psychiatric Association, 1994) in the last year and who used 
their cocaine predominantly by basing (‘crack’) for at least eight days per month. 
The most important exclusion criteria were: severe somatic problems (e.g. renal 
insufficiency or cardiovascular problems), severe psychiatric problems (e.g. acute 
psychosis, suicidality), need for inpatient treatment, and current pharmacological 
treatment with a potentially effective agent for cocaine dependence (i.e. 
naltrexone, baclofen, acamprosate, disulfiram, or methylphenidate). Given the 
agonistic nature of SR dexamfetamine, eligible patients in the dexamfetamine trial 
had to be cocaine dependent in the previous five years and had to be treatment-
refractory in terms of having a history of at least two failed treatments directed at 
reduction of or total abstinence from cocaine use. 
 
Outcome measures  
Study outcome measures included treatment retention in CBT (topiramate and 
modafinil trials), self-reported and urine-based crack-cocaine use, cocaine craving, 
other substance use, and improvements in health and social functioning (all three 
trials). In addition, acceptance in terms of willingness to participate in 
pharmacotherapy, medication adherence and patient satisfaction, as well as 
safety, assessed by the occurrence of (serious) adverse events, were measured. 
In the modafinil study, given the potentially cognitive enhancing capacities of 
modafinil, changes in cognitive performance (i.e. impulsivity and attentional bias) 
were also assessed. 
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Additional information on assessments (time points and instruments) and data 
analyses is described in the following chapters. 
 
Content of the present thesis 
This thesis presents the results of the CATCH project, investigating new 
pharmacological treatment options for crack-cocaine dependence in the 
Netherlands. In the Chapters 2 and 3, the acceptance, efficacy and safety of 200 
mg/day topiramate and 400 mg/day modafinil are evaluated in crack-cocaine 
dependent outpatients, respectively. The interrelationship between modafinil, 
impulsivity and attentional bias, and clinical outcomes in this study population is 
described in Chapter 4. Acceptance, efficacy and safety of 60 mg/day sustained-
release dexamfetamine as agonist pharmacotherapy in chronic, treatment-
refractory, cocaine dependent patients with comorbid opioid dependence in 
heroin-assisted treatment are evaluated in Chapter 5. Chapter 6 contains the 
Summary and general discussion in which the empirical findings of the three trials 
are summarised and discussed in a broader context, and ends with conclusions 
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Abstract 
Background: Crack-cocaine dependence is a complex disorder with limited 
treatment options. Topiramate is one of the promising medications with reported 
reductions in cocaine use and craving in former studies. The present study 
evaluated the acceptance and effectiveness of topiramate as an add-on to 
cognitive behavioural therapy (CBT) in crack-cocaine dependent patients. 
Methods: Seventy-four crack-cocaine dependent outpatients participated in an 
open-label, randomised feasibility trial. They were randomised to receive either 
12-week CBT plus topiramate (200 mg/day) or 12-week CBT only. The primary 
outcome measure was treatment retention. Secondary outcomes included 
medication adherence, safety, cocaine and other substance use, health, social 
functioning, and patient satisfaction.  
Results: Adherence to topiramate treatment was low. In the intent-to-treat 
analyses, topiramate neither improved treatment retention nor reduced cocaine 
and other substance use. Post hoc, exploratory analyses suggested a moderation 
effect of comorbid opioid dependence, with a significant effect of topiramate on 
cocaine use reduction only in crack-cocaine dependent patients with comorbid 
opioid dependence. 
Conclusions: Topiramate was safe and well-tolerated in this sample of crack-
cocaine dependent patients, but efficacy was not supported probably due to low 
acceptance of the treatment. Given the equivocal results of previous studies and 
the negative findings in our study, the potential of topiramate in the treatment of 
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Introduction  
Crack-cocaine use is associated with a wide range of medical, psychiatric and 
social problems for the individual and with significant public nuisance 
(Degenhardt and Hall, 2012; United Nations Office on Drugs and Crime, 2012). In 
the Netherlands, cocaine-related annual treatment demand increased from 9,300 
patients in 1995 to 19,000 in 2008, with a subsequent decline to 17,000 patients 
in 2010 (Trimbos-instituut, 2012). More than half of these patients are using 
crack-cocaine (Wisselink et al., 2013).  
Given the absence of proven effective medications for the treatment of 
cocaine dependence, virtually all cocaine dependent patients receive a standard 
offer of psychosocial treatment (Lingford-Hughes et al., 2012), but  with the 
exception of contingency management (Lussier et al., 2006; Prendergast et al., 
2006)  psychosocial interventions have shown modest results, mainly due to 
poor compliance (Dutra et al., 2008; Knapp et al., 2007; Shearer, 2007).  
The past decade has shown an upsurge in research investigating 
pharmacological agents for the treatment of cocaine dependence (Kampman et 
al., 2005; Karila et al., 2008; Preti, 2007; Van den Brink, 2012), including 
antipsychotics (Amato et al., 2007), anticonvulsants (Alvarez et al., 2010; Minozzi 
et al., 2008), antidepressants (Pani et al., 2011), psychostimulants (Castells et al., 
2010; Shearer, 2008), (other) dopamine agonists (Amato et al., 2011; Herin et al., 
2010), and  on an experimental basis  anti-cocaine vaccines (Kosten et al., 
2013).  
In these studies, two basic strategies can be distinguished: one focused at 
substantial reduction or abstinence from cocaine use, and the other directed at 
minimizing cocaine-related harm by replacing the short-acting, illicit stimulant 
cocaine by a long-acting, legal stimulant that can be taken orally (Grabowski et al., 
2004b; Shearer, 2008).  
The anticonvulsant topiramate and the alpha-adrenergic/glutamate agonist 
modafinil are examples of promising medications for the first strategy (Johnson, 
2005; Karila et al., 2008; Shearer, 2008; Shinn and Greenfield, 2010; Van den 
Brink, 2012), whereas the monoamine reuptake inhibitor dexamfetamine, 
particularly in sustained-release form, is an important candidate for the second 
strategy (Grabowski et al., 2004b; Shinn and Greenfield, 2010; Van den Brink, 
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2012). Against this background, topiramate, modafinil and sustained-release 
dexamfetamine were investigated in three separate feasibility trials in the 
Netherlands in project CATCH: Cocaine Addiction Treatments to improve Control 
and reduce Harm (Nuijten et al., 2011). The present paper reports on the results 
of the first trial, pertaining to topiramate. 
Topiramate is approved in Europe for the treatment of migraine and epilepsy. 
Among its different mechanisms of action, topiramate lowers dopamine levels by 
enhancing gamma-aminobutyric acid (GABA) and antagonizing the glutamatergic 
system (Johnson, 2005; Shinn and Greenfield, 2010). Previous studies with 
topiramate in the addiction field have suggested that it may be effective in the 
treatment of alcohol dependence (Arbaizar et al., 2010) and methamphetamine 
dependence (Elkashef et al., 2012; Vocci, 2012). Concerning cocaine dependence, 
two trials with topiramate were conducted prior to the start of the current study, 
with mixed results. In a double-blind randomised trial in 40 (predominantly crack-) 
cocaine dependent patients, topiramate (200 mg/day), as an adjunct to cognitive 
behavioural therapy, was significantly more effective in promoting (sustained) 
abstinence than placebo (Kampman et al., 2004). However, in an uncontrolled 
study among 28 intranasal cocaine users who received topiramate (maximum 300 
mg/day) and assertive strategic counselling, cocaine craving was significantly 
reduced, but only 25% of the urine samples were negative for cocaine metabolites 
(Reis et al., 2008).  
In the present trial we evaluate the acceptance and efficacy of topiramate as 
an add-on to cognitive behavioural therapy (CBT) compared to CBT alone in crack-
cocaine dependent patients with treatment retention as the primary outcome 
measure and with medication adherence, safety, cocaine and other substance 
use, cocaine craving, health, social functioning, and patient satisfaction as 




The study was an open-label, randomised controlled feasibility trial. After 
screening and baseline assessment, participants were randomly assigned to the 
experimental group (outpatient CBT plus topiramate) or the control group 
(outpatient CBT only).  
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Given the high dropout rates in control groups in previous placebo-controlled 
trials in cocaine dependent participants (Kampman et al., 2005), and the feasibility 
character of this study, a pre-randomisation, double-consent design (Zelen, 1979) 
was used. Prior to randomisation, all participants were asked to provide informed 
consent about participating in a study evaluating the effectiveness of CBT. 
Following randomisation, a second informed consent, pertaining to the treatment 
with topiramate, was obtained only in those participants randomised to the 
experimental group. Hence, participants were only informed about the assigned 
treatment and not about the condition they were compared with (Nuijten et al., 
2011). Randomisation was computer-generated and stratified by gender, cultural 
background (European/ non-European) and participation in methadone 
maintenance treatment (MMT). 
The study has been registered in The Netherlands National Trial Register 
(NTR2576) and The European Union Drug Regulating Authorities Clinical Trials 
(EUdraCT 2009-010584-16). 
 
Participants and treatment setting 
Crack-cocaine dependent patients of Brijder Addiction Treatment in The Hague, 
the Netherlands, were asked to participate in the study. They were either new 
referrals to the addiction treatment service or existing patients in (methadone) 
treatment with continuing cocaine abuse. Enrolment occurred from August, 2010 
to December, 2012. Eligible patients had to (a) be at least 18 years old, (b) be 
cocaine dependent according to the Diagnostic and Statistical Manual of Mental 
Disorders Fourth Edition (DSM-IV) (American Psychiatric Association, 1994), (c) 
regularly use cocaine (≥8 days in the previous month), (d) administer cocaine 
primarily by means of basing, (e) be able and willing to participate in the study 
treatment and associated assessments, and (f) provide written informed consent. 
Patients were excluded in case of (a) severe medical (e.g. renal insufficiency, 
cardiovascular problems) or psychiatric problems (e.g. acute psychosis, 
suicidality), (b) pregnancy or breastfeeding, (c) pharmacotherapy with a 
potentially effective medication for cocaine dependence (i.e. naltrexone, 
disulfiram, acamprosate, methylphenidate, modafinil, dexamfetamine or 
baclofen), (d) indication for residential treatment, (e) insufficient command of the 
Dutch language, and (f) current participation in another addiction treatment trial. 
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Treatments 
Psychosocial treatment 
All patients received outpatient CBT (Kadden, 2001; Monti et al., 1997; Project 
MATCH Research Group, 1993; Rohsenow et al., 2000), which is the standard 
psychosocial substance abuse treatment in the Netherlands (De Wildt et al., 
2002). CBT was delivered in 12 weekly individual sessions of 45 min each by 
trained, experienced psychologists. Treatment goals included abstinence as well 




In the experimental group topiramate was prescribed for a period of 12 weeks as 
an add-on to CBT. Topiramate was initiated at 25 mg/day and was titrated within 
three weeks to a maximum oral dose of 200 mg/day, depending on the 
occurrence of adverse events. During the first treatment week, topiramate was 
prescribed daily at the treatment centre to monitor intake and adverse events. In 
the remaining trial period, topiramate was dispensed once weekly and self-
reported topiramate intake was registered at each study visit. 
Discontinuation of topiramate treatment had no consequences for the 




Assessments were performed at baseline, week four and eight (experimental 
group only), and week 12. At baseline, DSM-IV cocaine, alcohol and opioid 
dependence diagnoses (American Psychiatric Association, 1994) were obtained 
using the Composite International Diagnostic Interview-Substance Abuse Module 
(CIDI-SAM) (Cottler, 1990; Cottler, 2000). The Addiction Severity Index (ASI) 
(Hendriks et al., 1989; Kokkevi and Hartgers, 1995; McLellan et al., 1992) was used 
to assess substance use and other clinical characteristics.  
At all assessment points, the Time Line Follow-Back (TLFB) calendar method 
(Hjorthoj et al., 2012; Sobell and Sobell, 1992) was administered to collect 
information about the patients’ self-reported crack-cocaine use in the 30 days 
preceding each assessment. Cocaine craving was measured with the short, 
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adapted version of the Obsessive Compulsive Drinking Scale (OCDS) (Anton et al., 
1996; De Wildt et al., 2005; Franken et al., 2002). The Maudsley Addiction Profile-
Health Symptoms Scale (MAP-HSS) (Marsden et al., 1998) was used to assess 
physical health, and the Symptom Checklist-90 (SCL-90) (Arrindell and Ettema, 
1986; Derogatis et al., 1973) to identify psychological problems. All post-baseline 
assessments included the ASI substance use items and questions about current 
illegal activities and social contacts with non-drug users. The week 12 assessment 
was supplemented with the Client Satisfaction Questionnaire (CSQ-8) (De Wilde 
and Hendriks, 2005; Larsen et al., 1979). 
Co-medications and adverse events (AEs) were registered by trained research 
nurses at each study visit, and blood pressure and heart rate were measured at 
baseline and week 12. Urine samples were collected at baseline, and once weekly 
in the four weeks preceding the week 12 assessment, and were analysed on the 
presence of cocaine metabolites (benzoylecgonine [BE]). The 210 urine samples 
that were submitted in the final four weeks of the study (out of a planned total of 
74 x 4=296 urine-samples; 70.9%), showed 91.5% agreement between self-
reported cocaine use and BE-outcome (kappa=0.81). Pregnancy tests were 
conducted at baseline and every four weeks (experimental group only).  
Participants received a remuneration of €120 (control subjects) or €150 
(experimental subjects) for participating in the study assessments. 
 
Outcome measures  
The primary outcome measure was treatment retention defined as the number of 
CBT sessions attended (range 0-12). Secondary outcome measures were 
medication adherence, safety, cocaine use, cocaine craving, use of other 




Given the feasibility character of the study, the sample size was limited and a 
lenient two-sided alpha of 0.10 was chosen to prevent type-II errors. With a 
minimum difference in 12-week retention between the treatment groups of 25%, 
a power of 0.80, and a two-sided alpha of 0.10, 36 patients were required in each 
treatment group (ntotal=72). 
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Data analyses 
An intent-to-treat (ITT) approach was used to examine between-group 
differences, incorporating all randomised patients who provided informed 
consent pertaining to their assigned treatment.  
Baseline characteristics between groups were compared using Chi-square tests 
for dichotomous variables, and t-tests or Mann-Whitney U-tests for normal and 
non-normal distributed continuous variables, respectively. 
The primary study question compared treatment retention in a Cox 
proportional hazards regression model, analysing group differences in retaining 
patients in treatment during the 12-week study period based on the log-rank 
(Kaplan-Meier) statistic, censoring the hazard at the tenth CBT session. Baseline to 
week 12 changes in cocaine use days was compared between the two groups 
using 2 (time) x 2 (group) repeated measures ANOVA. Similar analyses were 
conducted for craving, concurrent substance use, and other continuous and 
Likert-scale outcome measures.  
Week 12 data was available for 89% of the ITT-population. Missing data of four 
participants in each group were estimated with multiple imputation, using five 
imputed datasets, with baseline variables as predictors.  
The sum of BE positive weekly urine samples during the four weeks preceding 
the week 12 assessment was evaluated by means of Poisson regression analysis, 
considering missing urine samples as positive. 
Topiramate treatment duration was assessed by the registered total days of 
self-reported intake. Mean topiramate dose was computed by summing the dose 
of all topiramate tablets that were ingested as registered in the medication file, 




Of the 161 patients that were assessed for eligibility, 82 patients met all selection 
criteria and were randomised after giving the first informed consent (Figure 1). 
Thirty-six of the 44 participants (81.8%) in the experimental group accepted the 
additional treatment offer of topiramate and gave the second informed consent. 
The final ITT-population consisted of 36 patients in the experimental and 38 
patients in the control group. 
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Figure 1. Flowchart of participants in the topiramate study. 
 
Assessed for eligibility (n=161) 
- new referrals (n=120) 
- existing in treatment (n=41) 
Informed consent I/ randomised (n= 82) 
Allocated to control group  
(n=38) 
 
Allocated to experimental 
group (n=44) 
 
Excluded by not meeting inclusion  
criteria (n=73) 
- preference for inpatient treatment 
(n=20) 
- infrequent basecoke use (n=18) 
- no cocaine related treatment demand 
(n=10) 
- declined to participate (n=20) 
- other reasons (n=5) 
Allocation 
Lost to follow-up (n=4 ) 
- declined participation (n=4) 
Lost to follow-up (n=4 ) 
- declined participation (n=3) 
- imprisonment (n=1) 
Follow-Up 
Analysis 
Excluded by not giving informed 
consent II (n=8)  
- refused medication (n=4) 
- drop out (n=4) 
Informed consent II (n=36) 
Analysed: intention-to-treat 
(ITT) population (n=36) 
Barred by exclusion criteria (n=6) 
- kidney and cardiovascular problems  
(n=1) 
- severe psychiatric problems (n=2) 
- interfering medication (n=3) 
Enrolment 
Analysed: intention-to-treat  
(ITT) population (n=38) 
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M (sd)/ % 
Control group  
(N=38) 





Recruitment    
New referrals (%) 72.2  73.7  
0.89 
Existing in treatment (%) 27.8  26.3  
Demographic background    
Age (years) 43.3 (8.7) 41.3 (9.8) 0.36 
Gender male (%) 81.6  81.6  0.60 
European background (%) 66.7  60.5  0.58 
Education (years) 11.3 (2.7) 11.1 (2.8) 0.66 
Employed (%)
a,b
 33.3 39.5 0.58 
Homeless (%) 5.6  7.9  0.69 
Substance use    
Lifetime regular cocaine use (years) 11.9 (7.8) 13.8 (9.7) 0.54 
BE-positive baseline urine (%) 77.8  84.2  0.48 
Cocaine use (days)
a
 20.0 (7.6) 19.2 (7.0) 0.64 
Alcohol use ≥5 units (%)
a,b
 38.9  28.9  0.37 
Heroin use (%)
a,b
 27.8  31.6  0.72 
Cannabis use (%)
a,b
 50.0  57.9  0.50 
Treatment status& history    
Opioid dependence (%) 38.9 36.8 0.86 
Alcohol dependence (%) 16.7 10.5 0.44 
Prescribed medication for physical problems (%) 36.1 21.1 0.15 
Prescribed medication for mental problems (%) 16.7 28.9 0.21 
Methadone maintenance treatment (%) 36.1  36.8  0.95 
Methadone dose (mg) 64.2 (36.4) 66.3 (32.3) 0.84 
Multiple prior drug-related treatments (%) 58.3 57.9 0.97 
Health & social functioning    
MAP total score (0-40) 14.1 (6.7) 12.0 (6.9) 0.19 
SCL-90 total score (0-360) 91.4 (54.5) 86.1 (51.6) 0.96 
OCDS total score (0-20) 8.7 (3.9) 9.1 (3.6) 0.60 
Illegal activities to obtain money/ drugs (days)
a
 2.2 (5.1) 2.2 (6.1) 0.86 
Social contacts with non-drug users (days)
a
 22.5 (11.8) 23.5 (11.5) 0.75 
a
 In the preceding 30 days; 
b
 At least one day; 
c
 Using Chi-square tests for dichotomous variables; t-
tests for continuous variables; nonparametric Mann-Whitney U tests for continuous variables with 
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Baseline characteristics 
Baseline characteristics of the participants are summarised in Table 1. Participants 
could be characterised as chronic cocaine dependent patients, with a history of 
multiple treatments and concurrent drug use. About one-third of the patients in 
both treatment conditions were also in methadone maintenance treatment. 
Baseline characteristics did not differ significantly between the treatment groups. 
 
Medication adherence 
Topiramate titration (3 weeks) was completed by 28 participants (77.6%). Of 
these, 27 participants were prescribed the maximum dose of 200 mg/day and one 
patient received 150 mg/day due to adverse events. Twenty-two patients (61.1%) 
received topiramate treatment for at least 6 weeks, nine patients (25.0%) for at 
least 9 weeks and five patients (13.9%) completed at least 11 weeks. The mean 
dose of topiramate in the 28 ‘titration completers’ was 189 mg/day (sd=32.1).  
Of the 31 patients who discontinued topiramate treatment before week 11, 10 
received CBT for at least one more session after topiramate discontinuation 
(32.3%). Since the majority of patients who discontinued topiramate did not 
inform the clinical staff, reasons for medication non-adherence remained unclear 
for most patients. 
 
Treatment retention 
Participants in the experimental group attended a mean of 6.8 CBT sessions 
(sd=3.6) and those in the control group 5.2 (sd=4.1). Ten or more sessions were 
completed by 36.1% in the experimental group and 26.3% in the control group.  
Cox regression survival analysis (Figure 2) indicated somewhat better 
treatment retention in the experimental group compared to the control group, 
but the difference was not significant (HR=0.67; 95% CI=0.41.2; p=0.15). 
 
Crack-cocaine use  
Baseline to week 12 reductions in self-reported crack-cocaine use days were 
significant in both groups combined (F=76.0; df=1; p<0.001; Cohen’s d=1.11), but 
these reductions did not significantly differ between treatment groups (F=1.6; 
df=1; p=0.23) (Table 2). 
 
36  CATCH 
In the experimental group 25.7% and in the control group 32.2% of the urine 
samples in the last four weeks were not submitted and hence considered BE-
positive. The mean number of positive urine samples was rather high with 3.2 
(sd=1.4) and 3.1 (sd=1.2) positive samples in the experimental and control group, 
respectively. Poisson regression analysis did not show significant group 
differences (Exp(B)=0.96; 95% CI=0.741.25; p=0.78). 
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Other secondary outcome measures 
For the other outcome variables (Table 2) there were significant baseline to week 
12 time effects for craving (d=0.81), physical health (d=0.59) and mental health 
(d=0.65). However, repeated measures ANOVA did not show significant baseline 
to week 12 between-group differences for any of the outcome variables (Table 2).  
Satisfaction with the treatment offer (CSQ-8) at the end of the study did not 




No serious adverse events occurred. One or more adverse events were reported 
during the study by 72.2% in the experimental group and by 13.2% in the control 
group. The number of adverse events per patient in the experimental group 
varied between one (n=4) and 15 (n=1), with 38.5% (n=10) of the patients 
reporting two adverse events. Of the 95 reported adverse events in the 
experimental group, 27 (28.4%) were probably or definitely related to the study 
medication. The majority of the adverse events was transient and evaluated as 
mild (72.6%), with paraesthesia (29.5%), gastro-intestinal complaints (16.8%) and 
fatigue (12.6%) being most frequently reported.  
 
Post hoc, exploratory analyses 
Given the overall lack of treatment effect, we conducted two types of exploratory 
analyses to test whether differences in baseline characteristics may have 
confounded the effect of the topiramate treatment, in terms of treatment 
retention and reduction in crack-cocaine use. The following baseline 
characteristics that have been shown to affect treatment outcome in earlier 
studies, were selected: presence of baseline cocaine-positive urine (Ahmadi et al., 
2009; Kampman et al., 2001; Poling et al., 2007; Sofuoglu et al., 2003), days of 
cocaine use in the month before baseline (Ahmadi et al., 2009; Means et al., 1989; 
Poling et al., 2007; Westhuis et al., 2001), cocaine craving (Sinha et al., 2006; 
Weiss et al., 1997), and concurrent alcohol use (Alterman et al., 2000; Poling et 
al., 2007). In addition, comorbid opioid dependence was included as a potential 
confounder. Continuous covariates were dichotomised based on the median due 
to non-linearity with the outcome variable. First, each baseline characteristic was 
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entered to the original model as a covariate. Baseline covariates that resulted in a 
change of at least 10% in the B-value of treatment condition, were entered into 
the final regression model. Second, we analysed whether the selected baseline 
characteristics differentially moderated treatment outcome, by adding their 
interaction with treatment group into the regression model. 
Concerning treatment retention as outcome variable, adding number of 
cocaine use days in the month preceding baseline as a covariate to the original 
regression model resulted in a reduction in B from –0.41 to –0.49 (Table 3a). 
Similarly, opioid dependence resulted in more than 10% change in the B-value. 
Although alcohol use as a single variable resulted in ≥10% change in B, its 
contribution disappeared when this variable was added to the model together 
with the other covariates. In our final model – with baseline cocaine use and 
opioid dependence as covariates – CBT plus topiramate resulted in significantly 
better treatment retention than CBT only (B=–0.64; HR=0.53; 95% CI: 0.31.0; 
p=0.03). 
Concerning baseline to week 12 changes in crack-cocaine use as an outcome 
variable, number of baseline cocaine use days was identified as a confounder 
(reduction in B from 2.67 to 2.13), but did not improve the model significantly 
(Table 3b). 
 
Table 3a. Outcomes of explorative analyses: Treatment retention. 
 Treatment retention: 
Original model: B=–0.41; HR=0.67; 95% CI: 0.41.2 
 Original model 
+ covariate 
 Interaction  
group x covariate 
 
 B HR 95% CI  B HR 95% CI p 
Crack-cocaine use –0.49 0.61 0.4–1.1  –0.16 0.85 0.3–2.6 0.78 
Cocaine-positive urinalysis –0.42 0.66 0.4–1.2  –0.02 0.98 0.3–3.8 0.97 
Cocaine craving –0.41 0.67 0.4–1.2  0.12 1.13 0.4–3.4 0.83 
Alcohol use ≥5 units  –0.35 0.70 0.4–1.2  0.21 1.24 0.4–4.1 0.73 
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Table 3b. Outcomes of explorative analyses: Changes in crack-cocaine use. 
 Baseline to week 12 crack-cocaine use days: 
Original model: B=2.67; T=1.21; 95% CI: –1.77.0 
 Original model 
+ covariate 
 Interaction  
group x covariate 
 B 95% CI  B 95% CI p 
Crack-cocaine use 2.13 –2.0–6.2  1.72 –6.4–9.9 0.68 
Cocaine-positive urinalysis 2.72 –1.7–7.1  1.08 –10.2–12.4 0.85 
Cocaine craving 2.69 –1.7–7.1  –2.50 –11.2–6.2 0.57 
Alcohol use ≥5 units  2.72 –1.7–7.1  1.43 –8.0–10.9 0.77 
Opioid dependence 2.74 –1.6–7.0  9.14 0.4–17.9 0.04 
 
No moderators of the effect of topiramate on treatment retention were found, 
but there was a significant interaction effect of treatment group x opioid 
dependence on the reduction of cocaine use (B=9.14; 95% CI: 0.417.9; p=0.04) 
(Table 3b). In the opioid dependent subgroup, topiramate plus CBT resulted in 
greater reductions of mean cocaine use days than CBT only (M=11.6 vs. M=3.1, 
resp.), whereas the reduction in cocaine use was very similar for the experimental 
and control condition in the subgroup without opioid dependence (M=10.3 vs. 
M=11.0). 
 
Crack-cocaine use in treatment continuers 
An additional, explorative repeated measures ANOVA of baseline to week 12 
changes in crack-cocaine use was conducted among patients who attended at 
least six CBT sessions (both groups) and took topiramate for at least six weeks 
(experimental group only). Experimental ‘treatment continuers’ (n=19) reduced 
their mean crack-cocaine use from 18.4 days (sd=7.6) to 7.0 days (sd=7.1) and 
control ‘treatment continuers’ (n=16) from 17.0 days (sd=7.2) to 4.7 days (sd=5.6). 
There was a significant time effect (F=81.8; df=1; p<0.00), but the time x group 
interaction effect was not significant (F=0.1; df=1; p=0.74), indicating the absence 
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Discussion  
In the present open-label, randomised controlled feasibility trial, acceptance, 
safety and efficacy of max. 200 mg/day topiramate as an add-on to cognitive 
behavioural therapy (CBT) in crack-cocaine dependent patients were tested. The 
study found that topiramate’s acceptance was generally low. Although 82% of the 
patients in the experimental group agreed to start topiramate treatment (second 
informed consent), only 14% took topiramate for at least 11 of the 12 weeks. 
Similar patient satisfaction with the treatment received (i.e. CBT only versus CBT 
plus topiramate) in both groups suggested no perceived added value for 
topiramate. Topiramate was generally well-tolerated, with mostly mild and 
transient adverse events and no serious adverse events.  
There were also no indications of efficacy of topiramate in CBT retention (low 
retention rates in both treatment conditions), crack-cocaine use and craving, 
concurrent substance use, health and social functioning. How do these findings 
relate to those of previous studies?  
In the study of Kampman and colleagues (2004), topiramate-treated patients 
were more likely to be abstinent from cocaine than placebo-treated patients, but 
this effect occurred only during the last four weeks (‘full-dose period’) of the trial 
period. In a more recent study, Kampman et al. (2013) found no significant 
difference between topiramate and placebo in weekly cocaine abstinence during 
the total trial period. However, post hoc, exploratory analyses indicated that more 
topiramate-treated than placebo-treated patients had three consecutive weeks of 
cocaine abstinence at the end of the trial. Similarly, Johnson et al. (2013) found 
topiramate to be more efficacious than placebo at increasing the weekly 
proportion of cocaine abstinent days during the full-dose period (week 6-12) and 
topiramate increased the likelihood of cocaine abstinent weeks during both the 
full-dose and the total trial period. These results, however, were obtained in a 
model with age of onset of cocaine use, gender, ethnicity, and baseline cocaine 
use as covariates, and topiramate’s unadjusted effects were not reported. Lastly, 
Mariani and colleagues (2012) found that combined treatment with extended-
release mixed amphetamine salts (MAS-ER) plus topiramate was no better than 
placebo in achieving three consecutive weeks of cocaine abstinence during the 
trial period. Post hoc, exploratory analyses suggested that MAS-ER plus 
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topiramate was more effective in a subgroup of patients with high baseline 
cocaine use frequency.  
In sum, the evidence for topiramate in the treatment of cocaine dependence is 
mixed, with two studies (Johnson et al., 2013; Kampman et al., 2004) showing a 
favourable effect of topiramate during the full-dose period according to the a 
priori planned analysis, and two studies (Kampman et al., 2013; Mariani et al., 
2012) in which topiramate (with or without MAS-ER) was only better than placebo 
in post hoc, exploratory analyses or in subgroups. Our study most clearly 
represents a ‘negative trial’, with no effect of topiramate in any of the a priori 
planned analyses and with an indication of effect only in the subgroup with 
comorbid opioid dependence. Possible explanations for the negative findings in 
the current study are: (1) lower adherence to the study medication; (2) 
differences in patient characteristics; (3) differences in study design and 
treatment offer, and/ or (4) differences in treatment context.  
First, low medication adherence is very likely to have contributed to the 
negative outcomes in the current study: topiramate adherence was much lower 
(only 14% treatment completers) than in previous RCTs (Johnson et al., 2013; 
Kampman et al., 2004; Kampman et al., 2013; Mariani et al., 2012). It should be 
emphasised that, in contrast to the present study, medication adherence in all 
these studies was encouraged by remuneration of study visits or returning 
medication packages, and by compensating for transportation costs per visit, i.e. 
incentive-based interventions that are effective in reducing non-adherence 
(DeFulio and Silverman, 2012; Weiss, 2004). Hence, the lack of reinforcement to 
comply with study procedures in our trial might be a possible explanation for the 
generally low medication adherence. Moreover, previous studies suggest that 
topiramate dose and duration of exposure play an important role (Johnson et al., 
2003; Kampman et al., 2004). The limited and irregular intake of topiramate in the 
present study might have obscured the therapeutic potential of topiramate in our 
patients with crack-cocaine dependence.  
Second, cocaine dependent patients in previous RCTs generally showed lower 
baseline levels of cocaine use, ranging from 6-8 days/month (Kampman et al., 
2004) to 12-13 days/month (Johnson et al., 2013; Kampman et al., 2013; Mariani 
et al., 2012) and no serious polydrug use. In the current study, patients used 
crack-cocaine on 19-20 days/month at baseline. The lack of efficacy in our study 
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is, however, not likely to be caused by high cocaine addiction severity, because 
Mariani et al. (2012) and Kampman et al. (2013) found positive subgroup effects 
in frequent compared to less frequent cocaine users and in patients with more 
compared to patients with less severe cocaine withdrawal, respectively. 
Importantly, about one-third of the cocaine dependent patients in our study were 
also opioid dependent. Adjustments for both baseline cocaine use days and opioid 
dependence resulted in significant group differences in treatment retention, and 
efficacy of topiramate in crack-cocaine use reductions was observed in patients 
with comorbid opioid dependence. Thus, previous studies and our trial suggest 
that topiramate is more likely to be effective in patients with high cocaine 
addiction severity and/or comorbid opioid dependence. 
Third, the present study also differs in study design compared to the previous 
trials. Although our 12-week study period was comparable, our trial differed in 
length of titration period: three weeks compared to six (Johnson et al., 2013; 
Mariani et al., 2012) or eight (Kampman et al., 2004; Kampman et al., 2013). 
Moreover, the 200 mg/day dose was lower than the 300 mg/day dose in the 
studies of Kampman et al. (2013), Mariani et al. (2012) and Johnson et al. (2013). 
Despite the fact that our patients could take advantage of the full topiramate 
dose for a longer period, the daily dosage of 200 mg may have been too low and 
could therefore have contributed to topiramate’s observed inefficacy. 
Finally, this is the first study of topiramate in cocaine dependent patients 
outside the USA, where the health care and social security systems are different. 
In the Netherlands, drug services are freely accessible for every citizen and social 
security is guaranteed for everyone. As a consequence, patients may feel less 
pressured to participate in a trial to receive (free) treatment. These contextual 
differences might have affected levels of motivation and, thus, adherence and 
treatment outcomes. 
Several study limitations should be considered. First, the open-label character 
of the trial may have caused bias due to patients (and investigators) being aware 
of their treatment allocation, which may have influenced their post-
randomisation treatment decisions and reported outcome. Given that no 
differences in treatment were found, we believe this bias did not occur, however. 
Second, urine samples were collected once-weekly and only during the last four 
weeks of study treatment. However, agreement between self-reported cocaine 
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use and urinalysis outcome was high (kappa=0.81), and both measures were 
consistent in showing no difference in treatment outcome between the two study 
groups. 
In sum, topiramate with doses up to 200 mg/day was safe and well-tolerated 
in the treatment of crack-cocaine dependent patients, but its acceptance was low. 
Likely due to this low acceptance, there were no significant effects of topiramate 
on treatment retention, nor on cocaine and other substance use. Post hoc, 
exploratory analyses suggested that topiramate may be effective in reducing 
cocaine use in cocaine dependent patients with comorbid opioid dependence. To 
conclude, given the equivocal results of previous studies and the largely negative 
findings in our study, the potential of topiramate in the treatment of cocaine 
dependence seems limited.  
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Abstract 
Background: Crack-cocaine dependence is a serious disorder with no approved 
pharmacological treatment. Modafinil is a promising medication with increased 
cocaine abstinence and reduced craving in some previous studies. In the present 
study, we examined the acceptance, safety and potential benefits of modafinil as 
an add-on treatment to cognitive behavioural therapy (CBT) in crack-cocaine 
dependent patients. 
Methods: Sixty-five crack-cocaine dependent outpatients participated in an open-
label, randomised feasibility trial. Patients were randomised to receive either 12-
week individual CBT plus 400 mg/day modafinil or 12-week individual CBT only. 
The primary outcome measure was CBT treatment retention. Secondary 
outcomes included modafinil adherence, tolerability and safety, use of cocaine 
and other substances, cocaine craving, health, social functioning and patient 
satisfaction.  
Results: Modafinil adherence was low, with only 10% treatment completers. 
Intent-to-treat analyses showed that modafinil did not improve CBT treatment 
retention or any of the secondary cocaine-related outcomes. Both groups showed 
similar, large reductions in cocaine use during the study treatment. Post hoc 
exploratory analyses within the CBT plus modafinil group showed significantly 
larger baseline to week 12 reductions in cocaine use days in high (≥8 weeks) 
modafinil adherent patients. 
Conclusions: Acceptance and benefits of modafinil were not demonstrated in the 
present study. Since reduction in cocaine use was observed in high modafinil 
adherent patients, further research in the treatment of cocaine dependence, in 
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Introduction  
Cocaine use disorder, particularly use of cocaine in its base form ('crack'), puts a 
heavy burden on both the user and society worldwide, including medical, socio-
economic and judicial consequences (Degenhardt and Hall, 2012; United Nations 
Office on Drugs and Crime, 2012). In the Netherlands (16.8 million inhabitants), 
annual demand for cocaine-related addiction treatment increased from 8,500 
cases in 1994 to almost 16,000 in 2008, and subsequently declined somewhat to 
almost 13,000 in 2012 (Trimbos-instituut, 2013). Smoking or ‘basing’ cocaine is 
the predominant route of administration (52%) and most cocaine dependent 
patients have a history of multiple treatment episodes (Wisselink et al., 2014).  
With the exception of contingency management (Lussier et al., 2006; 
Prendergast et al., 2006), psychosocial interventions for cocaine dependence – 
including cognitive behavioural therapy (CBT) and relapse prevention – have 
shown modest results, and both study data and treatment practice indicate that 
poor compliance is a major factor complicating these treatments (Dutra et al., 
2008; Knapp et al., 2007; Shearer, 2007). Nevertheless, since there is no approved 
medication for cocaine dependence and contingency management is not very well 
socially accepted, the current treatment offer for virtually all cocaine dependent 
patients still consists of CBT and relapse prevention (Lingford-Hughes et al., 2012). 
However, increasing knowledge about the neurobiology of cocaine 
dependence has led to a growing number of studies searching for effective 
pharmacological agents with an effect on the neurochemistry of cocaine 
(Kampman et al., 2005; Karila et al., 2008; Preti, 2007). These agents include 
antipsychotics (Alvarez et al., 2013; Amato et al., 2007; Kishi et al., 2013), 
anticonvulsants (Alvarez et al., 2010; Minozzi et al., 2008), antidepressants (Pani 
et al., 2011), psychostimulants (Castells et al., 2010; Mariani and Levin, 2012; 
Shearer, 2008), other dopamine agonists (Amato et al., 2011; Herin et al., 2010; 
Perez-Mana et al., 2011), and anti-cocaine vaccines (Kosten et al., 2013). One of 
the most promising compounds directed at reduction of or abstinence from 
cocaine use is the alpha-adrenergic/glutamate agonist modafinil (Karila et al., 
2008; Shearer, 2008; Van den Brink, 2012). Modafinil is a wakefulness-promoting 
agent that is registered for the treatment of narcolepsy. It possesses stimulant-
like effects as a consequence of inhibiting dopamine reuptake (Volkow et al., 
 
50  CATCH 
2009) and it has been suggested that these neurobiological effects can normalise 
brain chemistry and reduce substance use (Herin et al., 2010). 
Prior to the start of this study, promising effects of modafinil were found in 
terms of reduction of cocaine use and craving in two studies. In a randomised 
placebo-controlled trial of 62 cocaine dependent patients, 400 mg/day modafinil 
significantly increased weekly cocaine abstinence (primary outcome) and 
protracted abstinence (secondary outcome)(Dackis et al., 2005). In another 
placebo-controlled trial of 210 cocaine dependent treatment seeking patients, no 
differences in the percentage of cocaine abstinent days (primary outcome) were 
found between 200 and 400 mg/day modafinil and placebo, but 200 mg/day 
modafinil showed effect in two secondary outcomes: increased maximum number 
of consecutive cocaine abstinent days and reduced craving. Post hoc analyses 
showed increased weekly abstinence in patients without comorbid alcohol use 
(Anderson et al., 2009). 
Given these promising findings, the present open-label randomised controlled 
feasibility trial evaluated the acceptance, safety and potential benefits of 400 
mg/day modafinil as an add-on to CBT compared with CBT only, in crack-cocaine 
dependent patients, with retention in CBT treatment as the primary outcome 
measure and with medication adherence, tolerability and safety, use of cocaine 
and other substances, cocaine craving, health, social functioning and patient 
satisfaction as secondary outcome measures.  
 
Materials and methods  
Design 
The study is the second trial of project CATCH (Cocaine Addiction Treatments to 
improve Control and reduce Harm) in which three pharmacological agents – 
topiramate, modafinil and slow-release dexamfetamine – are being investigated 
in three separate studies in crack-cocaine dependent patients in the Netherlands 
(Nuijten et al., 2011, 2014). Similar to the first trial of topiramate (Nuijten et al., 
2014), this study was designed as an open-label, randomised controlled feasibility 
trial. After screening and baseline assessment, participants were randomly 
assigned to the experimental group (individual outpatient CBT plus modafinil) or 
the control group (individual outpatient CBT only). Earlier studies have shown 
selective treatment discontinuation of patients in (placebo) control groups 
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(Kampman et al., 2005; Karila et al., 2008; Preti, 2007). In order to minimise this 
non-compliance and loss to follow-up among control patients due to 
disappointment about being randomised to the less attractive non-experimental 
intervention, a pre-randomisation, double-consent design (Zelen, 1979) was used. 
In this design, a first informed consent, pertaining to the standard psychosocial 
treatment (i.e. CBT), was provided by all participants, and a second informed 
consent, pertaining to the pharmacological treatment (i.e. modafinil), was 
obtained from those participants randomised to the experimental group. Hence, 
participants were informed only about the assigned treatment and not about the 
condition with which they were being compared (see also Nuijten et al., 2011).  
If indicated, patients received a short (maximum 7 days) inpatient 
detoxification and psychosocial stabilisation treatment. Randomisation was 
computer-generated and stratified by gender, cultural background 
(European/non-European), participation in methadone maintenance treatment 
(MMT; yes/no), and inpatient stabilisation (yes/no). 
The CATCH study is registered in The Netherlands National Trial Register 
(NTR2576) and The European Union Drug Regulating Authorities Clinical Trials 
(EUdraCT 2009-010584-16). 
 
Participants and treatment setting 
Crack-cocaine dependent patients at three addiction treatment centres in the 
Netherlands (Mentrum, Jellinek and Brijder) were asked to participate in the 
study. Patients at Mentrum already received substance use-related treatment, 
including case management or MMT, but with inadequate or no results in terms 
of cocaine use. Patients from Jellinek and Brijder were new referrals. Enrolment 
occurred from April 2012 till March 2014.  
Eligible patients had to: (a) be at least 18 years old; (b) be cocaine dependent 
according to the Diagnostic and Statistical Manual of Mental Disorders Fourth 
Edition (DSM-IV) (American Psychiatric Association, 1994); (c) have used cocaine 
on at least 8 days in the previous month; (d) administer cocaine primarily by 
means of basing; (e) be able and willing to participate in the study treatment and 
associated assessments; and (f) provide written informed consent. Patients were 
excluded in case of (a) severe medical (e.g. severe renal insufficiency or 
cardiovascular problems) or psychiatric (e.g. acute psychosis or suicidality) 
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problems; (b) pregnancy or breastfeeding; (c) pharmacotherapy with a potentially 
effective medication for cocaine dependence (i.e. naltrexone, disulfiram, 
acamprosate, methylphenidate, topiramate, dexamfetamine or baclofen); (d) 
need for residential treatment (>7 days); (e) insufficient command of the Dutch 




Psychosocial treatment of all patients consisted of 12 weekly individual CBT 
sessions (Kadden, 2001; Monti et al., 1997; Project MATCH Research Group, 1993; 
Rohsenow et al., 2000), delivered by trained, experienced therapists. CBT is the 
standard psychosocial treatment for substance abuse in the Netherlands (De 
Wildt et al., 2002). Treatment goals were based on a shared decision making 
process, and included abstinence and reduction in use of crack-cocaine. 
 
Pharmacological treatment 
In the experimental group, modafinil was prescribed for a period of 12 weeks as 
an add-on to CBT. Modafinil was initiated at 200 mg/day and after 1 week 
increased to 400 mg/day, if tolerated. During the first treatment week, modafinil 
was prescribed daily at the treatment centre to monitor intake and adverse 
events. In the remaining trial period, modafinil was dispensed once weekly, and 
self-reported modafinil intake was registered at each study visit. In case of 
discontinuation of modafinil treatment, CBT could be continued. 
 
Assessments 
Study assessments were performed at baseline, weeks 4 and 8 (experimental 
group only) and week 12. At baseline only, DSM-IV cocaine, alcohol and opioid 
dependence diagnoses (American Psychiatric Association, 1994) were obtained 
using the Composite International Diagnostic Interview-Substance Abuse Module 
(CIDI-SAM) (Cottler, 1990; Cottler, 2000). The Addiction Severity Index (ASI) 
(Hendriks et al., 1989; Kokkevi and Hartgers, 1995; McLellan et al., 1992) was used 
to assess substance use, illegal activities, social contacts and other clinical 
characteristics. 
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At all assessments, the Timeline Follow-Back (TLFB) calendar method (Hjorthoj 
et al., 2012; Sobell and Sobell, 1992) was used to collect information about self-
reported crack-cocaine use in the 30 days preceding each assessment. Cocaine 
craving was measured with a short, adapted version of the Obsessive Compulsive 
Drinking Scale (OCDS) (Anton et al., 1996; De Wildt et al., 2005; Franken et al., 
2002). The Maudsley Addiction Profile-Health Symptoms Scale (MAP-HSS) 
(Marsden et al., 1998) was used to evaluate physical health, and the Symptom 
Checklist-90 (SCL-90) (Arrindell and Ettema, 1986; Derogatis et al., 1973) was used 
to assess the presence of psychological problems. Week 4, 8 and 12 assessments 
also included ASI substance use items and questions about current illegal activities 
and social contacts with non-drug users. The week 12 assessment was 
supplemented with the Client Satisfaction Questionnaire (CSQ-8) (De Wilde and 
Hendriks, 2005; Larsen et al., 1979). 
At each study visit, co-medications and adverse events were registered. Blood 
pressure and heart rate were measured at baseline and week 12. At baseline and 
every four weeks, pregnancy tests were conducted with female participants 
(experimental group only).  
Urine samples were collected at baseline, and once weekly in the final four 
weeks of the study period, and were analysed for the presence of cocaine 
metabolites (benzoylecgonine). The 201 urine samples that were submitted in 
these weeks (out of a planned total of 65 x 4=260 urine-samples; 77.3%), showed 
86.8% agreement between self-reported cocaine use and presence of 
benzoylecgonine (kappa=0.68), with no difference between the experimental and 
control groups (kappa=0.73 and 0.65, respectively).  
Participants received a maximum of €120 (control subjects) or €150 
(experimental subjects) as remuneration for participating in the study 
assessments. 
 
Outcome measures  
Treatment retention, defined as the number of CBT sessions attended (range 
012), was the primary outcome measure. Secondary outcome measures included 
modafinil adherence, tolerability and safety, use of cocaine and other substances, 
cocaine craving, physical and mental health, social functioning and patient 
satisfaction.  
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Power calculation 
Given the feasibility character of the study, a lenient two-sided alpha of 0.10 was 
chosen to prevent type II errors. With a minimum difference of 25% in 12-week 
CBT treatment retention between the groups, a power of 0.80, and a two-sided 
alpha of 0.10, 36 patients were required in each treatment group (ntotal=72). 
 
Data analyses 
Between-group differences were tested in an intent-to-treat (ITT) approach, 
incorporating all patients who provided informed consent pertaining to their 
assigned treatment. Baseline characteristics between groups were compared 
using chi-square tests for dichotomous variables, and t tests or Mann-Whitney U-
tests for normally and non-normally distributed continuous variables, 
respectively. 
With regard to the primary outcome, CBT treatment retention was 
investigated using a Cox proportional hazards regression model, analysing group 
differences in retaining patients in CBT treatment during the 12-week study 
period based on the log-rank (Kaplan-Meier) statistic, censoring the hazard at the 
tenth session.  
With regard to the secondary outcomes, time x group (2 x 2) repeated 
measures analyses of variance (ANOVAs) were conducted to compare baseline to 
week 12 changes between the two groups in cocaine use days, craving, 
concurrent substance use, and other continuous and Likert-scale outcome 
measures. As suggested by Carroll et al. (2014), maximum days of consecutive 
abstinence, protracted abstinence (i.e. ≥3 weeks) during the study period, and 
abstinence during the last two weeks of treatment were also analysed between 
groups, using the t test and chi-square test.  
The sum of benzoylecgonine-positive urine samples during the four weeks 
preceding the week 12 assessment was evaluated using Poisson regression 
analysis; missing urine samples were considered as positive. Modafinil adherence 
was assessed by the self-reported total days of modafinil intake. Mean modafinil 
dose was computed by summing the dose of all modafinil tablets that were 
ingested, as registered in the medication file, divided by the total number of days 
of modafinil intake.  
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In addition, two types of exploratory analyses were performed with treatment 
retention and baseline to week 12 differences in number of crack-cocaine use 
days as dependent variables, treatment group as the independent variable and 
the following baseline variables as potential confounders: crack-cocaine use 
(Ahmadi et al., 2009; Poling et al., 2007; Westhuis et al., 2001), cocaine-positive 
urine (Ahmadi et al., 2009; Kampman et al., 2001; Poling et al., 2007; Sofuoglu et 
al., 2003), cocaine craving (Sinha et al., 2006; Weiss et al., 1997), concurrent 
alcohol use (Alterman et al., 2000; Anderson et al., 2009; Poling et al., 2007), and 
gender (Dackis et al., 2012). In addition, comorbid opioid dependence was 
included as a potential confounder, given its moderating effect on the efficacy of 
topiramate in the treatment of cocaine dependence in our earlier study (Nuijten 
et al., 2014). All continuous covariates were dichotomised based on the median, 
due to their non-linear relationship with both dependent variables. First, each 
baseline characteristic was entered into the original model to identify 
confounding. Baseline covariates that resulted in a change of at least 10% in the 
B-value of the treatment group were entered into the final regression model. 
Second, we analysed whether the baseline characteristics differentially 
moderated treatment outcome by adding their interaction with treatment group 
into the regression model. 
Week 12 data were available for 91% of the ITT population. Missing data of 
four participants in the experimental group and two patients in the control group 
were estimated with multiple imputation, using five imputed datasets, with 




Eligibility was assessed in 111 patients. Sixty-seven patients met all selection 
criteria and were randomised after giving first informed consent (Figure 1), 32 to 
the CBT + modafinil group and 35 to the CBT-only group. Thirty of the 32 patients 
randomised to the experimental group accepted the additional pharmacological 
treatment offer and gave second informed consent (94%), while two patients 
refused the offer of modafinil. The final ITT population consisted of 30 patients in 
the experimental group and 35 patients in the control group. Despite this 
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somewhat lower than intended sample size, the recruitment phase was 
terminated after 2 years due to time constraints. 
 
Figure 1. Participant flow. 
 
Assessed for eligibility (n=111) 
- new referrals (n=28) 
- existing in treatment (n=83) 
Informed consent I/ randomisation (n= 67) 
Control group  (n=35) 
 
Experimental group (n=32) 
 
Excluded by not meeting inclusion  
criteria (n=33) 
- infrequent basecoke use (n=6) 
- no cocaine related treatment demand 
(n=6) 
- declined to participate (n=15) 
- other reasons (n=6) 
Allocation 
Lost to follow-up (n=4 ) 
- declined participation (n=3) 
- passed away during study 
(n=1) 
Lost to follow-up (n=2 ) 




Excluded by not giving informed 
consent II (n=2)  
Informed consent II (n=30) 
Analysed: intention-to-treat 
(ITT) population (n=30) 
Barred by exclusion criteria (n=11) 
- cardiovascular problems  (n=2) 
- renal insufficiency (n=1) 
- severe psychiatric problems (n=5) 
- interfering medication (n=1) 
- inpatient treatment need (n=2) 
Enrolment 
Analysed: intention-to-treat  
(ITT) population (n=35) 
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Baseline characteristics 
Baseline characteristics of the participants are summarised in Table 1. Participants 
could be characterised as chronic cocaine dependent patients with a history of 
multiple treatments, who frequently used crack-cocaine (≥17 days/month on 
average) and other drugs and/or alcohol. The majority (77%) were already 
receiving substance use related treatment, including MMT (31%). There were no 
significant differences in patient characteristics between the two treatment 
groups, but the experimental group tended to use crack-cocaine on more days 
(p=0.06) and have more cocaine positive urine samples (p=0.07) at baseline. 
 
Medication adherence 
Modafinil intake was terminated within two weeks by 10 participants (33%). 
Among the patients who took modafinil at least two weeks (n=20), the mean dose 
was 361 mg/day (sd=32.7). Modafinil was taken for at least eight weeks by 11 
patients (37%), for at least 10 weeks by six patients (20%) and for at least 11 
weeks by three patients (10%).   
Six patients in the experimental group (20%) stopped modafinil intake within 
10 weeks due to adverse events that were probably or certainly related to 
modafinil (see also Tolerability and safety). 
 
Primary outcome: CBT treatment retention 
In the experimental group, participants attended a mean of 6.8 CBT sessions 
(sd=3.8), compared with 5.8 (sd=3.8) in the control group. At least 10 sessions 
were completed by 30.0% in the experimental group and 22.9% in the control 
group. Cox regression survival analysis (Figure 2) suggested slightly better CBT 
treatment retention in the experimental group compared with the control group, 
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Variable M (sd) / % M (sd) / %  
Recruitment    
Already in treatment (%) 73.3 80.0 0.53 
Demographic background    
Age (years)  47.1 (7.8) 45.3 (8.3) 0.31 
Gender: male (%) 83.3 77.1 0.53 
European background (%) 50.0 51.4 0.91 
Employed (%)
a,b
 30.0 40.0 0.40 
Homeless (%) 6.7 8.6 0.77 
Substance use    
Lifetime regular crack-cocaine use (years) 11.0 (7.9) 11.9 (8.9) 0.68 
Benzoylecgonine-positive baseline urine (%)  93.3 77.1 0.07 
Cocaine use (days)
a
  20.9 (8.2) 17.2 (7.6) 0.06 
Alcohol use (≥5 glasses/day) (%)
a,b
 36.7 34.3 0.84 
Heroin use (%)
a,b
 10.0 22.9 0.17 
Cannabis use (%)
a,b
 63.3 57.1 0.61 
Treatment status and history    
Opioid dependence (%) 26.7 37.1 0.37 
Alcohol dependence (%) 6.7 17.1 0.20 
Medication prescribed for mental health (%)
a
 26.7 31.4 0.67 
Methadone maintenance treatment (%) 23.3 37.1 0.23 
Methadone dose (mg) 103.0 (82.0) 71.4 (38.9) 0.45 
Multiple (≥2) prior drug-related treatments (%) 60.0 57.1 0.82 
Inpatient stabilisation period (≤ 7 days) (%) 6.7 17.1 0.20 
Health & social functioning    
MAP total score (0-40) 11.1 (7.8) 11.6 (6.1) 0.78 
SCL-90 total score (0-360) 93.3 (77.2) 101.0 (77.6) 0.70 
OCDS total score (0-20) 8.4 (3.7) 8.7 (4.9) 0.78 
Illegal activities (days)
a
 1.3 (3.0) 3.0 (7.4) 0.71 
Social contacts with non-drug users (days)
a
 21.4 (11.9) 19.0 (13.5) 0.35 
MAP: Maudsley Addiction Profile; SCL-90: Symptom Checklist-90; OCDS: Obsessive Compulsive 
Drinking Scale; 
a
 In the preceding 30 days; 
b
 At least 1 day; 
c
 Using chi-square tests for dichotomous 
variables; t tests for continuous variables; nonparametric Mann-Whitney U tests for continuous 
variables with skewed distributions.  
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Figure 2. Cox regression survival analysis. 
 
 
Main secondary outcome: crack-cocaine use  
Reductions in self-reported crack-cocaine use days from baseline to week 12 were 
significant and substantial in both treatment groups (F=63.0; df=1; p<0.01; 
Cohen’s d=1.08), but these self-reported reductions did not differ significantly 
between treatment groups (F=2.1; df=1; p=0.17) (Table 2). The mean longest 
duration of consecutive abstinence in the experimental group was 28.5 days 
compared with 22.4 days in the control group, with no significant between-group 
difference (t –0.91, 95% CI=–19.6–7.4, p=0.37). Protracted abstinence (≥3 weeks) 
was achieved by 12 patients in the experimental group (40.0%) and 11 in the 
control group (31.4%) and was not significantly different between groups 
(Χ2=0.52, df=1, p=0.47); nor was abstinence during the last two weeks of  
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treatment, which was accomplished by five (16.7%) and seven (20.0%) patients, 
respectively (Χ2=0.12, df=1, p=0.73). 
Of the urine samples expected in the last four weeks, 24.2% in the 
experimental group and 21.4% in the control group were not submitted and 
hence considered benzoylecgonine-positive. The mean number of cocaine-
positive urine samples was 3.1 (sd=1.4) in the experimental group and 3.2 (sd=1.3) 
in the control group. Poisson regression analysis did not show a significant group 
difference (Exp(B)=1.02; 95% CI=0.81.3; p=0.88). Restricting the analysis to 
submitted urine samples resulted in 27.8% cocaine-negative samples in the 
experimental group versus 25.9% in the control group. 
 
Other secondary outcome measures 
For the other secondary outcome variables (Table 2) there were significant 
baseline to week 12 improvements in cocaine craving, alcohol use days (≥5 
glasses/day), and mental health. Repeated measures ANOVA showed significant 
time x group effects for alcohol use in the preceding 30 days, with a mean 
reduction of 3.3 days in the experimental group compared with 0.4 days in the 
control group (F=4.4; df=1; p=0.04). None of the other secondary outcome 
variables showed significant time x group interactions. Additionally, satisfaction 
with the treatment offer (CSQ-8; range 8-32) at the end of the study did not differ 
between groups (Mexp=26.5 (sd=4.7) vs. Mcontr=25.2 (sd=3.9); t 1.14; df=57; 
p=0.26). 
 
Tolerability and safety 
A total of 106 adverse events were reported during the study, by 24 patients 
(80%) in the experimental group and two patients (6%) in the control group. The 
majority of the reported adverse events in the experimental group (n=55; 53.9%) 
were probably or certainly related to modafinil intake: tachycardia (18%), 
agitation, including restlessness and irritability (16%), and headache (13%) were 
most frequently (≥10%) reported. Of these adverse events, 22 were evaluated as 
severe (tachycardia 27%; agitation 18%; headache 14%). In two cases the 
modafinil dose was reduced due to adverse events, but nevertheless these 
patients prematurely withdrew from modafinil treatment.  
 
62  CATCH 
There were two serious adverse events, neither of which was related to 
modafinil. In the experimental group, one patient died during the study period. In 




The relation of treatment group with both treatment retention and baseline to 
week 12 differences in crack-cocaine use days changed (B-change >10%) by 
adding baseline crack-cocaine use days and cocaine-positive urine as covariates in 
the original model (see Table 3a,3b). However, the adjusted models containing 
both covariates did not reach statistical significance. For both outcome variables, 
there were no significant interactions between treatment group and any of the 
covariates (Table 3a,3b), indicating that the effects of modafinil were not 
moderated by these patient characteristics. 
A final post hoc comparison between low (<2 weeks), medium (27 weeks) and 
high (≥8 weeks) modafinil adherent patients showed baseline to week 12 
reductions in crack-cocaine use days in all subgroups (Figure 3). Repeated 
measures ANOVAs showed significant time differences (F=45.6, df=1, p<0.01) and 
significant time x group differences in crack-cocaine use days (F=6.39, df=2, 
p=0.01) in favour of the high adherent subgroup. 
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Table 3a. Exploratory analyses: Confounders and moderators of treatment retention. 
 Treatment retention: 
Original model: B=0.24; HR=0.79; 95% CI: 0.51.4 
 Original model 
+ covariate 
 Interaction  
group x covariate 
 
 B HR 95% CI  B HR 95% CI p 
Crack-cocaine use 0.34 0.71 0.4–1.3  0.59 0.55 0.2–1.8 0.32 
Cocaine-positive urinalysis 0.46 0.63 0.4–1.1  0.85 0.43 0.0–4.4 0.48 
Cocaine craving 0.24 0.79 0.5–1.4  0.12 1.12 0.4–3.6 0.85 
Alcohol use (≥5 glasses/day)  0.23 0.79 0.5–1.4  0.07 0.93 0.3–3.1 0.91 
Opioid dependence 0.23 0.79 0.5–1.4  0.38 0.69 0.2–2.5 0.56 
Gender 0.23 0.80 0.5–1.4  0.25 1.28 0.3–5.3 0.73 
HR: Hazard Ratio; CI: confidence interval. 
 
 
Table 3b. Exploratory analyses: Confounders and moderators of changes in days  
of crack-cocaine use. 
 Baseline to week 12 crack-cocaine use days: 
Original model: B=3.29; t=1.40; 95% CI: 1.37.9 
 Original model 
+ covariate 
 Interaction  
group x covariate 
 B 95% CI  B 95% CI p 
Crack-cocaine use 1.52 2.7–5.8  3.98 4.4–12.4 0.35 
Cocaine-positive urinalysis 3.67 1.1–8.4  6.12 10.1–22.3 0.46 
Cocaine craving 3.30 1.4–8.0  2.79 12.4–6.8 0.57 
Alcohol use (≥5 glasses/day)  3.45 1.1–7.8  4.28 5.1–13.6 0.37 
Opioid dependence 3.61 1.0–8.2  2.10 7.9–12.1 0.68 
Gender 3.29 1.4–8.0  0.42 11.5–12.3 0.95 







64  CATCH 
Discussion  
The acceptance, safety and potential benefits of 400 mg/day modafinil as an add-
on treatment to CBT in crack-cocaine dependent patients were tested in an open-
label, randomised controlled feasibility trial. The study found that modafinil 
acceptance was limited, given the low modafinil adherence. Modafinil was 
evaluated as an agent with considerable medication-related adverse events, 
which caused termination of modafinil intake in 20% of the patients within 10 
weeks of treatment. Modafinil did not improve CBT treatment retention or any of 
the secondary cocaine-related outcomes. However, a post hoc analysis suggested 
that modafinil was associated with large reductions in cocaine use among patients 
who took the medication for at least eight weeks. 
The observed overall lack of modafinil benefits can be explained at least partly 
by its low acceptance, as indicated by the 10% treatment completion rate in our 
study, which was much lower than the completion rates of around 5060% in all 
other studies of modafinil in cocaine dependent patients (Anderson et al., 2012; 
Dackis et al., 2005; Dackis et al., 2012; Schmitz et al., 2014; Schmitz et al., 2012). 
Moreover, the most important reason for non-adherence in our study was the 
occurrence of medication-related adverse events. Compared with previous 
studies, dropout due to adverse events was considerable in our study, at 20%. In 
the randomised controlled trial of Dackis et al. (2005), in six cases (20%) the 
modafinil dose was reduced from 400 to 300 or 200 mg/day due to adverse 
events, but all patients continued treatment. Anderson et al. (2009) found that 
modafinil discontinuation due to adverse events occurred more often in the 400 
mg/day group (10 out of 68; 14.7%) compared with the 200 mg/day group (1 out 
of 68; 1.5%). Hence, the observed high rate of treatment discontinuation due to 
adverse events in our study may have been dose related. 
Several laboratory studies have found that modafinil diminished cocaine-
related euphoria and craving in cocaine-using non-treatment-seeking participants 
(Dackis et al., 2003; Hart et al., 2008; Malcolm et al., 2006; Verrico et al., 2014). In 
the context of treatment, however, we did not observe reductions in craving for 
cocaine in our study, and neither did Dackis et al. (2005; 2012). Therefore, 
disappointment about the perceived lack of effect of modafinil on craving and 
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cocaine use may have led the (chronic) crack-cocaine dependent patients in our 
study to discontinue medication intake. 
Finally, differences in treatment and/or study procedures may possibly explain 
the low medication adherence in our study. In all studies except ours, patients 
had to attend the clinic three times a week (Anderson et al., 2009; Dackis et al., 
2005; Dackis et al., 2012; Schmitz et al., 2014; Schmitz et al., 2012), which created 
the opportunity to motivate and inform patients, stress the importance of 
medication adherence and discuss problems with medication intake. In addition, 
in both studies of Dackis et al. (2005; 2012), patients were remunerated for 
returning blister packages, and Schmitz et al. (2014) used a contingency 
management intervention to target medication compliance. The absence of 
incentives, combined with the less frequent opportunity to motivate patients in 
our study, may have contributed to low modafinil adherence (DeFulio and 
Silverman, 2012; Volpicelli et al., 2001; Weiss, 2004).  
Low adherence is very common and a major problem in medication trials 
(Servick, 2014). Strategies to improve adherence are essential if the efficacy of the 
study medication is to be validly determined, including strategies to improve the 
therapeutic alliance, provide external reinforcement, and formulation and dosing 
strategies (Weiss, 2004). Medication management interventions, such as BRENDA 
(an acronym for its six components: a biopsychosocial evaluation; a report of 
findings from the evaluation given to the patient; empathy; addressing patient 
needs; providing direct advice; and assessing patient reaction to advice and 
adjusting the treatment plan as needed (Starosta et al., 2006)), in which 
treatment motivation and individual patient needs are discussed on an ongoing 
basis during treatment (Volpicelli et al., 2001), and reinforcement of medication 
intake with (financial) incentives, have already demonstrated improved 
medication adherence (Petry et al., 2012; Starosta et al., 2006; Stitzer and 
Vandrey, 2008). In addition, we need more knowledge about the relationship of 
patient characterics with medication adherence and treatment response. With 
regard to the latter issue, it has been shown that modafinil was only effective in 
alcohol dependent patients with poor response inhibition at baseline (Joos et al., 
2013a) and in pathological gamblers with high self-reported impulsivity (Zack and 
Poulos, 2009). 
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Overall, our negative study findings are in line with most recent randomised 
controlled trials in which modafinil did not show any effects on cocaine use 
(Schmitz et al., 2014; Schmitz et al., 2012). In fact, the positive results of modafinil 
in the treatment of cocaine dependence found by Dackis et al. (2005) have never 
been replicated. In subsequent studies, positive results in favour of modafinil 
were found only in secondary outcomes or in post hoc defined subgroups 
(Anderson et al., 2009; Dackis et al., 2012).  
The present study differed from most previous studies in that patients with 
comorbid opioid or alcohol dependence were not excluded. Moreover, in our 
study the majority of patients had already had two or more prior treatment 
episodes. Together, these factors may reflect a more severe population with a 
worse prognosis (Ahmadi et al., 2009; Kampman et al., 2001; Poling et al., 2007).  
 
Limitations 
Our trial was limited by the once-weekly collection of urine samples in the last 
four weeks of study treatment. However, agreement between self-reported 
cocaine use and urinalysis outcome was good in both the experimental and the 
control group, and both measures were consistent in showing no difference in 
treatment outcome between the two study groups. Furthermore, fewer patients 
than planned according to our power calculation participated in our study. 
However, the observed results did not approach statistical significance and, 
hence, lack of power is unlikely to explain our negative results. Finally, given the 
feasibility character of our study, and in order to avoid selective non-compliance 
and dropout among control patients, we chose an open-label, non-placebo-
controlled design. As a consequence, this may have caused bias among patients, 
treatment staff and investigators. Since we did not find differences between the 
treatment groups in terms of retention in CBT and secondary, cocaine-related 




In sum, the acceptance, safety and benefits of 400 mg/day modafinil for the 
treatment of crack-cocaine dependence were not demonstrated in the present 
study. Medication adherence was low, partly attributable to adverse events, and 
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modafinil was not related to improvement in CBT treatment retention, cocaine 
use and other secondary outcomes. However, given that in a subgroup of high 
modafinil adherent patients crack-cocaine use was strongly reduced, the results of 
this study are inconclusive, and further research of the potential of modafinil in 
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Abstract  
Background: High impulsivity and attentional bias are common in cocaine 
dependent patients and predict poor treatment outcomes. The pharmacological 
agent modafinil is studied for its cognitive-enhancing capacities and may 
therefore improve clinical outcomes in crack-cocaine dependent patients. In this 
study, we investigated first whether pre-treatment impulsivity and attentional 
bias predict treatment outcome; next whether the drug modafinil given as an add-
on treatment to cognitive behavioural therapy (CBT) improves impulsivity and 
attentional bias; and last, whether changes in impulsivity and attentional bias are 
related to improvements in treatment outcome. 
Methods: Crack-cocaine dependent outpatients (n=65) were randomised to 12 
weeks CBT plus modafinil (400 mg/day) or only CBT. Self-reported impulsivity was 
assessed at baseline using the Barratt Impulsiveness Scale. At baseline and week 
12, we assessed inhibitory control as behavioural measure of impulsivity, in terms 
of cognitive interference (Stroop task) and response inhibition (‘stop-signal task’), 
and attentional bias with the addiction Stroop task. Clinical outcomes were CBT 
retention and crack-cocaine use.  
Results: At baseline, low self-reported impulsivity predicted better CBT retention; 
low self-reported and behavioural impulsivity and attentional bias predicted less 
crack-cocaine use. Changes in cognitive performance were not modafinil-related, 
but most likely due to low adherence. Improvements in impulsivity or attentional 
bias were not associated with CBT retention nor changes in crack-cocaine use. 
Conclusions: Baseline impulsivity and attentional bias predicted clinical outcomes 
in crack-cocaine dependent patients. There were no firm indications that 
modafinil reduced impulsivity nor attentional bias in this population. Future 
studies involving cognitive-enhancing medications should include strategies to 
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Introduction 
To date, there is no proven effective pharmacological treatment for cocaine 
dependence, despite the considerable research efforts undertaken in this area, 
pertaining to a wide range of pharmacological agents (Alvarez et al., 2010; Kishi et 
al., 2013; Minozzi et al., 2015a; Minozzi et al., 2015b; Pani et al., 2011; Rush and 
Stoops, 2012; Van den Brink, 2012). Of these agents, the psychostimulant 
modafinil has shown promising effects, in terms of increased and protracted 
cocaine abstinence, in several studies (Anderson et al., 2009; Dackis et al., 2005; 
Kampman et al., 2015); however, in a recent randomised controlled study in 
crack-cocaine dependent patients, we found that modafinil as an add-on to 
cognitive behavioural therapy (CBT) did not improve treatment retention or 
cocaine-related outcomes, compared with CBT alone, possibly due to low 
modafinil adherence (Nuijten et al., 2015). The current study aims to explore the 
role of impulsivity and attentional bias in the overall negative findings of this trial. 
High impulsivity and attentional bias are common in patient groups with 
substance use disorders, including cocaine use disorder (Fernandez-Serrano et al., 
2012; Liu et al., 2011; Madoz-Gurpide et al., 2011; Potvin et al., 2014; Spronk et 
al., 2013). Impulsivity is a multifaceted construct and is generally regarded to be a 
part of impaired executive functioning (Bari and Robbins, 2013). Inhibitory control 
represents different cognitive processes, including impulsive action, which can be 
divided into response inhibition (or motor inhibition) and cognitive interference 
(or interference control) (Nigg, 2000; Stevens et al., 2014). Response inhibition is 
the ability to inhibit a pre-potent action in a situation in which this is 
inappropriate (Stevens et al., 2014; Verbruggen and Logan, 2008a), whereas 
cognitive interference refers to the ability to focus attention during the 
presentation of interfering cognitive stimuli (Nigg, 2000). Attentional bias means 
that attention is distracted by emotionally (drug-related) salient stimuli in the 
environment (Cox et al., 2006; Field and Cox, 2008). Several studies suggest that 
the strength of attentional bias is reciprocally related to the degree of impairment 
of inhibitory control (Coskunpinar and Cyders, 2013; Field and Cox, 2008; Stevens 
et al., 2014), and that high impulsivity and attentional bias are predictive of poor 
outcomes of substance abuse treatment (Aharonovich et al., 2006; Sofuoglu, 
2010; Sofuoglu et al., 2013; Stevens et al., 2014; Verdejo-Garcia et al., 2012). 
Hence, cognitive enhancement may be an important target in the treatment of 
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substance dependence (Mereu et al., 2013; Sofuoglu et al., 2013), and given its 
cognitive-enhancing properties (Ballon and Feifel, 2006; Kumar, 2008; Minzenberg 
and Carter, 2008), treatment with modafinil may be a strategy to improve both 
cognitive functioning and clinical outcomes in patients with a substance use 
disorder, including cocaine dependence.  
In two randomised, placebo-controlled studies in patients with cocaine 
dependence, short 45-day modafinil treatment significantly improved 
performance on two measures of working memory span and normalised risk 
taking (Canavan et al., 2014; Kalechstein et al., 2013). In addition, in a randomised 
placebo-controlled cross-over study, a single dose of modafinil attenuated neural 
reactivity to cocaine-related cues and self-reported craving in treatment seeking 
cocaine dependent patients (Goudriaan et al., 2013).  
Modafinil was also studied in other addictive behaviours, for its cognitive-
enhancing effects. In a randomised, placebo-controlled crossover study in alcohol 
dependent patients, a single dose of modafinil resulted in improvements in 
cognitive control (Schmaal et al., 2013a) and impulsive decision making (Schmaal 
et al., 2014), and in improved response inhibition in patients with poor baseline 
response inhibition (Schmaal et al., 2013b). In another randomised, placebo-
controlled parallel trial in alcohol dependent inpatients, a 10-week modafinil 
treatment did not improve response inhibition and was not associated with 
reduced alcohol consumption; however, subgroup analyses showed that modafinil 
did prolong the time to alcohol relapse in patients with poor response inhibition 
at baseline (Joos et al., 2013a). Additional subgroup analyses showed that 
modafinil treatment was also associated with improvements in working memory 
and verbal short-term memory in alcohol dependent patients with the lowest 
baseline working memory skills, compared with patients with the highest baseline 
working memory skills (Joos et al., 2013b).  
Similarly, in methamphetamine dependent patients, four double-blind, 
randomised, placebo-controlled trials were conducted, with promising results for 
modafinil. Modafinil improved verbal memory recall after 5 days of administration 
(Hester et al., 2010); and modafinil-related improvements in working memory 
were found in a subgroup of methamphetamine dependent volunteers with poor 
baseline performance, as compared with high performers, after 3 days of 
administration (Kalechstein et al., 2010). In two other studies, a single dose of 
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modafinil was associated with overall improvements in learning performance 
(Ghahremani et al., 2011), and in inhibitory control and processing speed in a 
subgroup of methamphetamine dependent patients with high baseline frequency 
methamphetamine use, versus a subgroup with low baseline frequency 
methamphetamine use (Dean et al., 2011).  
Finally, a small, placebo-controlled, double-blind study in pathological 
gamblers showed that a single dose of modafinil decreased the desire to gamble, 
salience of gambling words, disinhibition and risky decision-making in high-
impulsive pathological gamblers, whereas the opposite was found in low-
impulsive pathological gamblers (Zack and Poulos, 2009), and increased the 
salience of environmental rewards in both the low and high impulsive gamblers 
(Smart et al., 2013). 
In summary, modafinil seemed to improve different aspects of cognitive 
functioning, especially in patients with suboptimal cognitive functions at baseline; 
however, with the exception of the study by Joos et al. (2013a) in alcohol 
dependent patients, there are no studies in substance use disordered patients 
that investigate modafinil-associated changes in cognitive functioning in relation 
to clinical treatment outcomes. 
The present study investigates the role of impulsivity and attentional bias as 
predictors of modafinil treatment on treatment outcome, in the sample of crack-
cocaine dependent patients that participated in a previous randomised controlled 
trial (RCT) that we performed (Nuijten et al., 2015). The following research 
questions were examined: 
 
1. What are the effects of pre-treatment self-reported impulsivity, inhibitory 
control and attentional bias on CBT retention and crack-cocaine use? 
2. Is modafinil, as an add-on to CBT, effective in improving inhibitory control 
and reducing attentional bias, compared with CBT alone? 
3. Are changes in inhibitory control and attentional bias during (modafinil) 
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Methods and materials 
Design 
This study was designed as an open-label, parallel-group, randomised controlled 
feasibility trial. After screening and baseline assessment, participants were 
randomly assigned to the experimental group (12 weeks individual, outpatient 
CBT plus modafinil) or the control group (12 weeks individual, outpatient CBT 
only), using a pre-randomisation, double-consent design (Zelen, 1979). For more 
details, see Nuijten et al. (2015).  
The study was approved by the medical ethics committee of the Academic 
Medical Centre in Amsterdam and all participants provided written informed 
consent. 
The study is registered in The Netherlands National Trial Register (NTR2576) 
and The EU Drug Regulating Authorities Clinical Trials (EUdraCT 2009-010584-16). 
 
Participants 
Eligible patients were at least 18 years old, were cocaine dependent according to 
the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) 
(American Psychiatric Association, 1994), and had used cocaine by means of 
basing (crack-cocaine) for at least 8 days in the previous month.  
Exclusion criteria were severe medical or psychiatric problems, being pregnant 
or breastfeeding, or receiving pharmacotherapy with a drug that could potentially 
be effective for treating cocaine dependence (e.g. naltrexone, disulfiram, 
acamprosate, methylphenidate, topiramate, dexamfetamine or baclofen).  
The intent-to-treat (ITT) population of the study consisted of 30 patients who 
were randomised to the experimental treatment group (CBT plus modafinil) and 
of 35 patients who were randomised to the control treatment group (CBT only 




All patients were offered 12 weekly individual CBT sessions (Kadden, 2001; Monti 
et al., 1997; Project MATCH Research Group, 1993; Rohsenow et al., 2000), 
provided by trained, experienced therapists. The treatment goals were based on a 
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Patients in the experimental group were offered modafinil for a period of 12 
weeks as an add-on treatment to CBT. Modafinil was initiated at 200 mg/day in 
the first week (week 1) and was then administered in 400 mg/day doses (week 
212), if tolerated. During week 1, modafinil was prescribed on a daily basis at the 
treatment centre; in the remaining trial period, modafinil was dispensed to the 




Baseline and clinical characteristics 
At baseline, we obtained the DSM-IV cocaine dependence diagnosis (American 
Psychiatric Association, 1994) using the Composite International Diagnostic 
Interview-Substance Abuse Module (CIDI-SAM) (Cottler, 1990; Cottler, 2000). We 
used sections of the Addiction Severity Index (ASI) (Hendriks et al., 1989; Kokkevi 
and Hartgers, 1995; McLellan et al., 1992) to collect sociodemographic and clinical 
baseline characteristics. In addition, at baseline and week 12, we used the Time 
Line Follow-Back (TLFB) calendar method (Hjorthoj et al., 2012; Sobell and Sobell, 
1992) to collect detailed information about self-reported crack-cocaine use in the 
30 days preceding the assessments; and the short, adapted version of the 
Obsessive Compulsive Drinking Scale (OCDS) to measure the level of the patients’ 
cocaine craving (Anton et al., 1996; De Wildt et al., 2005; Franken et al., 2002).  
 
Impulsivity 
Self-reported impulsivity was assessed with the Barratt Impulsiveness Scale, 
version 11 (BIS-11) (Patton et al., 1995). Given that the BIS-11 measures impulsive 
personality traits over an extended period of time, this measure was only 
administered at baseline; and, hence, it could only be used as a predictor variable 
and not as an intermediate or outcome measure. 
Inhibitory control as a behavioural measure of impulsivity, assessed in terms of 
response inhibition and cognitive interference, was measured with the stop-signal 
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task (SST) (Logan et al., 1984; Verbruggen and Logan, 2008b) and the Stroop 
colour-word task (Stroop, 1935), respectively. Both tasks were performed at 
baseline and week 12.  
To assess response inhibition, we used the computerised SST, programmed in 
E-Prime. Participants had to respond to an airplane facing left or right on the 
computer screen as fast and accurately as possible (i.e. the go-trial) via the 
keyboard (Schmaal et al., 2013b). Occasionally, on 20% of the trials, a stop-signal 
was presented, consisting of a crossed out airplane (i.e. the stop-trial) where the 
participants had been instructed to try to withhold the response (Bari and 
Robbins, 2013). The timing of that stop-signal (stop-signal delay (SSD)) was 
dynamically adjusted and the difficulty of stopping was varied using a staircase 
procedure (De Jong et al., 1990), targeted at 50% correct self-inhibitions. Upon 
successful stopping by the study participant, the SSD on the next stop-trial was 
increased by 50 milliseconds (ms), making it more challenging for the study 
subject to inhibit this stop-trial. The study subject’s failures to inhibit were 
followed by a 50 ms decrease in SSD, making it easier for that subject to withhold 
their response at the next stop-trial. The time required for the stop-signal to be 
successfully processed, the subject’s stop-signal reaction time (SSRT), was 
computed by subtracting the mean SSD from the mean go reaction time. A longer 
SSRT (in ms) indicated a poorer response inhibition.  
To assess cognitive interference, we used a computerised classic Stroop 
colour-word paradigm (Schmaal et al., 2013a), programmed in E-Prime. In this 
task, congruent colour words and incongruent colour words (e.g. the word ‘red’ 
written in green ink) were presented; participants were instructed to respond via 
the keyboard, as quickly and accurately as possible to the colour in which each 
word was presented, while attempting to ignore the meaning of the word given. 
The difference in mean reaction time (RT) between the incongruent and 
congruent Stroop words was interpreted as a measure of cognitive interference. 
Longer RTs (given in ms) indicate higher cognitive interference.  
  
Attentional bias 
In order to assess the subjects’ attentional bias to cocaine-related stimuli, the 
addiction Stroop task (Cox et al., 2006) was combined with the classic Stroop 
colour-word task in a block design, in which the congruent, incongruent, cocaine-
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related and neutral blocks were counterbalanced. The stimuli of the addiction 
Stroop task consisted of cocaine-related words (e.g. crack, high, ‘basecoke’, 
dealer) and neutral words that were traffic-related (e.g. gasoline, bike, ferry, 
road), presented in four different colours. Instructions were similar to the classic 
Stroop colour-word task, including the task administration at baseline and at week 
12. The difference in the study subjects’ mean RT between the cocaine-related 
and the neutral stimuli was interpreted as a measure of attentional bias. Longer 
RTs (in ms) indicate that there is higher attentional bias. 
 
Outcome variables 
The clinical outcome measures were: Treatment retention, defined as the number 
of CBT sessions attended (range, 012); self-reported crack-cocaine use days 
within the 30 days preceding the assessment at week 12; and the change in self-
reported crack-cocaine use days, from baseline to week 12.  
The cognitive outcome measures were: The changes in response inhibition, 
cognitive interference and attentional bias. They were calculated by subtracting 
the week 12 performance from the baseline performance.  
 
Data-analyses 
In our data analyses, we defined the outliers as the extreme values indicated by 
the statistics program, combined with considerations from the field (Band et al., 
2003; Congdon et al., 2012; Franken et al., 2004; Ratcliff, 1993). 
For the stop-signal task, we had missing baseline data for one patient, due to 
technical problems, and nine of the patients were outliers (>25% extreme 
reaction times: <200 ms or >3 SDs above the mean reaction time in their go-trials; 
>25% omissions; a negative trial delay (i.e. the stop-trial occurred before the go-
trial) in >50% of the stop-trials; or the correct inhibition percentage was <30% or 
>70%). Thus, the analyses of response inhibition at baseline included 28 patients 
in the experimental group and 27 patients in the control group. The week 12 data 
were missing for seven more patients. Analyses of the changes between baseline 
and week 12 SSRTs were therefore analysed in 48 patients (24 in the experimental 
group and 24 in the control group), as seen in the flowchart in Figure 1. 
Furthermore, due to study dropout, the week 12 data about crack-cocaine use 
were missing in six patients. 
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For the Stroop task, we had the baseline data of one patient missing due to 
technical problems and one patient was considered an outlier (i.e. >25% 
extremely fast reaction times (<200 ms) in the cocaine-related or neutral trials). 
Thus, baseline attentional bias was analysed in 30 patients in the experimental 
group and 33 patients in the control group. Of these 63 patients, the week 12 
Stroop data of seven patients were missing. Analyses of the changes between 
baseline and week 12 in attentional bias therefore included 56 patients (Figure 1). 
Cases that met the criteria of an outlier, and missing cases resulting from 
technical problems or study dropout, were excluded from the data analyses. 
There were no significant differences in the baseline level of self-reported 
impulsivity between the outliers and those retained. 
Between-group (experimental versus control) differences in baseline and 
clinical characteristics, baseline self-reported impulsivity, baseline inhibitory 
control and baseline attentional bias were analysed using the Chi-square test for 
dichotomous variables and the t-test for continuous variables.  
We investigated research question one addressing the effects of pre-treatment 
measures of self-reported impulsivity, inhibitory control and attentional bias on 
CBT retention and crack-cocaine use in the last 30 treatment days, using Poisson 
regression analyses. Because the independent variables of baseline self-reported 
impulsivity, inhibitory control and attentional bias were not linearly related to the 
dependent count variables (i.e. CBT retention and cocaine use), these 
independent variables were dichotomised based on the median score (Table 1).  
 
Table 1. Baseline cognitive measure ranges after dichotomisation. 
Variable  n Low/good range  n High/ poor range 
Self-reported impulsivity   32 49.068.0  33 69.097.0 
Response inhibition   27 188.7259.7  28 262.3426.3 
Cognitive interference   31 101.2114.6  32 115.2676.3 
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Figure 1. Flowchart of participants in the data-analyses. 
 
ITT: intent-to-treat; exp: experimental group; contr: control group; SST: stop-signal task.  
 
With regard to the second research question, the effect of modafinil on 
inhibitory control and attentional bias, we conducted 2 x 2 (treatment group x 
time: baseline versus week 12) repeated measures analyses of variance (ANOVA) 
to compare the baseline to week 12 changes in response inhibition, cognitive 
interference and attentional bias between the experimental and control 
treatment groups. In advance, we knew that modafinil adherence in the trial was 
found to be generally low (Nuijten et al., 2015); and hence, the contrast in actually 
received treatment between the experimental and control groups was limited. 
Therefore, we also explored the changes in inhibitory control and attentional bias 
within the experimental treatment group, comparing the low (<8 weeks) versus 




Excluded from analyses n=2 
- Technical problem (n=1) 
- Outlier (n=1) 





Baseline to week 12 population 




Excluded from analyses n=7 
- Technical problem (n=1) 
- Study dropout (n=6) 
Stroop task 
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- Technical problem (n=1) 
- Outlier (n=9) 
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- Technical problem (n=1) 
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- Outlier (n=1) 
Stop signal task 
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the high (≥8 weeks) modafinil-adherent patients, using a 2 x 2 (low versus high 
adherence x time: baseline versus week 12) repeated measures ANOVA. 
For the analyses of our research question three, we correlated the baseline to 
week 12 changes in cognitive performance with the treatment retention and 
changes in crack-cocaine use days, and we assessed whether these correlations 
differed between the low and high modafinil-adherent patients within the 
experimental treatment group. The correlations were standardised using Fisher’s 
r-to-z transformations, and together with a pooled standard error, Wald-tests for 
significance were conducted.  
In the case of significant results (p-values <0.05), we calculated the 




Table 2 shows the baseline characteristics of the participants. Patients in the 
experimental group tended to use crack-cocaine on more days (p=0.06) and have 
more cocaine-positive urine tests (p=0.07) than those in the control group. Self-
reported impulsivity and neurocognitive task performance were similar for both 
treatment groups. The correlations between baseline self-reported impulsivity, 
response inhibition, cognitive interference and attentional bias were low 
(r=0.010.18) and non-significant, except for the correlation between response 
inhibition and cognitive interference (r(52)=0.27, p=0.05; data not shown).  
 
Modafinil adherence 
Five patients (17%) suffered from adverse events at a modafinil dose of 200 
mg/day and their dose was not increased to the intended 400 mg/day after the 
first titration week: three of these patients discontinued modafinil treatment and 
two continued at a lower dose of 300 mg/day. During the study period, the 
modafinil dose was reduced due to adverse events in two patients, but they 
nevertheless withdrew prematurely from modafinil treatment. 
Modafinil intake was terminated within 2 weeks by 10 participants (33%). 
Modafinil was taken for at least 8 weeks by 11 patients (37%), for at least 10 
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weeks by six patients (20%) and for at least 11 weeks by three patients (10%) 
(Nuijten et al., 2015). 
 
Table 2. Baseline characteristics of the study sample. 
Variable Experimental group 
(n=30) 
M / % (sd)  
Control group 
(n=35) 
M / % (sd) 
p-value
b 
Demographic background    
Age (years)  47.1 (7.8) 45.3 (8.3) 0.31 
Gender male (%) 83.3 77.1 0.53 
Substance use    
Lifetime regular crack-cocaine use (years) 11.0 (7.9) 11.9 (8.9) 0.68 
Cocaine-positive baseline urine (%)  93.3 77.1 0.07 
Cocaine use (days in preceding 30 days)  20.9 (8.2) 17.2 (7.6) 0.06 
Treatment goal: abstinence (%) 86.7 80.0 0.48 
Neurocognitive functioning    
Self-reported impulsivity (BIS-11;  
range 30-120) 
67.8 (12.9) 72.0 (10.1) 0.15 
Stop signal task
a,c
    
 Go-trials reaction time  652.4 (93.7) 646.7 (108.5) 0.84 
 SSRT 278.0 (54.5) 268.8 (41.5) 0.48 
Stroop task
a,d
    
 Cognitive interference  169.7 (210.2) 156.5 (123.6) 0.77 
  Reaction time for congruent trials  818.7 (187.3) 839.7 (161.5) 0.63 
  Reaction time for incongruent trials 988.3 (241.8) 996.2 (220.7) 0.89 
 Attentional bias  32.4 (127.5) 61.6 (115.6) 0.34 
  Reaction time for neutral trials  841.2 (169.3) 878.0 (159.3) 0.38 
  Reaction time for cocaine trials  873.5 (163.7) 939.6 (207.5) 0.17 
a
 Responses measured in milliseconds. 
b
 Using Chi-square tests for dichotomous variables and  
t-tests for continuous variables. 
c
 Stop signal task n=55 (nexp=27; ncontr=28). 
d
 Stroop task n=63 
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Table 3a. Baseline cognitive functioning related to number of CBT sessions. 
Baseline cognitive  
functioning 
 CBT sessions 
 Mean (sd) Exp(B) 95%-CI p 
Self-reported impulsivity  - low  7.3 (3.7)    
 - high  5.3 (3.7) 0.73 0.6-0.9 <0.01 
Response inhibition - good  6.3 (3.7)    
 - poor  6.9 (3.8) 1.09 0.9-1.3 0.42 
Cognitive interference - low  6.7 (3.3)    
 - high  5.6 (4.1) 0.84 0.7-1.0 0.08 
Attentional bias - low  5.8 (3.7)    
 - high  6.5 (3.8) 1.12 0.9-1.4 0.27 
CBT: Cognitive Behavioural Therapy. 
 
 
Table 3b. Baseline cognitive functioning related to cocaine use. 
Baseline cognitive  
functioning 
 Crack-cocaine use days in last 30 treatment days  





  Baseline  Week 12    
Self-reported impulsivity  - low 19.0 (8.3)  6.8 (5.9)    
 - high 18.1 (8.0)  11.8 (9.8) 1.82 1.53-2.17 <0.01 
Response inhibition - good 19.2 (8.0)  8.3 (6.0)    
 - poor 18.4 (8.2)  10.6 (9.3) 1.30 1.08-1.56 0.01 
Cognitive interference - low 19.1 (8.0)  8.2 (6.1)    
 - high 18.2 (8.4)  10.3 (9.9) 1.30 1.09-1.54 <0.01 
Attentional bias - low 17.9 (8.5)  7.9 (7.1)    
 - high 19.4 (7.9)  10.7 (9.2) 1.29 1.09-1.54 <0.01 
a
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Prediction of treatment outcomes by baseline impulsivity and attentional bias  
Table 3a shows that patients with low self-reported baseline impulsivity attended 
significantly more CBT sessions than the high impulsivity patients (7.3 vs. 5.3 
sessions, respectively; p<0.01, d=0.54). The patients with good versus poor 
baseline response inhibition, patients with low versus high cognitive interference, 
and those with low versus high baseline attentional bias did not differ in the 
number of CBT sessions that they attended. 
Concerning crack-cocaine use, Table 3b and Figure 2 show that the number of 
crack-cocaine use days within the last 30 treatment days was significantly lower in 
the patients with low self-reported baseline impulsivity than in those with high 
baseline impulsivity (6.8 versus 11.8 days, respectively; p<0.01, d=0.72), as well as 
in the patients with good compared with poor baseline response inhibition (8.3 vs. 
10.6 days, respectively; p=0.01, d=0.38) and in patients with low compared with 
high baseline cognitive interference (8.2 vs. 10.3 days, respectively; p<0.01, 
d=0.36). Similarly, patients with low baseline attentional bias used cocaine on 
fewer days than those with high baseline attentional bias (7.9 vs. 10.7 days, 
respectively; p<0.01, d=0.15)  
 
Effects of modafinil on inhibitory control and attentional bias 
Table 4 shows that the baseline to week 12 changes in response inhibition and 
attentional bias in both treatment groups combined did not reach statistical 
significance, but cognitive interference did significantly decrease over time 
(F(1,54)=7.53; p=0.01; d=0.27). The changes in cognitive measures over time were 
not significantly different between the experimental and the control treatment 
groups, as indicated by the non-significant treatment-by-time interaction terms. 
Regarding our additional exploration within the experimental treatment group 
only, we found that cognitive interference significantly improved over time 
(F1,24)=7.28; p=0.01; d=0.44), but the baseline to week 12 changes in cognitive 
performance did not differ between the patients with low and high modafinil 
adherence (Table 5).
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Relationship between changes in neurocognitive task performance and clinical 
outcomes 
Tables 6a and 6b show the correlations between baseline to week 12 changes in 
cognitive performance and treatment outcomes. In the total study sample, the 
correlations between the changes in the various measures of cognitive 
performance and CBT retention, as well as between changes in cognitive 
performance and changes in cocaine use, were low and non-significant 
(r=0.050.16).  
Within the experimental treatment group only, the Wald-tests showed that 
the relationships between the various cognitive measures and treatment 
outcomes were not significantly different between the low and high modafinil-
adherent patients.  
 
Table 6a. Correlations between baseline to week 12 changes in cognitive performance and CBT 
retention. 
Cognitive measure Total study sample  Within experimental treatment group 
 CBT retention  CBT retention 





   Pearson’s r Pearson’s r   
 Response inhibition 0.00  0.00 0.03 0.06 0.52 
 Cognitive interference 0.01  0.12 0.30 0.40 0.66 




tests were performed between low and high modafinil adherent patients; CBT: cognitive behavioural 
therapy; delta: change in. 
 
 
Table 6b. Correlations between baseline to week 12 changes in cognitive performance and changes 
in cocaine use. 
Cognitive measure Total study sample  Within experimental treatment group 
  Cocaine use   Cocaine use 





   Pearson’s r  Pearson’s r   
 Response inhibition 0.05  0.49 0.51 0.04 0.52 
 Cognitive interference 0.11  0.04 0.27 0.68 0.75 
 Attentional bias 0.08  0.02 0.21 0.49 0.69 
a
 Wald X
2 tests were performed between low and high modafinil adherent patients; delta: change in. 
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Discussion  
In a previous report on this open-label, randomised controlled study among 65 
crack-cocaine dependent patients, we showed that 12 weeks of treatment with 
modafinil in addition to CBT did not improve treatment retention nor cocaine-
related outcomes, compared with CBT alone (Nuijten et al., 2015). In the present 
study, we found that CBT retention was better among the patients with low 
baseline self-reported impulsivity, and crack-cocaine use in the last 30 treatment 
days was lower among the patients with low self-reported impulsivity, good 
response inhibition, low cognitive interference and low attentional bias at 
baseline. Moreover, cognitive interference decreased during treatment, but this 
cognitive improvement during treatment was not related to better CBT retention 
nor to crack-cocaine use reductions. Changes in impulsivity or attentional bias did 
not differ between the CBT plus modafinil and CBT-only treatment groups, which 
could be expected given the low modafinil adherence in the trial; and hence, the 
limited contrast in actually received treatment between the two conditions. 
Additional analyses within the CBT plus modafinil treatment group to explore the 
changes in cognitive performance between the low and high modafinil-adherent 
subgroups did not show an advantage for modafinil intake either. 
Our findings that high baseline self-reported and behavioural impulsivity did 
predict poorer treatment outcomes can be added to the conclusions of two 
recent reviews indicating that impulsivity is likely to be a robust predictor of 
treatment outcomes (Loree et al., 2014; Stevens et al., 2014); therefore, our 
prognostic findings are of clinical relevance.  
Regarding our findings on attentional bias, there is less consistency in the 
literature. Although the predictive value of attentional bias on cocaine use in our 
study is in line with some previous findings in various substance use disorders 
(Field and Cox, 2008), to our knowledge only one study in cocaine dependent 
patients shows that having a better baseline Stroop performance is related to 
better treatment outcomes (Carpenter et al., 2006). Moreover, in more recent 
studies, the relationship between attentional bias and relapse is described as 
equivocal (Carpenter et al., 2006; Christiansen et al., 2015; Field et al., 2014); and 
thus, given the small effect size pertaining to the predictive value of attentional 
bias on cocaine use, careful interpretation of our findings is warranted.  
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Several more fundamental factors also have called into question the 
prognostic value of attentional bias on treatment outcomes. First, attentional bias 
is not a stable characteristic, but is susceptible to motivational and affective 
states, as well as contextual factors (Christiansen et al., 2015; Leeman et al., 
2014). To control for possible situational influences on attentional bias, our 
baseline and week 12 assessments took place approximately at the same time of 
the day, in the same place and order, and mostly with the same researcher. 
Recent use of alcohol, drugs, coffee and nicotine prior (i.e. ≤24 hours) to the 
Stroop task was not related to patients’ performance, and neither was cocaine 
craving (data not shown). Nevertheless, other individual differences, including 
motivation, were not assessed and might have affected attentional bias.  
Secondly, the cognitive process of attentional bias may not have been 
completely captured by the Stroop task, because it has been questioned whether 
the Stroop task measures attentional bias specifically, or a broader process of 
inhibitory control regarding distracting word content (Christiansen et al., 2015). 
Also, it was recently suggested that attentional bias can be assessed more 
adequately with visual, rather than manual, responses to drug-related stimuli 
(Dias et al., 2015; Marks et al., 2014b), given that eye fixation time is a sensitive 
and reliable method for measuring attention allocation to cocaine-related cues 
with a high test-retest reliability, in contrast to motor response time (Marks et al., 
2014a). In summary, it is widely accepted that attentional bias to cocaine-related 
cues is present in cocaine dependent patients (Leeman et al., 2014), but its 
prognostic value as measured with the addiction Stroop task remains to be more 
firmly established. 
Various pharmacological and behavioural treatments have focused on 
improving the cognitive deficits in patients with substance use disorder (Keshavan 
et al., 2014; Sofuoglu, 2010; Sofuoglu et al., 2013; Vocci, 2008), based on the 
assumption that an improvement in cognitive functioning is likely to improve 
treatment outcomes; however, there are hardly any studies addressing this 
relationship. In our study, we did not find support for this assumption: From all 
investigated cognitive measures, only cognitive interference showed a decrease 
over time (d=0.27), and although crack-cocaine use decreased as well (d=1.08; 
(Nuijten et al., 2015)), both improvements were not interrelated. Hence, our 
study suggested that patients had reduced their cocaine use, regardless of the 
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occurrence of cognitive improvements. Nevertheless, we did find some trend-
level indications that suggested that within the experimental group, better 
modafinil adherence might be associated with more improvements in cognitive 
interference (Table 5); and if so, this would argue for more intensive measures to 
improve medication adherence, including compliance enhancement therapy 
(Weiss, 2004) or contingency management directed at medication adherence 
(Petry et al., 2012), as well as cocaine abstinence (Prendergast et al., 2006).  
Some of the limitations of our study (e.g. low modafinil adherence and a 
relatively short treatment period) have already been discussed above or in our 
previous paper about the study (Nuijten et al., 2015). Regarding the study design, 
we chose an open-label, non-placebo-controlled design in order to avoid selective 
non-compliance and dropout among control patients, as explained in Nuijten et 
al. (2015); however, as a consequence, due to the absence of a blinded placebo-
controlled condition, the role of placebo or expectancy effects in the responses to 
clinical outcomes could not be established. A further limitation was that valid 
cognitive assessments could not be obtained for all patients, resulting in a smaller 
sample and reduced power. 
To our knowledge, this is the first study simultaneously assessing (changes in) 
cognitive function and clinical outcomes in a pharmacological trial with a cognitive 
enhancer, modafinil, as an add-on treatment to CBT for crack-cocaine 
dependence. We have concluded that self-reported impulsivity, response 
inhibition, cognitive interference and attentional bias may all be valuable 
predictors of CBT retention and subsequent crack-cocaine use; however, we 
found no firm indications that modafinil reduces impulsivity nor attentional bias in 
this population. Future studies involving cognitive-enhancing medications should 
include multiple strategies to optimise adherence, to be better able to evaluate 
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Abstract 
Background: Heroin-assisted treatment is effective for methadone treatment-
refractory heroin dependent patients, but continued comorbid cocaine 
dependence remains problematic. Sustained-release dexamfetamine is a 
promising agonist pharmacotherapy for cocaine dependence and we aimed to 
assess its acceptance, efficacy, and safety. 
Methods: In this multicentre, randomised, double-blind, placebo-controlled trial, 
patients who were treatment-refractory, as indicated by at least two earlier failed 
treatments aimed at reducing or abstaining from cocaine use, and who regularly 
(≥8 days/month) used crack-cocaine were enrolled from four heroin-assisted 
treatment centres in the Netherlands. Eligible patients were randomly assigned 
(1:1) to receive either 12 weeks of daily, supervised prescription of 60 mg/day oral 
sustained-release dexamfetamine or placebo in addition to co-prescribed 
methadone and diacetylmorphine. Randomisation was done by the collaborating 
pharmacist, using a computer-generated random number sequence with 
stratification by treatment centre in blocks of four per stratum. Randomisation 
was masked to patients, staff, and researchers throughout the study. The primary 
outcome was the number of self-reported days of cocaine use during study 
treatment, assessed every 4 weeks. Primary and safety analyses were done in the 
intention-to-treat population. The study was registered with The European Union 
Drug Regulating Authorities Clinical Trials (EUdraCT 2013-004024-11) and with 
The Netherlands Trial Register (NTR2576). 
Findings: Between Aug 8, 2014, and Feb 27, 2015, 111 patients were assessed for 
eligibility, of whom 73 were enrolled and randomised; 38 patients were assigned 
to the sustained-release dexamfetamine group and 35 to the placebo group. 
Sustained-release dexamfetamine treatment resulted in significantly fewer days 
of cocaine use than placebo treatment (mean 44.9 days [sd=29.4] vs 60.6 days 
[24.3], respectively [95% CI of difference 3.1–28.4]; p=0.031; Cohen’s 
standardised effect size d=0.58). One or more adverse events were reported by 28 
(74%) patients in the dexamfetamine group and by 16 (46%) patients in the 
placebo group. Most adverse events were transient and well-tolerated. 
Interpretation: Sustained-release dexamfetamine is a well accepted, effective, and 
safe agonist pharmacotherapy for comorbid treatment-refractory cocaine 
dependence in heroin dependent patients in heroin-assisted treatment. Future 
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research should aim to replicate these findings in chronic cocaine dependent and 
other stimulant dependent patients in more routine treatment settings, including 
strategies to optimise treatment adherence like medication management 
interventions and contingency management. 
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Research in context 
Evidence before this study 
Our reference point was the Cochrane review 
(Castells et al [2010]), based on 16 
randomised parallel group placebo-controlled 
clinical trials (RCTs) on the efficacy and safety 
of stimulant medications (bupropion, 
dexamfetamine, methylphenidate, modafinil, 
mazindol, methamfetamine, and selegiline) 
for the treatment of cocaine use disorders 
until July 24, 2008. As a group, these 
stimulants did not reduce cocaine use. When 
type of medication was included in the 
analysis, the proportion of patients achieving 
sustained cocaine abstinence was higher with 
bupropion (three RCTs) and dexamfetamine 
(three RCTs) than with placebo. The authors 
concluded that the evidence for stimulants in 
the treatment of cocaine dependence was 
inconclusive, but also that promising results 
existed for dexamfetamine and bupropion. 
We searched MEDLINE, Embase, PsycINFO, 
and the Cochrane Central Register of 
Controlled Trials for clinical trials—published 
between July 25, 2008 and Nov 1, 2013—on 
the efficacy of dexamfetamine in the 
treatment of cocaine dependence, using the 
same search terms as Castells et al in 2010. 
Restricting our results to RCTs on the efficacy 
of dexamfetamine among treatment seeking 
cocaine dependent patients in terms of 
clinical (cocaine use) outcomes, we retrieved 
two potentially relevant articles. One study 
(n=81) tested a combination of mixed 
amphetamine salts and topiramate (Mariani 
et al [2012]), making it impossible to know 
the contribution of dexamfetamine to the 
effect.  
The second study (n=73) compared the 
effects of dexamfetamine, modafinil, and the 
combination of dexamfetamine plus 
modafinil with placebo (Schmitz et al [2012]). 
Modafinil and the combination of modafinil 
plus dexamfetamine were associated with 
increased cocaine use and dexamfetamine 
alone did not clearly separate from placebo in 
terms of cocaine use. 
 
Added value of this study 
Previous studies on the effect of 
dexamfetamine in cocaine dependent 
patients were promising, but often restricted 
by small sample size, high treatment dropout 
and, consequently, cocaine use-related 
outcomes did not reach statistical 
significance. Our study on sustained-release 
dexamfetamine in comorbid cocaine and 
heroin dependent patients, participating in 
heroin-assisted treatment, offered a context 
in which medication adherence could be 
optimised, allowing us to assess the real 
potential of sustained-release dexamfetamine 
in the treatment of cocaine dependence. 
 
Implications of all the available evidence 
Sustained-release dexamfetamine is an 
effective and safe agonist medication for the 
treatment of patients with cocaine 
dependence when medication adherence can 
be established. Replication of these findings 
in treatment-refractory cocaine dependent 
and other stimulant dependent patients in 
routine, optimised treatment settings, with 
clinical measures to enhance medication 
adherence, is warranted. 
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Introduction 
Heroin-assisted treatment is an effective treatment for methadone treatment-
refractory heroin dependent patients, resulting in reduced illicit heroin use and 
improvements in mental status, physical health, and social functioning, as has 
been shown in seven randomised controlled trials (Ferri et al., 2011) and two 
cohort studies (Blanken et al., 2010b; Rehm et al., 2001). However, many heroin 
dependent patients are also cocaine dependent, which worsens the prognosis of 
treatment (Marsden et al., 2009), as is also shown among patients in heroin-
assisted treatment, who often show no or only slight reductions in cocaine use 
(Blanken et al., 2010b). Agonist pharmacotherapy for chronic cocaine dependence 
among patients in opioid agonist treatment might be a viable strategy. However, a 
recent randomised placebo-controlled trial with immediate-release 
methylphenidate (30 mg twice daily) in cocaine dependent patients currently in 
heroin-assisted treatment did not show benefits in terms of reduced cocaine use 
(Dürsteler-MacFarland et al., 2013). 
Reviews of substitution treatments for cocaine dependence, including 
psychostimulants and (other) dopamine agonists (Castells et al., 2010; Herin et al., 
2010), suggest that sustained-release dexamfetamine is probably the most 
promising agonist drug with respect to reductions in cocaine use and craving, but 
previous studies were restricted by low adherence, and cocaine-related outcomes 
often did not reach statistical significance (Grabowski et al., 2001; Grabowski et 
al., 2004a; Shearer et al., 2003). 
We aimed to assess the acceptance, efficacy, and safety of a robust dose of 60 
mg/day oral sustained-release dexamfetamine in chronic crack-cocaine 




Study design and participants 
This multicentre, randomised, double-blind, placebo-controlled trial was part of a 
larger project testing three pharmacological drugs (topiramate, modafinil, and 
sustained-release dexamfetamine) in separate studies in crack-cocaine dependent 
patients in the Netherlands (Nuijten et al., 2011). 
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Study participants were recruited from the population of patients currently 
receiving oral methadone plus inhalable or injectable diacetylmorphine for their 
concurrent heroin dependence in supervised heroin-assisted treatment 
programmes in two treatment centres in Amsterdam, one in Rotterdam, and one 
in The Hague. Eligible patients: (1) met inclusion criteria for heroin-assisted 
treatment, including minimum age of 25 years, methadone treatment-refractory 
heroin dependence, (nearly) daily heroin use, and poor physical, mental or social 
functioning (for full details, see Van den Brink et al., 2003); (2) met cocaine 
dependence criteria according to the Diagnostic and Statistical Manual of Mental 
Disorders IV edition (American Psychiatric Association, 1994) in the past year and 
previous 5 years; (3) used cocaine on at least 8 days in the previous month; (4) 
administered cocaine primarily by means of basing (also known as freebasing and 
means smoking crack-cocaine); (5) had at least two earlier failed treatments 
aimed to reduce or abstain from cocaine use (treatment-refractory); (6) were able 
and willing to participate in the 12-week study; and (7) provided written informed 
consent. 
Patients were excluded in case of (1) severe medical problems (e.g. 
electrocardiography or blood abnormalities) or severe psychiatric problems (e.g. 
acute psychosis or suicidality); (2) pregnancy or breastfeeding; (3) 
pharmacotherapy with a potentially effective drug for cocaine dependence (i.e. 
disulfiram, acamprosate, methylphenidate, modafinil, topiramate, immediate-
release dexamfetamine, or baclofen); (4) insufficient command of the Dutch 
language; and (5) current participation in another addiction treatment trial. 
The study was approved by the medical ethics committee of the Academic 
Medical Centre of the University of Amsterdam. The study protocol is available 
online (https://www.brijder.nl/study_protocol_sr_dexamfetamine). 
 
Randomisation and masking 
Following screening and baseline assessment, eligibility was determined by the 
treatment physician, and eligible patients were randomly assigned (1:1) to receive 
either 12 weeks oral sustained-release dexamfetamine or identical placebo along 
with continued heroin-assisted treatment. Randomisation was conducted by the 
collaborating pharmacist, using a computer-generated random number sequence 
with stratification by treatment centre (four centres) in blocks of four per stratum.   
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Treatment packs with sufficient study medication or placebo for the 12-week 
period were numbered sequentially and dispensed by the pharmacist to eligible 
patients in order of study entry. Randomisation was concealed for patients, staff, 
and researchers throughout the study. 
 
Procedures 
All patients were offered pharmaceutical-grade diacetylmorphine (maximum 
single dose 400 mg; maximum daily dose 1000 mg) 3 times per day and 7 days per 
week in designated treatment centres, along with once daily oral methadone 
(maximum dose 150 mg). Methadone was co-prescribed to achieve a stable base 
of opioid plasma concentrations and to prevent withdrawal symptoms in case 
patients missed a visit at the heroin-assisted treatment centre for supervised use 
of diacetylmorphine. 
The study treatment consisted of either ongoing heroin-assisted treatment 
along with 12 weeks of treatment with sustained-release dexamfetamine, 
prescribed in a robust, single oral dose of 60 mg/day (2 tablets of 30 mg) in the 
experimental group or ongoing heroin-assisted treatment along with 12 weeks of 
identical placebo (2 tablets of 30 mg) in the placebo group. Study medication was 
dispensed once daily during the patient’s morning visit at the heroin-assisted 
treatment centre, and had to be taken under supervision to allow intensive safety 
monitoring. 
Study assessments were done at baseline, and at weeks 4, 8, and 12. At 
baseline, the Composite International Diagnostic Interview Substance Abuse 
Module (cocaine and alcohol dependence) (Cottler, 2000) and the Mini-
International Neuropsychiatric Interview on suicide risk (Sheehan et al., 1998) 
were undertaken. At all assessments we administered the substance use section 
of the Addiction Severity Index, supplemented with questions about illegal 
activities (Hendriks et al., 1989; Van den Brink et al., 2003); the Time Line Follow-
Back on self-reported cocaine use (Sobell and Sobell, 1992); the Obsessive 
Compulsive Drug Use Scale on past week cocaine craving (De Wildt et al., 2005); 
the Maudsley Addiction Profile Health Symptoms Scale (MAP-HSS) on physical 
health (Marsden et al., 1998); and the Brief Symptom Inventory (BSI) on mental 
health (Derogatis and Melisaratos, 1983). In the final 4 study weeks, urine 
samples were collected (non-supervised) twice weekly, on Mondays and 
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Thursdays. Samples were analysed for the presence of the cocaine-metabolite 
benzoylecgonine (>300 ng/mL), using qualitative rapid tests (nal von minden 
GmbH, Moers, Germany). The urine tests had a sensitivity of 95% and a specificity 
of 90%, and had no cross-reactivity with dexamfetamine sulphate. Additional 
assessments included blood sampling and electrocardiography (screening and 
week 12 assessment); weekly medical monitoring of heart rate, blood pressure, 
and bodyweight; weekly standardised registration of (serious) adverse events and 
co-medication; monthly pregnancy testing; daily registration of supervised 
medication adherence; and at week 12 the Client Satisfaction Questionnaire, 
supplemented with a question to rate the study medication on a scale ranging 
from 0 (very bad) to 10 (excellent) (De Wilde and Hendriks, 2005). Participants 




The primary outcome was the number of self-reported days of cocaine use during 
the 12-week study (range 0–84 days) and was centrally assessed. Secondary 
cocaine use-related outcomes were number of cocaine-negative urine samples in 
the last 4 study weeks, and the following TimeLine FollowBack-based outcomes: 
longest period of consecutive cocaine abstinence; percentage of patients with at 
least 21 consecutive days of cocaine abstinence; days of cocaine abstinence 
during the last 4 study weeks; and changes in so-called cocaine hits (i.e. cocaine 
self-administrations on days patients used cocaine) and changes in days of 
cocaine abstinence comparing the 4 weeks preceding the baseline and week 12 
assessment.  
Other secondary outcomes were changes in cocaine craving, (self-reported) 
use of other substances, physical and mental health, criminality, as well as 
medication adherence, and safety (i.e. [serious] adverse events) during the 12-
week study. Safety was assessed in terms of the number of patients that reported 
at least one (serious) adverse event, the number of (serious) adverse events, and 
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Statistical analysis 
For the power analysis, the mean difference between the sustained-release 
dexamfetamine group and the placebo group in number of days of cocaine use 
during the 12-week treatment period was estimated to be 10, with a pooled SD of 
17 days (d=0.59; i.e. moderate effect size). For this proof-of-principle study, a 
lenient alpha of 0.10 was chosen to minimise the risk of a false negative outcome 
(type 2 error) (Nuijten et al., 2011). With a two-sided alpha of 0.10 and power of 
0.80, 36 patients were required per study group. 
An intention-to-treat approach, including all randomised patients, was used to 
test group differences in all primary, secondary, and safety analyses. This 
definition is more strict than the one in the study protocol, which additionally 
required that patients took at least one dose of the study drug. 
The primary outcome  i.e. number of self-reported days of cocaine use during 
the 12-week study was analysed with negative binomial regression analyses with 
treatment group as the only independent variable and the interaction of 
treatment group with treatment centre as the only effect modifier. To fit the 
negative binomial regression model, a reflection transformation was done on the 
negatively skewed data of the primary outcome (i.e. 84 days minus cocaine use 
days). 
Concerning the secondary cocaine use-related outcomes, different statistical 
analysis strategies were used based on the nature and distribution of the 
outcome. Negative binomial regression analyses with treatment group as the only 
independent variable were used for the longest period of consecutive cocaine 
abstinence and the mean number of cocaine metabolite-free urine samples in the 
4 weeks preceding the week 12 assessment. Achievement of cocaine abstinence 
for at least 21 consecutive days was analysed by logistic regression analysis, using 
treatment group as the only independent variable. Group differences in changes 
in number of days of cocaine abstinence and cocaine hits in the 4 weeks 
preceding baseline and week 12 were analysed by multilevel analyses (generalised 
linear mixed models) with a random intercept, and with the two assessments and 
treatment group as fixed effects. Multilevel analyses were used, instead of 
repeated measures analyses of variance mentioned in the study protocol, to fit 
the non-normal distribution of the data. Cohen’s d effect sizes were calculated for 
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continuous outcomes and numbers needed to treat (NNT) for dichotomous 
outcomes. 
The other secondary outcomes  i.e. changes in craving, use of other 
substances, health status, and criminality  were analysed by generalised 
estimating equation models with treatment group, assessment (baseline, weeks 4, 
8, and 12) and the interaction between treatment group and assessment as 
independent variables, and using an unstructured correlation matrix. Except 
craving, all secondary outcomes were non-normally distributed and, therefore, 
dichotomised based on the presence or absence of past month illicit heroin use, 
or cannabis use, or heavy (≥5 units per day) alcohol use (all ≥1 day); poor physical 
health (MAP-HSS total score ≥8); poor mental health (BSI total score ≥0.56 for 
men and ≥0.71 for women); and past month criminality (≥1 day) (Blanken et al., 
2010b). 
Because the medication was dispensed daily and intake was supervised, 
adherence with the study medication was registered on a daily basis. Differences 
between the study groups and treatment centres were described and analysed by 
means of negative binomial regression analyses in terms of the number of days of 
medication intake during the 12-week study, the number of consecutive weeks in 
which patients were fully compliant, and days of medication intake in the final 4 
weeks. 
Data for one patient in the dexamfetamine group was missing from week 4 
onward due to imprisonment, and, following the most conservative strategy, all 
missing TimeLine FollowBack-days were considered as cocaine use days. 
Furthermore, 516 (88%) of the 584 scheduled urine samples were submitted, and 
the remaining 68 missing urine samples were considered cocaine-positive. 
Agreement between self-reported crack-cocaine use in the 3 days before the last 
urine sample (week 12) and a cocaine-positive urine was 89.2% with a Kappa-
value of 0.64 in both study groups; almost 50% of the patients with no self-
reported crack-cocaine use (n=15) did have a cocaine-positive urine. 
Data monitoring was conducted by the investigators and the independent 
supervisory pharmacist (Amsterdam Academic Medical Centre); there was no 
independent data monitoring committee. Data were analysed with SSPS (version 
23). 
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The study was registered with The European Union Drug Regulating Authorities 
Clinical Trials (EUdraCT 2013-004024-11) and with The Netherlands Trial Register 
(NTR2576). 
 









38 assigned to sustained-
release dexamfetamine 
35 assigned to placebo 




- 1 imprisonment 
- 2 adverse events 
- 1 no experienced    
treatment effect 
31 completed treatment 34 completed treatment 




- 2 imprisonment 
- 2 adverse events 
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Demographic background   
Age (years)  48.4  (6.6) 49.0  (5.3) 
Men  35 (92.1%) 31 (88.6%) 
European descent  26 (68.4%) 23 (65.7%) 
Substance use   
Lifetime regular crack-cocaine use (years) 19.1  (7.7) 19.9  (7.1) 
Cocaine-positive baseline urine  38 (100.0%) 34 (97.1%) 
Cocaine use days (past month) 23.5  (7.6) 23.7  (7.6) 
Lifetime regular heroin use (years) 21.1  (8.4) 23.0  (8.5) 
Heavy (≥5 units/day) alcohol use (≥1 day, past month) 13 (34.2%) 12 (34.3%) 
Cannabis use (≥1 day, past month) 21 (55.3%) 13 (37.1%) 
Treatment status and treatment history   
Time in heroin-assisted treatment (months) 46.2 (34.3) 57.5 (35.1) 
Medical heroin dose (mg) 582.2 (200.8) 635.0 (188.3) 
Methadone dose (mg) 67.6 (28.1) 70.1 (24.3) 
Previous addiction treatments  6.2 (3.2) 8.4 (7.2) 
Data are mean (SD) or n (%).  
 
Results 
Between Aug 8, 2014, and Feb 27, 2015, 111 patients were assessed for eligibility, 
of whom 73 were enrolled; 38 patients were randomly assigned to sustained-
release dexamfetamine and 35 to placebo (Figure 1). Patient recruitment was 
terminated when the aimed number of patients according to the power 
calculation was achieved. 
Patients were mainly men from European descent, on average 49 years old 
(sd=6), with a long history of regular illicit heroin and cocaine use, who had 
multiple previous treatments, and who had used cocaine on an average of 24 days 
(sd=8) in the past month (Table 1). Patients participated in heroin-assisted 
treatment for on average 4 years (sd=3). One patient injected cocaine; all others 
smoked crack-cocaine. Baseline characteristics were balanced between the two 
treatment groups. 
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Analysis of the primary outcome showed that the mean number of self-
reported days of cocaine use in the 84 days treatment period was significantly 
lower in the dexamfetamine group than in the placebo group (44.9 days 
[sd=29.4]) vs 60.6 days [24.3], respectively [95% CI of difference 3.1–28.4 days]; 
Wald χ²=4.66, df=1; p=0.031) (Table 2). There was no significant interaction 
between treatment centre and treatment group (Wald χ²=2.02, df=3, p=0.569). 
 
Table 2. Primary and secondary cocaine use-related outcomes.  
 
 




Exp(B) (95%-CI) Wald Χ2 
(df=1) 
p value Effect size 
Primary outcome        
Days of cocaine use during 12-
week study 
44.9 (29.4) 60.6 (24.3) 1.67 (1.05-2.67) 4.66 0.031 d=0.58 
Secondary cocaine use-related outcomes      
Longest period of consecutive 
cocaine abstinence (days) 
17.9 (24.9) 6.7 (11.7) 2.69 (1.66-4.36) 16.17 <0.0001 d=0.58 
Consecutive cocaine abstinence 
for ≥21 days 
11 (28.9%) 2 (5.7%) 6.72 (1.37-32.97) 5.52 0.019 NNT=4.3 
Days of cocaine abstinence in 
final 4 weeks 
15.2 (10.8) 7.5 (9.1) 2.04 (1.26-3.31) 8.45 0.004 d=0.77 
Proportion cocaine-negative 
urine samples in final 4 weeks 
10.6 (25.1) 3.9 (17.9) 2.60 (1.14-5.94) 5.11 0.024 d=0.31 
SR DEX=sustained-release dexamfetamine group; PLAC=placebo group. Data are mean (SD) or n (%), unless 
otherwise specified. Exp(B) = exponentiated value of regression coefficient B;  odds ratio. df=degrees of freedom. 
d=Cohen’s d which is a standardised effect size. NNT = number needed to treat.  
 
With regards to secondary cocaine use-related outcomes, the longest 
consecutive period of self-reported cocaine abstinence was significantly higher in 
the dexamfetamine group than in the placebo group (Wald χ²=16.17, df=1, 
p<0.0001; Table 2). Similarly, patients in the dexamfetamine group were more 
often abstinent from cocaine for at least 3 consecutive weeks than those in the 
placebo group (Wald χ²=5.52, df=1, p=0.019), and reported more days of cocaine 
abstinence in the final 4 weeks of the study (Wald χ²=8.45, df=1, p=0.004; Table 
2). Eight patients (21%) in the dexamfetamine group had at least one cocaine-
negative urine in the last 4 weeks compared with two patients (6%) in the placebo 
group, with a significantly higher proportion of cocaine-negative urine samples in 
the dexamfetamine group (Wald χ²=5.11, df=1, p=0.024).  
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Additionally, the average number of days of cocaine abstinence in the 4 weeks 
preceding baseline compared with the 4 weeks preceding week 12 increased 
significantly more in the dexamfetamine than in the placebo group (6.5 days 
[sd=6.9] to 15.2 days [10.8] days vs 5.4 days [7.2] to 7.5 [9.1], respectively 
[treatment by time interaction: F=4.70; df=1; p=0.032; d=0.94]). Moreover, 
patients in the dexamfetamine group showed higher reductions in the mean 
number of cocaine hits than did patients in the placebo group on days they used 
cocaine (8.9 cocaine hits per day [sd=5.9] to 5.1 [4.4] vs 8.3 cocaine hits per day 
[4.4] to 7.7 [5.9], respectively [treatment by time interaction: F=7.45; df=1; 
p=0.007; d=0.59]). 
With respect to the other secondary outcomes  cocaine craving, use of other 
substances, health, and criminality  we noted significant changes from baseline 
to week 12 for cocaine craving, heavy alcohol use, and physical health problems, 
but no significant group differences over time on any of these variables (all 
p≥0.098; Table 3). Finally, patients in the dexamfetamine group rated the study 
medication at week 12 on average more positively than patients in the placebo 
group (7.6 [sd=1.4] vs 5.7 [2.3], respectively; t=4.27, df=55.1, p<0.0001). 
At the week-12 assessment, the study blind was tested. In the dexamfetamine 
group, 54% of the patients correctly identified their group allocation compared 
with 60% in the placebo group (Kappa=0.14), indicating that blinding was 
successful until the end of the study and that patients were not able to discern 
beyond chance what they had been prescribed. Study medication was taken on a 
mean of 77 (sd=15.2) of the 84 study days (92%), with no difference between the 
study groups (75 days [sd=16.9] in the dexamfetamine group vs 79 days [12.9] in 
the placebo group; Wald χ²=0.05, df=1, p=0.828). Similarly, no group differences 
were noted between the number of consecutive weeks with full medication 
adherence (mean 8.7 weeks [sd=3.7] in the dexamfetamine group vs 9.3 weeks 
[3.4] in the placebo group; Wald χ²=0.09, df=1, p=0.767) and medication 
acceptance in the final 4 weeks (24.7 days [sd=8.1] in the dexamfetamine group vs 
25.1 days [7.0] in the placebo group; Wald χ²=0.01, df=1, p=0.943). Additionally, 
medication adherence did not differ between the four treatment centres (all 
p>0.91). Four patients in the dexamfetamine group and four in the placebo group 
discontinued their medication intake prematurely: three were imprisoned, four 
due to adverse events, and one had limited treatment effects (Figure 1).       
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One or more adverse events were reported by 28 (74%) patients in the 
dexamfetamine group and by 16 (46%) patients in the placebo group (OR 3.33 
[95% CI 1.25–8.87]; p=0.016). Together, 95 adverse events were registered and 
adverse events that were reported by at least two patients are summarised in 
Table 4. Patients in the dexamfetamine group reported 69 adverse events, of 
which 58 (84%) events were possibly, probably, or certainly related to the study 
medication. Most of these adverse events (51 events; 74%) were resolved before 
the end of the study treatment. Sleeping problems was the adverse event 
reported by most patients (n=13; 34%). In the placebo group, 26 adverse events 
were reported, of which 18 (69%) were possibly, probably, or certainly related to 
the study medication. 
 
Table 4. Adverse events reported by at least two patients. 
 
Sustained-release 
dexamfetamine group (n=38) 
Placebo group 
(n=35) 
Sleeping problems 13 (34%) 3 (9%) 
Agitation/ irritability 6 (16%) 2 (6%) 
Physical arousal 5 (13%) 2 (6%) 
Gastrointestinal problems 5 (13%) 3 (9%) 
Changes in appetite 6 (16%) 2 (6%) 
Changes in weight 5 (13%) 2 (6%) 
Influenza 3 (8%) 3 (9%) 
Dizziness 3 (8%) 0 (0%) 
Respiratory complaints 0 (0%) 2 (6%)* 
Craving 0 (0%) 2 (6%) 
Headache 1 (3%) 1 (3%) 
Data are n of patients (%). * Including one patient with a serious adverse event  
(admission to hospital). 
 
One serious adverse event occurred: a patient in the placebo group was 
admitted to hospital during the study period due to an exacerbation of chronic 
obstructive pulmonary disease, which was not related to the study drug. After 
admission, this patient resumed treatment. In six other patients, adverse events 
resulted in (temporary) discontinuation of study treatment: two in the placebo 
group and four in the dexamfetamine group. Of the latter four patients, two 
resumed treatment with a dose of 30 mg/day sustained-release dexamfetamine, 
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one patient discontinued medication intake due to psychotic symptoms, and one 
patient due to concurrent adverse events of mild to moderate severity.  
Heart rate significantly increased from baseline to week 12 among patients in 
the dexamfetamine group compared with those in the placebo group (Table 5). 
No significant group by time interaction effects were noted for blood pressure or 
bodyweight. Week 12 ECG data were available for 67 patients (dexamfetamine 
n=34; placebo n=33) with only one abnormality in terms of a repolarisation 
disturbance in a patient in the placebo group. 
 







Group x Time 
 Baseline Week 12 Baseline Week 12  
Heart rate (beats per min)  68.2 (11.9) 76.1 (11.6) 69.3 (10.0) 68.7 (12.6) F=9.58, df=1, p=0.003 
Systolic blood pressure  
(mm Hg) 
128.1 (15.7) 127.4 (14.7) 126.5 (15.8) 124.9 (14.8) F=0.06, df=1, p=0.809 
Diastolic blood pressure  
(mm Hg) 
79.3 (9.3) 81.2 (9.2) 80.5 (9.6) 79.3 (9.7) F=2.34, df=1, p=0.130 
Body weight (kg) 76.9 (18.7) 77.2 (18.4) 74.0 (18.2) 73.9 (17.9) F=0.21, df=1, p=0.645 
Data are mean (SD), unless otherwise specified. 
 
Discussion 
This multicentre, randomised, double-blind, placebo-controlled trial shows the 
acceptance, efficacy, and safety of 60 mg/day oral sustained-release 
dexamfetamine as a substitution drug in the treatment of chronic crack-cocaine 
dependence in heroin dependent patients, currently in heroin-assisted treatment. 
Sustained-release dexamfetamine was superior to placebo in terms of the primary 
cocaine-related outcome (d=0.58), and all self-reported and urine-based 
secondary cocaine use-related outcomes (d=0.58–0.94 and d=0.31, respectively). 
Sustained-release dexamfetamine was generally well-accepted, with high 
medication adherence. No serious adverse events occurred in the 
dexamfetamine-treated patients. There were no unexpected adverse events and 
most adverse events were transient and well-tolerated. 
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Our findings are an important contribution to the search for effective 
pharmacotherapies for cocaine dependence: it is the first study that shows the 
benefits of a robust dose of sustained-release dexamfetamine as a valuable 
agonist medication in the treatment of cocaine dependence. This is by contrast 
with previous studies in which strong inferences could not be made because of 
high rates of premature treatment discontinuation and promising, but often non-
significant, indications of cocaine use reductions. In two randomised controlled 
trials by Grabowski and colleagues (Grabowski et al., 2001; Grabowski et al., 
2004a), reductions in cocaine use were larger in the 60 mg/day sustained-release 
dexamfetamine group than in the 30 mg/day sustained-release dexamfetamine 
and placebo groups, but both studies had treatment discontinuation rates of up to 
60% and the reported effects were only significant in subgroup analyses. In a 
small randomised controlled trial of 30 cocaine injectors, significant reductions in 
cocaine use and cocaine-related improvements were noted in the dexamfetamine 
group (60 mg/day), but not in the between-group comparison (Shearer et al., 
2003). In a randomised placebo-controlled trial (n=73) on the efficacy of 60 
mg/day sustained-release dexamfetamine, 400 mg/day modafinil, and the 
combination of both compounds, 60% of the patients had discontinued treatment 
at 12 weeks and no benefits of sustained-release dexamfetamine over placebo 
were noted (Schmitz et al., 2012). Finally, in a recent pilot randomised placebo-
controlled trial, 70 mg/day of the prodrug lisdexamfetamine (containing 
approximately 30 mg/day dexamfetamine) resulted in reduced craving but not in 
an increase of cocaine abstinence (Mooney et al., 2015). Thus, sustained-release 
dexamfetamine has repeatedly shown to be a promising treatment for cocaine 
dependence, but no studies so far have shown a convincing benefit in terms of 
significant and substantial reductions in cocaine use, most likely due to small 
samples and low treatment adherence. By contrast, our study shows very good 
medication adherence and superiority of dexamfetamine in reducing self-
reported and urine-based cocaine use. 
We believe that our high medication adherence resulted from daily supervised 
intake that enabled the treatment staff to motivate patients and intensively 
monitor potential side effects of the study medication, which are important 
strategies to optimise adherence (Weiss, 2004). Additionally, increased doses of 
sustained-release dexamfetamine, such as 60 mg/day, are likely to result in more 
 
Chapter 5: SR dexamfetamine treatment 109 
robust findings (Grabowski et al., 2004a; Mooney et al., 2015). The observed 
effect sizes in our study were fair (urine-based cocaine use) to moderate (self-
reported cocaine use) and at least comparable to effect sizes in studies on other 
chronic disorders, including alcohol dependence (Maisel et al., 2013) and many 
other psychiatric and general medical conditions (Leucht et al., 2012).  
Efficacy of sustained-release dexamfetamine was not shown for our secondary, 
health-related outcome measures. This could be due to the fact that our study 
population already participated in heroin-assisted treatment for on average 4 
years, whereas much improvement in physical and mental health and reduction in 
criminality already occurs at an early phase of heroin-assisted treatment, as was 
shown by Blanken and colleagues (Blanken et al., 2010b). Hence, in this ageing 
population with a long history of cocaine and heroin dependency in heroin-
assisted treatment, there might be little room for further improvements in these 
areas. 
The study has several limitations. First, the sample size was limited, but in view 
of the a priori expected effect size, the study was adequately powered and a 
larger sample would not be approved by a medical ethics committee for this the 
proof-of-principle study. Moreover, the study was undertaken in four treatment 
centres and the effects were not driven by only one specific centre. Second, a 
study with a duration of 12 weeks can not give a conclusive answer about the best 
treatment for a chronic relapsing disorder such as cocaine dependence. However, 
at 12 weeks, 89% of the patients were still in treatment and there are no reasons 
to expect that drop-out was imminent or that the effect of the treatment was 
waning. We therefore believe that this study provides a strong indication for the 
potential long-term effectiveness of sustained-release dexamfetamine as an 
agonist pharmacotherapy for cocaine dependence. Third, the efficacy of 
sustained-release dexamfetamine on self-reported cocaine abstinence might be 
somewhat overestimated in our study in view of the substantially smaller effect 
size in urine-based cocaine use and the modest agreement between self-reported 
and urine-based cocaine use in the final 4 weeks of the study. Therefore, we did a 
post hoc sensitivity analysis with days of cocaine abstinence in the last 4 study 
weeks as dependent variable, in which self-reported days of cocaine abstinence in 
the 2 days preceding the urinalysis were converted into non-abstinent days in 
case of a cocaine-positive or missing urine sample (data not shown). This analysis 
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showed that patients in the dexamfetamine group on average still had 
significantly more cocaine-free days (8.9 days) than did those in the placebo group 
(3.9 days), with a comparable effect size (adjusted d=0.71 vs original d=0.77). 
However, we also have to consider the possibility that our urine-based efficacy of 
sustained-release dexamfetamine on cocaine abstinence is an underestimation of 
the true effect, because qualitative urine tests only provide dichotomous 
outcomes (cocaine-positive or cocaine-negative) and can not detect reductions in 
the amount of cocaine that was used, such as those noted in our study. In view of 
the rationale for agonist substitution treatment with sustained-release 
dexamfetamine, cocaine use reductions and stabilisation rather than cocaine 
abstinence are also valid treatment goals. Fourth, the study was undertaken in a 
quite specific treatment setting, and it is an important question whether the 
demonstrated efficacy of sustained-release dexamfetamine can be generalised to 
cocaine dependent patients outside heroin-assisted treatment. We believe that 
the results are generalisable to chronic cocaine dependent patients with 
comorbid heroin dependence in methadone maintenance treatment with daily 
visits and supervised methadone intake, because these patients have very similar 
patterns of cocaine use, largely similar clinical characteristics, and daily supervised 
intake of sustained-release dexamfetamine can be established in this context. 
Generalisability is less clear when it comes to cocaine and comorbid heroin 
dependent patients in methadone maintenance treatment without daily 
supervised methadone intake and regular take home doses of methadone. In this 
context, sustained-release dexamfetamine prescription should be made 
conditional on regularly supervised intake of the medication and on other 
measures to improve compliance, such as compliance enhancement therapy 
(Weiss, 2004) or contingency management directed at treatment attendance and 
cocaine-free urines (Petry et al., 2012; Prendergast et al., 2006). Similar measures 
are needed in cocaine dependent patients without comorbid heroin dependence, 
and thus not in substitution treatment. In view that in previous studies of 
dexamfetamine twice weekly visits to the treatment centre were related to high 
treatment discontinuation rates (Grabowski et al., 2001; Grabowski et al., 2004a; 
Schmitz et al., 2012), future studies on the efficacy of sustained-release 
dexamfetamine among more general populations of cocaine dependent patients 
in routine addiction treatment services should incorporate medication 
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management interventions, including frequent monitoring of medication 
adherence and adverse events, frequent dose evaluations and motivational 
enhancement (Weiss, 2004), combined with providing relevant incentives for both 
treatment attendance and cocaine abstinence (Schierenberg et al., 2012) to 
improve treatment outcomes. 
Finally, our findings might not only be relevant for the treatment of patients 
with cocaine dependence, but possibly also for the many patients with other 
stimulant addictions, although the efficacy of sustained-release dexamfetamine in 
these populations still has to be established (Galloway et al., 2011). Our study has 
shown that agonist pharmacotherapy with a robust dose of sustained-release 
dexamfetamine is possible and safe, and shows at least one way to improve 
medication adherence and treatment outcomes in chronic patients with a 
stimulant dependence, and our approach and the discussed strategies can be 
examples for future studies in the field of addiction. 
We conclude that sustained-release dexamfetamine is a well-accepted, 
effective, and safe agonist drug for the treatment of cocaine dependent patients 
currently in heroin-assisted treatment. Replication of these findings in treatment-
refractory cocaine dependent and other stimulant dependent patients in less 
specific treatment settings is warranted, using multiple strategies to optimise 
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Summary 
Introduction 
Compulsive cocaine use, particularly crack-cocaine (i.e. smoking or ‘basing’ 
cocaine), is associated with a great burden for both the user and society, including 
physical and mental health problems and social marginalisation. In Dutch 
addiction care, about half of the cocaine-related treatment demand concerns 
crack-cocaine use, and the majority of these patients have relatively long and 
recurrent treatment episodes, as well as concurrent use of other substances, 
including heroin and alcohol. The efficacy of cognitive behavioural therapy for 
(crack-)cocaine dependence, which is the most common psychosocial treatment 
in addiction care, is modest at best and there are no proven effective 
pharmacological treatments to date, despite numerous research attempts. Hence, 
crack-cocaine dependence is a serious and complex problem with as yet no 
adequate treatment.  
The CATCH project (Cocaine Addiction Treatments to improve Control and 
reduce Harm) was initiated to explore new pharmacological treatment options for 
crack-cocaine dependence in the Netherlands. In three separate parallel-group, 
randomised controlled, feasibility trials, three promising medications were 
investigated for their acceptance, efficacy, and safety in the treatment of crack-
cocaine dependence: (1) topiramate 200 mg/day, (2) modafinil 400 mg/day, and 
(3) sustained-release (SR) dexamfetamine 60 mg/day. The aim was to identify one 
or more candidate medications for future investigation in a large-scale 
confirmatory trial. The selection of these medications and the design of the 
studies are presented in Chapter 1. 
 
Topiramate pharmacotherapy 
Topiramate is an anticonvulsant with gamma-aminobutyric acid (GABA) enhancing 
and glutamatergic antagonizing properties, which modulates the reward system. 
In cocaine dependence, topiramate had been shown to promote (sustained) 
cocaine abstinence and to reduce cocaine craving in two studies that were 
conducted before the start of the CATCH project, and was thus considered to be a 
promising pharmacotherapy.  
Therefore, in the first trial of the CATCH project, topiramate was studied as an 
add-on to cognitive behavioural therapy (CBT) in crack-cocaine dependent 
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patients (Chapter 2). Seventy-four crack-cocaine dependent outpatients 
participated in an open-label, randomised, feasibility trial. They were randomised 
to receive either 12-week CBT plus 200 mg/day topiramate (n=36) or 12-week CBT 
only (n=38). The primary outcome measure was CBT treatment retention. 
Secondary outcomes included medication adherence, safety, cocaine and other 
substance use, cocaine craving, health, social functioning, and patient satisfaction. 
Adherence to topiramate treatment was low with only 14% of the patients 
who completed the 12-week topiramate treatment, and reasons for non-
adherence remained largely unknown. In the intent-to-treat analyses, topiramate 
neither improved treatment retention nor reduced cocaine and other substance 
use. Post hoc, exploratory analyses suggested a moderation effect of comorbid 
opioid dependence, with a significant favourable effect of topiramate on cocaine 
use only in crack-cocaine dependent patients with comorbid opioid dependence. 
An explorative comparison between patients with low (<6 weeks) and high (≥6 
weeks) topiramate adherence did not show differences in the reduction of crack-
cocaine use. Finally, topiramate was related to adverse events, mostly 
paraesthesia, gastro-intestinal complaints and fatigue, which were generally mild 
and transient. There were no serious adverse events.  
It was concluded that topiramate was safe and well-tolerated in this sample of 
crack-cocaine dependent patients, but efficacy was not supported, probably due 




Modafinil is a wakefulness-promoting agent that possesses stimulant effects, 
mainly as a consequence of dopamine reuptake inhibition, which is suggested to 
normalise brain chemistry in dependent people and to reduce substance use. 
Before the start of the CATCH project, promising effects of modafinil were 
reported in terms of reductions of cocaine use and craving. In Chapter 3, the 
acceptance, efficacy and safety of 400 mg/day modafinil as an add-on treatment 
to cognitive behavioural therapy (CBT) in crack-cocaine dependent patients were 
examined.  
Sixty-five crack-cocaine dependent outpatients participated in an open-label, 
randomised, feasibility trial. Patients were randomised to receive either 12-week 
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individual CBT plus 400 mg/day modafinil (n=30) or 12-week individual CBT only 
(n=35). The primary outcome measure was CBT treatment retention. Secondary 
outcomes included modafinil adherence, tolerability and safety, use of cocaine 
and other substances, cocaine craving, health, social functioning and patient 
satisfaction. 
Modafinil adherence was low, with only 10% treatment completers. In 20% of 
the modafinil-treated patients, discontinuation of modafinil treatment was 
related to adverse events. Intent-to-treat analyses showed that modafinil did not 
improve CBT treatment retention or any of the secondary cocaine-related 
outcomes. Both groups showed similar, large reductions in cocaine use during the 
study treatment. Post hoc exploratory analyses within the CBT plus modafinil 
group showed significantly larger baseline to week 12 reductions in cocaine use 
days in patients with at least 8 weeks of modafinil adherence, compared with 
patients using modafinil for less than 8 weeks. Satisfaction with the treatment 
offer did not differ between the CBT plus modafinil and CBT only groups. Most 
adverse events occurred in the CBT plus modafinil group and tachycardia, 
agitation and headache were the most frequently reported adverse events. There 
were two serious adverse events, but they were not related to modafinil.  
To conclude, acceptance and benefits of modafinil were not demonstrated in 
the present study, most likely due to low adherence. However, in a post hoc 




High impulsivity and attentional bias are common in cocaine dependent patients 
and have been shown to predict poor treatment outcomes in earlier studies. 
Modafinil has been shown to improve cognitive functions and this may mediate 
improvements in clinical outcomes in crack-cocaine dependent patients. In 
Chapter 4, we investigated: (1) whether pre-treatment impulsivity and attentional 
bias predicted treatment outcome; (2) whether modafinil as an add-on treatment 
to cognitive behavioural therapy (CBT) improved impulsivity and attentional bias; 
and (3) whether changes in impulsivity and attentional bias were related to 
improvements in treatment outcome.  
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This study was an extension of the main modafinil trial and the study 
population thus consisted of the same 65 crack-cocaine dependent outpatients, 
who were randomised to either 12-week CBT plus modafinil or 12-week CBT only. 
Self-reported impulsivity was assessed at baseline using the Barratt Impulsiveness 
Scale (BIS-11). At baseline and week 12, we assessed inhibitory control as a 
behavioural measure of impulsivity, in terms of cognitive interference (Stroop 
task) and response inhibition (‘stop-signal task’), and attentional bias with the 
addiction Stroop task. Clinical outcomes were CBT retention and crack-cocaine 
use. 
At baseline, low self-reported impulsivity predicted better CBT retention, 
whereas low self-reported and behavioural impulsivity and attentional bias 
predicted less crack-cocaine use at week 12. Cognitive performance improved 
during treatment, but the improvements were not modafinil-related and this was 
most likely due to low modafinil adherence. Post hoc comparisons within the 
modafinil treatment group suggested the presence of improved cognitive 
interference in high modafinil adherent (≥8 weeks) compared to low modafinil 
adherent (<8 weeks) patients. However, improvements in impulsivity or 
attentional bias were not associated with CBT retention or with changes in crack-
cocaine use. 
It was concluded that baseline impulsivity and attentional bias predict CBT 
retention and clinical outcomes in crack-cocaine dependent patients, but 
modafinil did not seem to reduce impulsivity or attentional bias in this population. 
Future studies involving cognitive-enhancing medications should include 
strategies to optimise adherence, to be better able to evaluate their potential for 
improving cognitive functioning and reducing cocaine use. 
 
Dexamfetamine pharmacotherapy 
Heroin-assisted treatment is effective for methadone treatment-refractory heroin 
dependent patients, but their continued comorbid cocaine dependence remains 
problematic. Sustained-release (SR) dexamfetamine is a promising agonist 
pharmacotherapy for the treatment of (comorbid) cocaine dependence. In 
Chapter 5, the acceptance, efficacy and safety of a robust dose of 60 mg/day SR 
dexamfetamine were investigated. As was described in Chapter 1, this trial was 
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different from the previous two trials and consisted of a multicentre, randomised, 
double-blind, placebo-controlled design.  
Seventy-three chronic crack-cocaine and heroin dependent patients in heroin-
assisted treatment were randomly assigned to receive either 12 weeks of daily 
supervised 60 mg oral SR dexamfetamine (n=38) or 12 weeks of daily supervised 
identical placebo (n=35) in addition to daily co-prescribed pharmaceutical heroin 
and methadone. The primary outcome measure was the number of self-reported 
days of cocaine use during study treatment. Secondary outcomes were 
medication adherence, tolerability and safety, self-reported and urine-based 
cocaine use-related outcomes (e.g. longest period of consecutive abstinence), 
cocaine craving, physical and mental health, social functioning, and patient 
satisfaction.  
Medication adherence was high (92%) with no differences between the 
dexamfetamine and placebo groups. Study blinding was successful, given that in 
the dexamfetamine group only 54% of the patients correctly identified their 
medication compared with only 60% in the placebo group.  
SR dexamfetamine treatment resulted in significantly fewer days of cocaine 
use, a longer period of consecutive cocaine abstinence, a higher proportion of 
participants who achieved a period of at least 21 days of abstinence, and a higher 
proportion of cocaine-negative urines than placebo treatment. In addition, on 
days that patients used crack-cocaine, their mean number of cocaine hits 
decreased, with larger reductions in the dexamfetamine group than in the 
placebo group. SR dexamfetamine was not superior to placebo on other 
secondary outcomes.  
One or more adverse events were reported by 74% of the patients in the 
dexamfetamine group and by 46% of the patients in the placebo group. Most 
adverse events were transient and well-tolerated. One serious adverse event 
occurred in the placebo group. 
It was concluded that SR dexamfetamine is a well-accepted, effective, and safe 
agonist treatment for comorbid treatment-refractory cocaine dependence in 
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Results in an updated context 
Since the start of the CATCH project, several other studies on the effects of 
pharmacological treatment with topiramate, modafinil and SR dexamfetamine in 
crack-cocaine dependent patients have been conducted. In this section, our 
conclusions regarding these treatments will be positioned within the context of 
more recent findings. 
 
Topiramate 
In our first trial, topiramate was not efficacious in the treatment of cocaine 
dependence, and findings from other studies that were published prior and during 
the execution of our trial were equivocal. Therefore, we concluded in Chapter 2 
that the evidence for topiramate’s efficacy was inconsistent and limited at best.  
Since then, two additional 12-week randomised controlled trials (RCTs) were 
conducted, again with inconsistent results. Umbricht and colleagues (2014) 
investigated the efficacy of 15 weeks 300 mg/day topiramate versus placebo with 
and without contingency management in 171 American cocaine dependent 
patients in methadone maintenance treatment. They found that treatment 
retention was 72% and did not differ between patients receiving topiramate and 
those receiving placebo. In addition, topiramate was not different from placebo in 
reducing cocaine use. They therefore concluded that topiramate is not efficacious 
for increasing cocaine abstinence in methadone patients (Umbricht et al., 2014). 
In contrast, in the most recent placebo-controlled RCT on 200 mg/day topiramate 
treatment in 60 Brazilian crack-cocaine dependent men without comorbid 
substance or psychiatric disorders, clear efficacy of topiramate was demonstrated 
(Baldaçara et al., 2016). Treatment compliance was excellent (97%), significantly 
more topiramate-treated patients achieved cocaine-abstinence during treatment, 
and the quantity and frequency of cocaine use was significantly lower in the 
topiramate compared with the placebo group (Baldaçara et al., 2016).  
Despite this recent positive study, the overall evaluation of topiramate’s 
efficacy in the treatment of cocaine dependence still tends to be negative. In line 
with our conclusions, a Cochrane review on anticonvulsants (Minozzi et al., 
2015b) and a systematic review and meta-analysis specifically on topiramate 
(Singh et al., 2016) both concluded that there is no current evidence for the 
efficacy of topiramate, but it has to be mentioned that the study of Baldaçara 
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(2016) was not included. However, even though the outcomes of this latter trial 
indicate that there might be potential for topiramate, it remains unclear which 
factors are important contributors to this positive evaluation of topiramate, and 
to date, no clear explanations have been found for the inconsistency of the 
findings. Therefore, we still conclude that, to date, the evidence for topiramate’s 
efficacy in the treatment of cocaine dependent patients is insufficient.  
 
Modafinil 
Concerning modafinil, we concluded in Chapter 3 that our negative study findings 
were in line with two randomised controlled trials of Schmitz et al. (2014; 2012). 
In addition, we concluded that the positive results of modafinil in the treatment of 
cocaine dependence found by Dackis et al. (2005) had never been replicated so 
far, because positive modafinil-related results from subsequent trials were only 
observed in secondary outcomes or in post hoc defined subgroups (Anderson et 
al., 2009; Dackis et al., 2012). Nevertheless, we emphasised that further research 
on the potential of modafinil treatment in cocaine dependence was warranted, 
given the positive indications of modafinil-related cocaine use reductions in high 
adherent patients in our study. 
Two additional randomised placebo-controlled studies on the efficacy of 
modafinil in the treatment of cocaine dependence were published since the 
execution of our trial and both studies reported positive results on cocaine-
related outcomes. In a recent trial by Kampman et al. (2015), 8 weeks treatment 
with modafinil (300 mg/day) showed good compliance (75%) and resulted in 
significantly higher cocaine abstinence rates than placebo among cocaine 
dependent patients without comorbid alcohol dependence. In another recent trial 
in cocaine dependent patients, 6 weeks treatment with modafinil (400 mg/day ) 
showed excellent retention (95%) and resulted in significantly higher abstinence 
rates in the modafinil compared to the placebo group (Morgan et al., 2016). In 
both trials, the simultaneous use of contingency management may have been 
responsible for the high medication adherence. These recent studies are the first 
studies after the trial of Dackis et al. (2005) that convincingly demonstrated 
efficacy of modafinil in cocaine dependence. Altogether, we conclude that 
modafinil might be efficacious in the treatment of cocaine dependence if good 
medication adherence can be achieved.  
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SR dexamfetamine  
Regarding SR dexamfetamine in the treatment of cocaine dependence, both 
positive and negative results have been reported in previous research and in 
Chapter 5 we concluded that, taken together, our study most convincingly 
showed the benefits of SR dexamfetamine in cocaine use reductions, albeit in a 
specific study population. We also concluded that “Future research should aim to 
replicate these findings in chronic cocaine dependent and other stimulant 
dependent patients in more routine treatment settings, including strategies to 
optimise treatment adherence like medication management interventions and 
contingency management”. 
Only one trial with an amphetamine-analogue comparable to SR 
dexamfetamine has been published in cocaine dependent patients since our SR 
dexamfetamine study was conducted and the results of this study were thus not 
included in the discussion of Chapter 5. In a randomised placebo-controlled trial 
among patients with cocaine dependence and co-occurring attention-deficit/ 
hyperactivity disorder (ADHD), 12 weeks treatment with extended-release mixed 
amphetamine salts (MAS-ER; 60 or 80 mg/day) was significantly more effective 
than placebo in the reduction of cocaine use and in the reduction of ADHD 
symptoms (Levin et al., 2015). In the most recent Cochrane review on the 
effectiveness of psychostimulants in the treatment of cocaine dependence, 
dexamfetamine was (again) identified as a promising agonist treatment, 
particularly in patients with dual heroin and cocaine dependence (Castells et al., 
2016). Therefore, we see no reasons to deviate from our positive conclusion 
about SR dexamfetamine in Chapter 5.  
 
Overall 
In sum, findings from the CATCH project concerning the pharmacotherapeutic 
potential of topiramate, modafinil and SR dexamfetamine, are in line with findings 
from other studies, which show great promise for agonist therapy with SR 
dexamfetamine, some promise for modafinil, but no convincing evidence for 
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Medication adherence 
In all three CATCH trials, patients’ willingness to participate in pharmacotherapy 
was assessed during the eligibility phase, either before study inclusion 
(dexamfetamine trial) or before providing second informed consent pertaining to 
pharmacological treatment participation (topiramate and modafinil trial). In the 
topiramate and modafinil trials, the vast majority (i.e. 82% and 94%, respectively) 
gave second consent. Notwithstanding their initial willingness, however, 
medication adherence was low in these two trials and most patients prematurely 
discontinued treatment. In the modafinil trial, some patients indicated that 
medication-related adverse events contributed to their non-adherence, but in 
general reasons for non-adherence remained unknown.  
Medication non-adherence and treatment discontinuation are well-known 
problems in medication research (Servick, 2014) and in the treatment of chronic 
diseases, with average adherence rates in developed countries reaching about 
50% only (World Health Organization, 2003). For example, in physical illnesses, 
medication non-adherence rates vary from 30% in diabetes (Iglay et al., 2015) to 
50% in hypertension (Krousel-Wood et al., 2004) and in mental illnesses, non-
adherence rates were estimated to be more than 40% in psychosis and ADHD 
(Colizzi et al., 2016; Frank et al., 2015) and 50% in depression (Sansone and 
Sansone, 2012). In addiction care, it was demonstrated that one third to half of 
the alcohol dependent patients prematurely discontinue their medications 
(Blodgett et al., 2014; Stout et al., 2014). Non-adherence rates in our topiramate 
and modafinil trials were even higher, 86% and 90%, respectively (Nuijten et al., 
2014, 2015), which is comparable to the high non-adherence (>80%) to oral 
naltrexone in patients with opiate dependence (Bart, 2012). In contrast, non-
adherence rates are relatively low in various agonist replacement therapies: less 
than 40% in methadone maintenance or buprenorphine treatment (Bart, 2012), 
around 20% in heroin-assisted treatment (Blanken et al., 2010b), and even less 
than 10% in our dexamfetamine trial (Nuijten et al., 2016a). 
Poor adherence to long-term therapies severely compromises the potential 
effectiveness of treatment, resulting in poor treatment outcomes, decreased 
quality of life and increased health care costs (World Health Organization, 2003). 
In clinical trials, adherence is essential, given that the real potential of medication, 
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as well as the implication of its side effects, can only be demonstrated when 
medication intake is optimal (Servick, 2014).  
Reasons for non-adherence in our trials were mostly not clear, but from a review 
on medication adherence, examples of major predictors of low adherence are side 
effects of medication, disbelief in the benefit of treatment, missed appointments, 
and complexity of treatment (Osterberg and Blaschke, 2005). Also, insufficient 
benefits from pharmacotherapy, which might be reflected in continued or 
increased substance use, can contribute to non-adherence (Stout et al., 2014), as 
well as inappropriate dosing (Faggiano et al., 2003; Salamina et al., 2010). 
Strategies to optimize medication adherence include enhancing motivation, 
providing information, monitoring of adverse events and dosing, involving 
patients in treatment decisions when possible, sending reminders, and providing 
social support (Brown and Bussell, 2011; Corneli et al., 2015; Hollands et al., 2015; 
Weiss, 2004). Obviously, a good doctor-patient relationship with effective 
communication between the two is essential to improve adherence (Brown and 
Bussell, 2011; Weiss, 2004; World Health Organization, 2003). Administration of 
extended-release formulations can also improve compliance, as has been 
demonstrated in opiate dependence treatment with extended-release naltrexone 
provided as intramuscular injections lasting about four weeks or subcutaneous 
implants lasting three to six months (Kunøe et al., 2014; Larney et al., 2014), and 
with subcutaneous buprenorphine implants lasting six months (Ling et al., 2010; 
Rosenthal et al., 2013; Rosenthal et al., 2016). 
Medication management interventions can also be helpful to support and 
optimise the use of medications in the treatment of patients with substance use 
disorders (Weiss, 2004). An example in the addiction field is the BRENDA-
approach, which is a motivation and treatment-compliance enhancing support 
strategy with the following elements: Biopsychosocial evaluation; Report to the 
patient; Empathy; Needs collaboratively identified; Direct advice; and Assessment 
of outcomes (Volpicelli et al., 2001). BRENDA facilitates both therapeutic alliance 
and treatment compliance and, thus, improves clinical outcomes (Starosta et al., 
2006). Another strategy is behavioural reinforcement or contingency 
management using incentive- or voucher-based interventions to improve 
medication adherence (DeFulio and Silverman, 2012; Petry et al., 2012).  
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Finally, the measurement of medication adherence deserves attention since 
there are large differences in medication adherence rates depending on 
measurement method, ranging from approximately 30% with a medication event 
monitor to 80% with a urine-based biochemical tracer (e.g. riboflavin) and nearly 
90% with self-report (Mooney et al., 2004). This suggests that medication 
adherence can be overestimated and medication event monitoring should be 
used additionally to other methods for measuring adherence (El Alili et al., 2016; 
Mooney et al., 2004). 
In sum, medication adherence is an overall problem in chronic disease 
management, including that of patients with substance use disorders, but with 
agonist treatment, particularly for opiates, being an important exception. 
However, even in some of the dexamfetamine trials in cocaine dependent 
patients, medication adherence and treatment retention were low (Grabowski et 
al., 2001; Grabowski et al., 2004a; Schmitz et al., 2012). Therefore, medication 
management and contingency management interventions should be implemented 
to promote adherence. Finally, medication adherence has to be carefully 
monitored in order to accurately assess actual adherence.  
 
Agonist treatment 
Substitution treatment with the agonist SR dexamfetamine clearly showed the 
most positive effects on cocaine use in our trials. This finding is in accordance with 
the increasing evidence that agonist therapy might be the most promising 
strategy in cocaine dependence (Mariani and Levin, 2012). The goal of 
(supervised) agonist therapy is to replace uncontrolled and harmful substance use 
by the use of an agonist medication, that can be used more safely in terms of 
dose, route of administration, and adverse effects, resulting in reduced 
intoxication, withdrawal, and illicit substance use (Herin et al., 2010; Mariani and 
Levin, 2012; Shearer, 2008). Given that abstinence is not always an acceptable or 
feasible treatment goal for chronic crack-cocaine users, it might be more 
appropriate to reduce cocaine use-related harms by the use of (partial) 
substitution of cocaine by an agent with similar neurotransmitter targets (i.e. 
dopaminergic, serotonergic and noradrenergic receptors) and comparable – but 
less harmful – neurochemical and behavioural effects (Herin et al., 2010). This 
approach fits into the more general strategy of harm reduction, in which recovery 
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in other life domains, such as health and social functioning, is more important 
than reducing or quitting substance use per se (Marlatt, 1996). 
There are numerous positive results of harm reduction strategies using 
substitution pharmacotherapy, albeit not (yet) in crack-cocaine dependence. For 
instance, an average of four years of heroin-assisted treatment was associated 
with stable physical, mental and social health and with absence of illicit heroin use 
(Blanken et al., 2010a); prescribed heroin along with methadone was associated 
with a decrease in the use of illicit substances, a decrease in criminal activities and 
incarcerations, a possible reduction in mortality, and an increase in treatment 
retention (Ferri et al., 2011). In addition, a treatment regimen targeted at 
maintenance and harm reduction with emphasis on retaining low adherent 
patients was found to be one of the main predictors of the effectiveness of opioid 
substitution therapy (Kourounis et al., 2016).  
Potentially effective agonist substitution therapy for cocaine dependence 
concerns a wide range of agents. They share some of their effects with cocaine, 
mostly by increasing extracellular dopamine levels, but they have different 
pharmacological profiles in terms of both their mechanism of action and their 
neurotransmitter targets. It is important to understand why some of the 
dopamine agonists seem to be more effective in treating cocaine dependence 
than others. 
The efficacy of dopamine agonists might be related to the presence of a 
psychostimulant working mechanism. In a Cochrane review, direct dopamine 
agonists without psychostimulant characteristics (i.e. amantadine, bromocriptine, 
levodopa/carbidopa, pergolide, cabergoline, hydergine and pramipexole) were 
not effective in the treatment of cocaine dependence (Minozzi et al., 2015a). In 
contrast, indirect dopamine agonists that function as cocaine-like drugs, 
particularly bupropion and dexamfetamine, were identified as promising agonist 
substitution treatments for cocaine dependence (Castells et al., 2016). These 
reviews thus suggest that only indirect dopamine agonists with psychostimulant 
properties produce positive outcomes.  
However, not all indirect agonists (psychostimulants) seem to be equally 
effective. Some authors argue that amphetamine-analogues like 
methamphetamine and dexamfetamine, which cause a direct release of 
monoamines, in particular dopamine and norepinephrine (dela Peña et al., 2015), 
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are more effective than monoamine/dopamine reuptake inhibitors like modafinil, 
methylphenidate, and bupropion (Stoops and Rush, 2013). Sustained-release 
methamphetamine, which causes a massive release of multiple 
neurotransmitters, including dopamine and norepinephrine (Herin et al., 2010), 
was convincingly superior to placebo in reducing cocaine use (Mooney et al., 
2009), and several trials have now provided support for the efficacy of 
dexamfetamine in the treatment of cocaine dependence, albeit mostly among 
patients with comorbid ADHD (Levin et al., 2015) or comorbid heroin dependence 
in opioid maintenance treatment (Grabowski et al., 2004a; Nuijten et al., 2016a). 
Moreover, dosing seems to be related to efficacy, with a tendency of higher 
dexamfetamine doses (e.g. ≥60 mg/day) being more effective than lower doses 
(e.g. 30 mg/day) (Grabowski et al., 2001; Grabowski et al., 2004a; Levin et al., 
2015). Hence, the efficacy of amphetamine-analogues might be restricted to 
certain subpopulations and/or adequate dosing. 
The positive results of modafinil that we referred to in a previous section 
(Kampman et al., 2015; Morgan et al., 2016), suggest that not only monoamine 
releasers but also (certain) dopamine reuptake inhibitors may be effective in the 
treatment of cocaine dependence. This also applies to the norepinephrine-
dopamine reuptake inhibitor bupropion, an antidepressant and anti-smoking 
medication (Castells et al., 2016). Methylphenidate, another dopamine reuptake 
inhibitor, showed inconsistent findings in a review of Dürsteler and colleagues 
(2015), with generally positive results in open-label studies and case-reports, but 
negative results in randomised controlled trials (Dürsteler et al., 2015). As with 
dexamfetamine, methylphenidate’s efficacy may be dependent on dosing or 
restricted to subpopulations. In the trials reviewed by Dürsteler et al. (2015), 
doses did not exceed 90 mg/day, but in a trial among amphetamine dependent 
patients with comorbid ADHD doses up to 180 mg/day showed better treatment 
outcomes than placebo (Konstenius et al., 2014). Dopamine agonists may also 
reduce cocaine use through their positive effect on cognitive functions due to 
increases in dopamine levels in other regions than the reward system, such as the 
prefrontal cortex (e.g. Sofuoglu et al., 2013; Volkow et al., 2010; Wood et al., 
2014). However, the evidence for this mechanism of action is currently still 
limited. 
 
128  CATCH 
Finally, despite the promising status of agonist treatment for cocaine 
dependence, there are also concerns about its use, including the lack of specific 
receptors to target, the cardiovascular and psychosis inducing risk (Darke and 
Farrell, 2015), and the risk for abuse (Mariani and Levin, 2012). Indeed, when 
psychostimulants are used in substitution treatment in cocaine dependent 
patients, this has to be done with caution. To determine the most  appropriate 
agonist medication, severity of cocaine use should be taken into account, for 
instance a dopamine reuptake inhibitor such as modafinil to patients with low-to-
moderate cocaine dependence, and a dopamine releaser such as dexamfetamine 
to highly severe cocaine dependent patients (Herin et al., 2010). In addition, risks 
can be reduced by establishing a good therapeutic relationship, the use of 
sustained-release preparations, distribution of small amounts of medication, pill 
counts, regular health check-ups, frequent patient visits, and supervised intake 
(Mariani and Levin, 2012). At the same time, however, despite the potential 
health risks of agonist substitution therapy, one has to realise that ongoing 
compulsive (crack-)cocaine use, with its illegal status and its unknown purity and 
adulterants, is likely to be more harmful than agonist medication. 
To summarize, with regard to agonist substitution treatment for cocaine 
dependence, indirect dopamine agonists with psychostimulant effects seem to be 
most effective, with most of the evidence pointing to amphetamine-analogues. 
However, so far there are too many unknown associations with dosing, 
comorbidity and cognitive performance to determine which agonists are most 
effective. Hence, both mechanistic and efficacy studies are needed to identify the 
most effective agonist treatment(s) in cocaine dependence. This will be discussed 
in more detail in the next paragraph.  
 
Conclusions & future directions 
The aim of the CATCH project was to investigate the feasibility, efficacy and safety 
of topiramate, modafinil, and SR dexamfetamine in the treatment of crack-
cocaine dependent patients. Based on our findings and previous research, we 
conclude that topiramate should not be recommended as a medication for the 
treatment of crack-cocaine dependence, whereas the potential efficacy of 
modafinil needs to be further explored. Agonist therapy with SR dexamfetamine 
currently seems to be the best option for patients with chronic crack-cocaine 
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dependence. This implies that the focus of treatment is moved from abstinence to 
harm reduction, in which recovery and improvement of quality of life are at least 
as important as abstinence from cocaine. 
Given the diversity of agonist agents, each with a specific pharmacological 
profile, future research should be aimed at finding the most efficacious agonist 
treatment for cocaine dependence, taking into account target populations, dosing 
strategies, effects on cognitive functions and side effects. Mechanistic studies 
should be conducted in order to further understand the neurobiological and 
neurocognitive processes involved in cocaine dependence and its treatment. 
Imaging techniques can contribute to the identification of new receptor targets 
and to the development of individualised treatment strategies (Ghitza et al., 2010; 
Gould et al., 2014; Gould et al., 2013; Hu et al., 2015). This might also result in the 
discovery of new, promising agonists, such as atypical dopamine transporter 
(DAT) inhibitors (e.g. CTDP-32 476 (Xi et al., 2016)) or long-acting dopamine 
uptake inhibitors (Velazquez-Sanchez et al., 2013) that are associated with 
inhibited cocaine self-administration in rats. In addition, the agonistic compounds 
that are currently investigated in humans should be further explored with respect 
to their neurotransmitter targets (Crunelle et al., 2013), cognitive effects (Moeller 
et al., 2014), and mechanisms of action (Konova et al., 2013). Given that certain 
psychostimulants enhance cognitive functioning (e.g. improve inhibitory control), 
most likely by increasing cortical excitability (Bisagno et al., 2016), mechanisms of 
actions of cognitive enhancers, as well as their specific effects in relation to 
clinical outcomes are important targets for future studies (Nuijten et al., 2016b; 
Sofuoglu et al., 2013).  
Efficacy studies should be performed in which agonist treatments with 
different mechanisms of action are studied in placebo-controlled head-to-head 
comparisons, e.g. placebo versus dexamfetamine and versus modafinil or versus 
methylphenidate. Moreover, the superiority of specific agonist treatments within 
different target populations, such as in cocaine versus other stimulant dependent 
patients, with and without ADHD or comorbid heroin dependence, should be 
investigated. Different dose levels and treatments of longer duration than 
investigated in our trials (i.e. >12 weeks) should be considered, with a proper 
balance between desirable and adverse effects.  
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Apart from agonist pharmacotherapy as ‘stand-alone’ treatment, combined 
agonist therapy and psychological treatment deserves attention in future 
research. Although dexamfetamine was superior to placebo in reducing cocaine 
use in our study, patients in the dexamfetamine group still used cocaine on more 
than half of the study treatment days and in the last month of treatment the 
percentage of cocaine-negative urine samples was rather low (11%). Additional 
psychological treatments, in which patients learn to adequately cope with their 
addiction and related problems may enhance the efficacy of agonist treatment. 
Cognitive behavioural treatment (CBT) is a treatment targeted at improving 
coping and social skills, but as described in Chapter 1, CBT is associated with 
rather low retention rates in cocaine dependent patients (Dutra et al., 2008; 
Shearer, 2007). To improve retention, contingency management (CM) 
interventions might be most useful. CM as an add-on to CBT has been shown to 
improve treatment retention (Fitzsimons et al., 2015; Miguel et al., 2016; 
Schierenberg et al., 2012), and enhance cocaine abstinence, both factors that are 
likely to result in a greater impact of CBT treatment (Petitjean et al., 2014; 
Schierenberg et al., 2012; Vocci and Montoya, 2009). Also, when post-treatment 
effects of CM are waning, sustained effects of CBT might still be present (Carroll 
and Onken, 2005).  
When treatment is aimed at harm reduction instead of abstinence, this will 
require adaptation of treatment goals and reinforcement procedures in CM. For 
instance, vouchers might be earned when benzoylecgonine (BE) concentrations, 
indicating the presence of cocaine-metabolites, are reduced in subsequent urine 
samples until predefined stabilised levels are achieved, or when urine samples are 
BE-negative on pre-specified days of the week. To date, the literature on this topic 
is scarce, but one randomised controlled study described the differences between 
CM for cocaine-abstinence compared with CM for shaping cocaine abstinence 
(Preston et al., 2001). The authors found that reinforcement of behaviour that 
patients will readily engage in (i.e. BE-concentrations ≤25% compared with 
previous urine sample) increased compliance with behaviours that patients will 
not readily engage in (i.e. complete abstinence).  
In the context of combined agonist pharmacotherapy and psychological 
treatment, it is also worthwhile to investigate cognitive outcomes, and the 
relation between these cognitive outcomes and reductions in cocaine use and 
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improvements in quality of life. Previous research showed improvements in 
various executive functions after sustained (≥2 weeks) cocaine-abstinence 
(Schulte et al., 2014), and small but consistent cognitive improvements in 
attention, working memory, declarative memory and executive functions were 
related to reduced cocaine use within one year (Vonmoos et al., 2014). In 
addition, improved cognitive functioning was found to be related to better 
treatment retention (Aharonovich et al., 2008) and to better learning, practicing, 
and implementation of new cognitive skills (Sofuoglu et al., 2013).  
 
To conclude, our study on new pharmacological treatment options for cocaine 
dependent patients is an important contribution to the addiction research field, 
with negative findings pertaining to the efficacy of topiramate, ambiguous 
findings for modafinil, and promising findings for agonist substitution treatment 
with SR dexamfetamine. The latter finding is a major step towards an effective 
pharmacotherapy for cocaine dependence and an encouragement for future 
research, that should be focused on extending the results to other chronic 
cocaine/ stimulant dependent patients, and on improving and maintaining the 
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Introductie 
Compulsief cocaïnegebruik, met name van crack-cocaïne (de rookbare variant van 
cocaïne, ook wel ‘basecoke’ genoemd) gaat gepaard met een grote belasting voor 
zowel de gebruiker zelf als voor de samenleving, zoals op het gebied van 
lichamelijke en psychische gezondheidsproblemen en sociale marginalisatie. In de 
Nederlandse verslavingszorg heeft ongeveer de helft van alle cocaïnegerelateerde 
hulpvragen betrekking op het gebruik van crack-cocaïne, en de meerderheid van 
de cocaïneafhankelijke patiënten heeft een relatief lange behandelduur en keert 
regelmatig terug in zorg. Ook gebruiken zij vaak andere middelen naast cocaïne, 
zoals heroïne en alcohol. 
Het meest gebruikelijke behandelaanbod in de verslavingszorg is een 
psychosociale behandeling, vaak in de vorm van cognitieve gedragstherapie, maar 
de effectiviteit hiervan is bij (crack-) cocaïneafhankelijkheid gering en er zijn tot op 
heden geen bewezen effectieve farmacologische behandelingen, ondanks de vele 
onderzoeken die reeds gedaan zijn op dit vlak. Kortom, crack-
cocaïneafhankelijkheid is een serieus en complex probleem waarvoor geen 
adequate behandeling beschikbaar is. 
De CATCH-studie (CATCH is een acroniem voor “Cocaine Addiction Treatments 
to improve Control and reduce Harm”) werd geïnitieerd om nieuwe 
farmacologische behandelmogelijkheden te onderzoeken voor de behandeling 
van crack-cocaïne afhankelijkheid in Nederland. In drie aparte, gerandomiseerde, 
gecontroleerde haalbaarheidsstudies met parallelle groepen werden drie 
veelbelovende medicamenten onderzocht op acceptatie, effectiviteit en veiligheid 
bij de behandeling van crack-cocaïneafhankelijkheid: (1) topiramaat, (2) modafinil, 
en (3) vertraagde afgifte dexamfetamine. Het doel van het onderzoek was om uit 
deze drie medicamenten een of meer kandidaten te selecteren om in toekomstig 
onderzoek in een grotere studie verder te bestuderen. De selectie van deze 
medicamenten en het ontwerp van de onderzoeken worden beschreven in 
Hoofdstuk 1.  
 
Farmacotherapie met topiramaat 
Topiramaat is een anti-epilepticum met gamma-aminoboterzuur (GABA) 
versterkende en glutamaat tegenwerkende eigenschappen, wat van invloed is op 
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het beloningssysteem. Twee eerdere onderzoeken die voorafgaand aan de 
CATCH-studie werden uitgevoerd onder cocaïneafhankelijke patiënten, toonden 
aan dat topiramaat bijdroeg aan (langdurende) cocaïne-abstinentie en hunkering 
naar cocaïne verminderde, waardoor topiramaat als een veelbelovend 
medicament werd beschouwd.  
Tegen deze achtergrond werd in het eerste deelonderzoek van de CATCH-
studie topiramaat bestudeerd als aanvulling op cognitieve gedragstherapie (CGT) 
bij crack-cocaïneafhankelijke patiënten (Hoofdstuk 2). Vierenzeventig crack-
cocaïneafhankelijke patiënten namen deel aan dit open-label, gerandomiseerd 
haalbaarheidsonderzoek. Zij werden gerandomiseerd naar ofwel een behandeling 
bestaande uit 12 weken CGT plus 200 mg/dag topiramaat (n=36) ofwel een 
behandeling bestaande uit alleen 12 weken CGT (n=38). De primaire 
uitkomstmaat was CGT behandelretentie. Secundaire uitkomsten betroffen 
topiramaat innametrouw, veiligheid, cocaïne- en ander middelengebruik, cocaïne 
hunkering, gezondheid, sociaal functioneren en patiënttevredenheid.  
De innametrouw van topiramaat was laag: slechts 14% van de deelnemers 
nam gedurende de volledige studieperiode van 12 weken hun medicatie. Redenen 
voor het niet-innemen van topiramaat bleven grotendeels onbekend. Uit de 
‘intent-to-treat’ analyses bleek dat topiramaat de CGT behandelretentie niet 
verbeterde, en evenmin het cocaïne- en ander middelengebruik verminderde. 
Post hoc exploratieve analyses lieten een moderatie-effect zien van 
opiaatafhankelijkheid: topiramaat leidde alleen tot een vermindering van het 
cocaïnegebruik bij crack-cocaïneafhankelijke patiënten met een bijkomende 
opiaatafhankelijkheid. Uit een exploratieve vergelijking tussen patiënten die hun 
topiramaat meer of minder dan 6 weken hadden ingenomen bleek geen verschil 
in het cocaïnegebruik. Topiramaat-inname ging gepaard met bijwerkingen, vooral 
tintelingen, maag/darmklachten en vermoeidheid, maar deze waren vaak mild en 
van voorbijgaande aard. Er waren geen ernstige ongewenste medische 
gebeurtenissen. 
Geconcludeerd werd dat topiramaat een veilig en goed getolereerd 
medicament is voor deze groep crack-cocaïneafhankelijke patiënten, maar dat de 
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Farmacotherapie met modafinil 
Klinische uitkomsten 
Modafinil is een medicament dat de waakzaamheid vergroot en stimulerende 
effecten heeft als gevolg van het vertragen van dopamine-heropname. Het 
vermoeden bestaat dat deze effecten de chemie in de hersenen van verslaafde 
mensen normaliseren en het middelengebruik verminderen. Voorafgaand aan de 
start van de CATCH-studie werden er veelbelovende resultaten van modafinil 
gerapporteerd ten aanzien van de vermindering van het cocaïnegebruik en de 
hunkering naar cocaïne. In Hoofdstuk 3 zijn de acceptatie, effectiviteit en 
veiligheid van modafinil (400 mg/dag ) als aanvulling op cognitieve 
gedragstherapie (CGT) bij crack-cocaïneafhankelijke patiënten onderzocht.  
Vijfenzestig crack-cocaïneafhankelijke patiënten namen deel aan een open-
label, gerandomiseerde haalbaarheidsstudie. Deelnemers werden 
gerandomiseerd naar ofwel een 12 weken durende behandeling met individuele 
CGT plus 400 mg/dag modafinil (n=30), ofwel een 12 weken durende behandeling 
met alleen individuele CGT (n=35). De primaire uitkomstmaat was CGT 
behandelretentie. Secundaire uitkomstmaten bestonden uit modafinil 
innametrouw, tolerantie en veiligheid, cocaïne- en overig middelengebruik, 
cocaïne hunkering, gezondheid, sociaal functioneren en patiënttevredenheid. 
De modafinil innametrouw was laag: slechts 10% van de deelnemers maakte 
hun modafinil-behandeling af. Bij 20% van de deelnemers aan de modafinil-
behandeling had het voortijdig stoppen met modafinil te maken met ongewenste 
medische gebeurtenissen. De ‘intent-to-treat’ groepsanalyses lieten zien dat 
modafinil de CGT behandelretentie niet verbeterde en ook niet positief bijdroeg 
aan de secundaire cocaïnegerelateerde uitkomsten. Beide groepen hadden 
vergelijkbaar grote verminderingen in het cocaïnegebruik gedurende de 
studieperiode. In exploratieve analyses die onder de deelnemers aan de 
modafinil-behandeling werden uitgevoerd, werd gevonden dat het cocaïnegebruik 
tussen het begin en einde van de studie sterker verminderde bij patiënten die hun 
modafinil minimaal 8 weken hadden ingenomen dan bij patiënten die hun 
modafinil minder trouw (<8 weken) hadden ingenomen. De tevredenheid over de 
ontvangen behandeling verschilde niet tussen de groep die CGT plus modafinil 
ontving en de groep die alleen CGT kreeg. De CGT plus modafinil groep 
rapporteerde de meeste ongewenste medische gebeurtenissen, en de meest 
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genoemde klachten waren hartkloppingen, agitatie en hoofdpijn. Er vonden twee 
ernstige medische ongewenste gebeurtenissen plaats, maar deze waren niet 
gerelateerd aan de modafinil-behandeling.  
Geconcludeerd werd dat de acceptatie en de effectiviteit van modafinil niet 
aangetoond konden worden in de huidige studie, en dat dit waarschijnlijk te 
wijten was aan de lage innametrouw. Echter, in exploratieve analyses werden 
substantiële verminderingen in het cocaïnegebruik gevonden in een subgroep met 
een hoge innametrouw van modafinil.  
 
Cognitief functioneren 
Hoge impulsiviteit en een aandachtsbias komen vaak voor bij cocaïneafhankelijke 
patiënten en in eerdere studies is aangetoond dat dit tot slechte 
behandelresultaten leidt. Het is aangetoond dat modafinil cognitieve functies 
verbetert en dit zou kunnen bijdragen aan een verbetering van de klinische 
uitkomsten bij crack-cocaïne afhankelijke patiënten. In Hoofdstuk 4 onderzochten 
we: (1) of impulsiviteit en een aandachtsbias bij aanvang van de behandeling 
voorspellend was voor de behandeluitkomsten; (2) of modafinil als aanvulling op 
cognitieve gedragstherapie (CGT) impulsiviteit en aandachtsbias verminderde; en 
(3) of veranderingen in impulsiviteit en aandachtsbias gerelateerd waren aan 
verbeteringen in behandeluitkomsten.  
Dit onderzoek was een uitbreiding op de hoofdstudie met modafinil en daarom 
bestond deze onderzoeksgroep uit dezelfde 65 crack-cocaïneafhankelijke 
patiënten die gerandomiseerd waren naar 12 weken CGT plus modafinil, of alleen 
CGT. Zelfgerapporteerde impulsiviteit werd bij aanvang van de behandeling 
gemeten met de Barratt Impulsiviteitsschaal (BIS-11). Bij de beginmeting en in 
week 12 werden ‘inhibitie controle’ als een gedragsmaat van impulsiviteit, in 
termen van cognitieve interferentie (Stroop taak) en respons inhibitie (‘stop 
signaal taak’), en aandachtsbias met de verslavingsvariant van de Stroop taak, 
vastgesteld. Klinische uitkomsten waren CGT behandelretentie en crack-
cocaïnegebruik. 
Een lage zelfgerapporteerde impulsiviteit bij de beginmeting voorspelde een 
betere CGT behandelretentie, terwijl een lage impulsiviteit, gebaseerd op 
zelfrapportage en op de gedragstaken, en een lage aandachtsbias bij de 
beginmeting minder cocaïnegebruik op week 12 voorspelden. Cognitieve 
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prestaties verbeterden tijdens de onderzoeksbehandeling, maar deze 
verbeteringen konden niet worden toegeschreven aan de modafinil-behandeling, 
vooral vanwege de lage innametrouw. Exploratieve vergelijkingen binnen de 
modafinilgroep suggereerden dat de patiënten met een hoge modafinil-
innametrouw (≥8 weken) sterker verbeterden op cognitieve interferentie dan 
patiënten met een lage modafinil-innametrouw (<8 weken). Verbeteringen in 
impulsiviteit of aandachtsbias hingen niet samen met CGT behandelretentie of 
veranderingen in cocaïnegebruik. 
Er werd geconcludeerd dat impulsiviteit en aandachtsbias bij het begin van de 
behandeling de CGT behandelretentie en klinische uitkomsten voorspellen bij 
crack-cocaïne afhankelijke patiënten, maar er waren geen aanwijzingen dat 
modafinil de impulsiviteit of aandachtsbias verminderde in deze groep. 
Toekomstige onderzoeken met cognitief-versterkende medicijnen zouden 
strategieën moeten includeren om de medicatietrouw te optimaliseren, zodat 
beter bepaald kan worden of de medicamenten het cognitief functioneren 
verbeteren en daarmee uiteindelijk het cocaïnegebruik verminderen. 
 
Farmacotherapie met dexamfetamine 
De behandeling met heroïne op medisch voorschrift (HMV) is effectief voor 
methadonresistente, heroïneafhankelijke patiënten, maar hun bijkomende 
cocaïneafhankelijkheid blijft problematisch. Vertraagde afgifte dexamfetamine is 
een veelbelovende agonistische farmacotherapie voor de behandeling van 
(bijkomende) cocaïneafhankelijkheid. In Hoofdstuk 5 werden de acceptatie, 
effectiviteit en veiligheid van een robuuste dosering van 60 mg/dag vertraagde 
afgifte dexamfetamine onderzocht. Zoals beschreven in Hoofdstuk 1, was het 
design van dit deelonderzoek anders dan dat van de eerste twee 
deelonderzoeken, en het betrof een multicenter, gerandomiseerd, dubbelblind, 
placebogecontroleerd design.  
Drieënzeventig chronische crack-cocaïne- en heroïneafhankelijke patiënten, 
die een HMV-behandeling ontvingen, werden random toegewezen aan een 12 
weken durende gesuperviseerde behandeling met 60 mg/dag vertraagde afgifte 
dexamfetamine (n=38) of een identiek lijkend placebo (n=35) als aanvulling op 
hun dagelijkse behandeling met methadon en diacetylmorfine. De primaire 
uitkomstmaat was het aantal zelfgerapporteerde dagen waarop cocaïne werd 
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gebruikt gedurende de onderzoeksperiode. Secundaire uitkomsten waren 
medicatie-innametrouw, tolerantie en veiligheid, cocaïnegebruik-gerelateerde 
uitkomsten, gebaseerd op zelfrapportage en urinetesten (bijv. de langste periode 
van aaneengesloten cocaïne-abstinentie), cocaïne hunkering, lichamelijke en 
psychische gezondheid, sociaal functioneren, en patiënttevredenheid. 
De innametrouw van de onderzoeksmedicatie was hoog (92%) in zowel de 
dexamfetamine- als placebogroep. De blindering van de studiemedicatie was 
succesvol aangezien slechts 54% van de patiënten in de dexamfetaminegroep en 
60% in de placebogroep correct kon aangeven welke studiemedicatie zij hadden 
ontvangen. 
De behandeling met vertraagde afgifte dexamfetamine leidde tot significant 
minder dagen cocaïnegebruik, een langere periode van aaneengesloten cocaïne-
abstinentie, een hoger percentage deelnemers dat minimaal 21 dagen 
aangesloten cocaïne-abstinent kon blijven, en een hoger percentage cocaïne-
negatieve urinetesten dan de behandeling met placebo. Op de dagen dat 
patiënten wel crack-cocaïne gebruikten, nam het gemiddeld aantal ‘basejes’ af, 
waarbij de vermindering groter was in de dexamfetaminegroep vergeleken met 
de placebogroep. Behandeling met vertraagde afgifte dexamfetamine was niet 
beter dan behandeling met een placebo op andere secundaire uitkomstmaten. 
Een of meerdere medische ongewenste gebeurtenissen werden gerapporteerd 
door 74% van de deelnemers in de dexamfetaminegroep en door 46% van de 
deelnemers in de placebogroep. De meeste medische ongewenste gebeurtenissen 
waren van voorbijgaande aard en werden goed getolereerd. Er vond één ernstige 
medische ongewenste gebeurtenis plaats bij een patiënt in de placebogroep. 
Er werd geconcludeerd dat vertraagde afgifte dexamfetamine een goed 
geaccepteerde, effectieve en veilige agonistische farmacotherapie is voor 




Het doel van de CATCH-studie was om de haalbaarheid, effectiviteit en veiligheid 
van topiramaat, modafinil en vertraagde afgifte dexamfetamine te onderzoeken 
in de behandeling van crack-cocaïneafhankelijke patiënten. Op basis van onze 
bevindingen en eerder onderzoek concluderen we dat topiramaat niet 
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aanbevolen wordt als medicamenteuze behandeling van crack-
cocaïneafhankelijkheid, terwijl de potentiële effectiviteit van modafinil verder 
onderzocht zou moeten worden. 
Agonistische behandeling met vertraagde afgifte dexamfetamine is voor 
patiënten met chronische cocaïneafhankelijkheid op dit moment de beste optie. 
Dat betekent dat de focus van behandeling verschuift van abstinentie naar 
schadebeperking, waarbij herstel en het verbeteren van de kwaliteit van leven ten 
minste even belangrijke doestellingen worden als cocaïne-abstinentie. 
De veelbelovende bevindingen uit ons onderzoek ten aanzien van een 
substitutiebehandeling met vertraagde afgifte dexamfetamine is een belangrijke 
stap naar een effectieve farmacotherapie voor cocaïneafhankelijkheid en is een 
aanmoediging voor toekomstig onderzoek dat zich zou moeten richten op het 
uitbreiden van de resultaten naar chronische cocaïne (en andere stimulantia) 
afhankelijke patiënten, en op het verbeteren en behouden van de effecten van 
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